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Abstract
The aim of the work described in this thesis was to develop and evaluate two rapid, 
colloidal gold-based, immunochromatographic assays, a ‘cassette’ and ‘wick’ type, 
both for the qualitative detection of the glycoprotein hormone, human chorionic 
gonadotrophin (hCG) in human urine and serum. hCG is present in large quantities in 
the urine and serum of pregnant women and thus, provides a means for diagnosing 
pregnancy. A key element of this work was to develop assays, which would be 
capable of competing strongly in this market.
The outcome of this project was a highly sensitive and specific cassette and wick 
hCG assay, having the capability to detect as low as 25 IU/L hCG on the first day of 
a missed period. These assays also had the capacity to detect levels up to 250,000 
IU/L hCG before a ‘hook’ effect was observed. This analytical range was equal to 
the majority of the tests already on the market. Evaluation of the two assays yielded 
100% sensitivity and specificity for the cassette assay with urine samples and 98.5% 
sensitivity and 100% specificity for serum samples. A sensitivity of 99.4% (urine) 
and 100% (serum) and a specificity of 100% (urine) and 98% (serum) were obtained 
for the wick assay. It should be emphasised that these assays are limited to the 
qualitative detection of hCG and subsequently, all positive results should be 
confirmed by a doctor. It is a measure of the success of the assays that predicted sales 
for the first six months of 2000 are estimated at -$60,000 for the cassette assay and 
-$100,000 for the wick assay.
l
Section 1: 
Introduction
1.1 History of hCG detection methods
In 1905 Halban suggested that the placenta was an endocrine organ. The 
investigations, which followed, led to the discovery, in 1920, of the placental 
formation of steroid, protein and polypeptide hormones, of which one was human 
chorionic gonadotropin (hCG). This was deduced by a Japanese scientist, Hirose, 
who transplanted placental tissue under the skin of female rabbits, which resulted in 
the stimulation of the ovaries and other reproductive organs (Saxena, 1983). In 1927 
Aschheim and Zondek confirmed these findings. They also provided a detailed 
characterisation of hCG and its presence in the urine of pregnant women. This work 
by Aschheim and Zondek, as reported by Saxena (1983), established the 
measurement of hCG as the basis of pregnancy tests. It has since been recognised 
that hCG is secreted by the syncytiotrophoblast cells of the placenta and is present in 
the serum and urine during pregnancy (Gabbe et al., 1996).
During the ensuing seventy years a number of biological, immunological and 
radioreceptor assays have been developed for measuring hCG in the urine and blood 
of pregnant women. The first reliable bioassay for hCG (the AZ test) was introduced 
with the publication of Aschheim and Zondek’s work in 1928. This bioassay 
involved injecting mice with urine over a two-day period and four days later 
examining their ovaries for corpus luteum formation. According to Beers (1981), this 
method served as a source of qualitative as well as quantitative information for at 
least 20 years. In 1931 the Friedman and Haplan test reduced the time-span involved 
in the AZ test by using mature female rabbits. A number of variations of these time- 
constricting bioassays were developed over the next 20 years.
In 1944 Salk published his work on haemagglutination and in 1951 Boyden applied a 
method of protein attachment following acid treatment of sheep red blood cells, thus 
paving the way for the first immunological hCG assay introduced in 1960 by Wide 
and Gemzell. This assay was based on haemaglutination inhibition (see Figure 1.1.1, 
page 3). Various latex and radioisotope versions of this test were introduced in the 
1960’s. For the determination of hCG in urine, the tube and slide method was used 
with a sensitivity of -0.200-1.250 IU/mL. Quantitation of hCG was carried out using 
radio-immunoassays (RIA’s), enzyme-linked immunosorbent assays (ELISA’s) and
by immunoassay particle counting (IMPACT) as well as by fully automated 
turbidometric methodology. Latex-based tests have also been popular, one method 
being the latex inhibition procedure. In the early 1980s dyed latex particles were 
utilised for rapid ‘one-step’ pregnancy tests (e.g.: Clearblue™ One Step by Unipath). 
Colloidal gold and carbon labels have also been used for similar purposes (Price et 
al., 1997).
(a) ( j ? ) —  hCG =  Particles coated hCG ( 3  = Anti9en
=  Antibody to hCG with two combining sites
(b)
(c)
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hCG
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d H
hCG
+
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Figure 1.1.1: The Agglutination Inhibition Assay, (a) Shows diagram key. (b) The 
agglutination o f particle labelled anti-hCG antibodies when no hCG is present in the 
sample, (c) The presence o f hCG in the sample prevents agglutination of these 
labelled anti-hCG antibodies (Adapted from Chamberlain, 1995).
Within 7 to 10 days after conception hCG is detectable in the urine of pregnant 
women using current methods, thus, providing the ideal tool for pregnancy diagnosis. 
The older assays typically yielded inaccurate results due to the reliance on older and 
relatively impure hCG standards. These tests were unable to differentiate hCG from 
the pituitary hormones. Thus, they would only indicate a positive result when the 
concentrations of hCG were much higher than normal physiological levels of either 
luteinising hormone (LH), follicle stimulating hormone (FSH) and thyroid
3
stimulating hormone (TSH). This meant that many of the tests would not give a 
positive pregnancy test result until about the third month of the pregnancy (Gard, 
1998). Since then, the reliability and ease of use of pregnancy tests has greatly 
improved due to technical advances. The refinement of enzyme immunoassays and 
other non-radiometric methods coupled with automated instrumentation has greatly 
improved the accuracy of test results. A major landmark in the optimisation of hCG 
assays was the development of rapid one-step assays, which can be used at home as 
they do not require specialised equipment or training. While an ELISA may prove to 
be more sensitive than these one-step assays, the time involved in obtaining a result 
from an ELISA was found to be a disadvantage, particularly in emergency situations 
where potentially embryotoxic procedures, such as x-ray studies, might be carried 
out. Generally, the sensitivity and specificity of the rapid assays are good, as the 
average level of hCG at time of presentation for pregnancy testing (invariably around 
the time of the first missed period) is approximately 100-200mIU/mL. This level is 
well within the detectable range for the majority of the rapid assay tests. This thesis 
describes the development of two such assays for use with either urine or serum 
samples.
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1,2 Properties and Chem ical Characteristics of hCG
1.2.1 The Glycoprotein Hormones
The purpose of any pregnancy test is to detect human chorionic gonadotropin in 
human urine and/or serum. The glycoprotein hormones comprise a group of pituitary 
hormones bearing carbohydrate moieties; luteinising hormone (LH), thyroid 
stimulating hormone (TSH) and follicle stimulating hormone (FSH), and the 
placental hormone human chorionic gonadotropin (hCG). The average molecular 
weight, carbohydrate content and pi of these hormones are shown in Table 1.2.1 
below.
Hormone Molecular
Weight
Carbohydrate Content (g/100g)
Neutral
Sugar
Acetyl
Hexosamine
Sialic
Acid
Fucose pH
hCG 36700 11.0-11.2 10.8-11.1 8.5-9.0 1.2 4.9
FSH 35500 3.9-12.2 2.9-9.0 1.4-5.1 - 5.5
LH 28500 11.3 4.9 2 - 7.4
TSH 25000 5.9 4.1 * 0.5 m
Table 1.2.1: Approximate molecular weight, carbohydrate content and p i o f the 
glycoprotein hormones. (From George, 1996)
These glycoprotein hormones are composed of two non-covalently linked, non­
identical peptide chain subunits, designated a  and P (Cole, 1999b; Bischof et al., 
1997; Morgan and Canfield, 1971 and Ross, 1977). The amino acid sequence of the 
a-subunit is identical among all four hormones and is encoded for by the same gene. 
The P-subunit genes are distinct for each hormone but they share many conserved 
sequences. Their gene products are 40-45% homologous in their primary structure. 
However, it is the differences in the 3-subunit sequences which confers the unique 
biological activity and immunologic specificity of each hormone (Cole et al., 1991 
and Morgan et al., 1974). It has also been suggested that the biological activity is 
dependent on reversible tertiary or quaternary structural configuration of subunits in 
the intact molecule (Ross, 1977). Recombination of an a  and P-subunit of the four
glycoprotein hormones gives rise to a molecule with biological activity characteristic 
of the hormone from which the (3-subunit was derived (Cunningham et a l, 1989).
1.2.2 The Structure of hCG
Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone 
which is secreted by trophoblastic tissue of the placenta and by certain tumours. In 
comparison with the other glycoprotein hormones, hCG has a unique amino acid 
extension at the carboxy terminal end (-COOH-terminal peptide, 109-145), which is 
less important for its intrinsic biological activity, but has a strong bearing on its 
metabolic clearance rate (Hoermann, 1996).
hCG is composed of two dissimilar subunits, a  and (3, associated non-covalently (see 
Figure 1.2.1, page 7). They are held together by electrostatic and hydrophobic forces 
and can be separated by treatment with acidified urea (Cunningham et a l, 1989). The 
molecular weight of the dimer is approximately 36.7kDa, the a-subunit contributing 
14.5kDa and the P-subunit 22.2kDa. The a-subunit of hCG consists o f a 92 amino 
acid sequence essentially identical and shared in common with the pituitary 
glycoprotein hormones (see Figure 1.2.2, page 8) (Cole et al., 1991 and Gabbe et al., 
1996). Within this a-chain 5 intrachain disulfide bonds and 2 N-linked glycosylation 
sites (asparagines 52 and 78) are found (Bischof et a l, 1997). The a-subunit has 
been shown to have a biological activity of less than 1% of the native hormone 
(Morgan and Canfield, 1971).
The P-subunit, although structurally similar to the a-subunit, differs enough to 
confer specific biological activity on the intact (dimer) hormone (Gabbe et al, 1996). 
The P-subunit itself has no intrinsic biological activity, appearing to be unable to 
bind to the receptor (Cunningham et al., 1989). The P-subunit of hCG is composed 
of 145 amino acids (see Fig. 1.2.2, page 8), 6 intrachain disulfide bonds, 2 N-linked 
oligosaccharides (asparagines 13 and 30) and 4 O-linked oligosaccharides (serines 
121,127,132 and 145) (Cole et al., 1991 and Bischof et a l, 1997). The P-subunits of 
hCG, LH, TSH and FSH exhibit considerable homology. This is particularly true of 
the P-subunits of hCG and LH (Bischof et a l, 1997).
6
~«X)H
Figure 1.2.1: The structure ofhCG. Disulfide bonds are marked with dark lines. 
(Taken from Gabbe et al., 1996, with permission).
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A review of the amino acid and carbohydrate compositions of the P-subunits of hCG 
and LH reveals similarities. hCG, however, possesses more total carbohydrates and 
specifically much more sialic acid. At the C terminus of the peptide P-hCG is 23 
amino acids longer than P-LH, the remainder of the p-chain differs only by 24 
residues out of 121 (80% homology) and none of these residues is involved in 
disulfide bonds. It is thus apparent why many hCG assays have fallen victim to the 
high immunologic cross-reactivity with LH (Bischof e t  al., 1997).
(a)
1 10 
Ala -  Pro -  Asp -  Val -  Gin -  Asp  -  Cys -  Pro -  Glu -  Cys -  T h r -  Leu -  Gin -  Glu -  Asp  -  Pro  -
Phe -  Phe -  S e r -  Gin 20 - P r o -  Gly -  Ala - P r o -  lie -  Leu -  Gly -  Cys -  Met -  Gly 30 -  Cys - C y s -
Phe -  S e r -A r g  -  Ala -  T y r -P r o  -  T h r -P ro  -  Leu -  Arg -  S e r -L y s  -  Lys -  Thr -  M et -  Leu  -  Val
-  Gin 0 -  Lys -  Asn ° -  Val -  T h r -  S e r -  Glu -  S e r -  T h r -  Cys -  Cys 0 -  Val -  Ala -  Lys -  S e r -  
Tyr -  Asn -  Arg -  Val -  Thr -  Val 70 -  M et  -  Gly - G l y - P h e -  Lys -  Val -  Glu  -  Asn CH0 -  His -  T h r80
90
-  Ala -  Cys -  His -  Cys -  S e r -  T h r -  Cys -  Tyr -  Tyr  -  His  -  Lys -  Ser
(b)
S er 1 -  Lys -  Glu -  Pro -  Leu  -  Arg  -  Pro  -  Arg  -  Cys -  Arg 10 -  Pro  -  lie -  Asn CH0 -  Ala -  Thr -  
Leu -  Ala -  Val -  Glu  -  Lys 20 -  Glu -  Gly -  Cys - P r o -  Val -  Cys -  lie -  T h r -  Val -  Asn CH0 30 -  Thr
-  T h r - l ie  -  Cys -  Ala  -  G ly -  T y r -  C y s -P r o  -  Thr -  M et -  T h r -A rg  -  V a l -  Leu -  Gin -  Gly -  Val
-  Leu -  Pro  3 -  Ala -  Leu -  Pro -  Gin -  Val -  Val -  Cys -  Asn -  T y r -  Arg 60 -  Asp -  Val -  Arg  -  Phe
-  Glu -  S e r -  lie  -  Arg -  Leu -  Pro 70 -  G ly -  Cys  -  Pro Arg -  Gly -  Val -  Asn -  Pro -  Val - V a l  0 -
90
S e r -  T y r -  Ala  -  Val -  A la -  Leu - S e r -  Cys -  Gin -  Cys -  Ala -  Leu -  Cys -A rg  -  Arg -  S e r -  Thr
-  Thr-Asp -  Cys -  Gly -  Gly -P ro  -  Lys -  Asp -  His -  Pro -  Leu -  T h r- Cys '10 -  Asp -  Asp -  
Pro -  Arg -  Phe -  Gin -  Asp -  S e r- S e r- S er120 -  Ser CH0 -  Lys -  Ala -  Pro -  Pro -  Pro -  Ser CH0
-  Leu -  Pro -  S er 30 -  Pro -  S e r -  Arg -  Leu -  Pro -  Gly  -  Pro -  Ser -  Asp -  
T h r140 - P r o -  lie -  Leu - P r o -  S er  CH0 145
Figure 1.2.2: Amino acid sequences of (a) the a-subunit of hCG and (b) the 
fi-subunit ofhCG. Residue numbers and glycosylation sites are 
superscripted in red (Saxena, 1983).
The folding of the peptide and carbohydrate extensions that are attached to certain 
amino acids dictates the three-dimensional structure of the glycoprotein hormones 
(O’Connor e t  al., 1994). The polypeptide portion accounts for 66% of the molecular 
weight of hCG and amino acid analysis reveals remarkably high values for proline, 
cysteine and serine, with no free SH groups (Reid e t  al., 1972). The carbohydrate 
moiety is abundant in hCG in comparison to the other glycoprotein hormones, (refer
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to Table 1.2.1, page 5), making up 30% of the weight of the hCG molecule. This is 
the largest carbohydrate content of any human hormone, with 11 residues of N-acetyl 
glucosamine, 9 of mannose and galactose, 8 of sialic acid, 3 of N- 
acetylgalactosamine and 1 residue of fucose per glycopeptide chain (Reid el al., 
1972). The hCG molecule contains four N-linked carbohydrate antennae bound to 
two asparagine residues o f the a-subunit and the {3-subunit and four O-linked sugar 
chains bound to serine residues at the carboxyterminus of the p-subunit, all of which 
terminate with sialic acid. The carbohydrate moiety, especially the terminal sialic 
acid, plays an important role in prolonging the half-life of hCG in plasma and 
preserving the biological activity of the molecule by protecting it from catabolism. It 
is essential for biological activity since enzymatic removal of sialic acid abolishes 
the hormones biologic properties (Reid et al., 1972). Furthermore, it forms the basis 
for glycosylation variants of the hormone (Hoermann, 1996).
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1.3 Cellular Origin of hCG
hCG mRNA is detectable in blastomeres of 6-8 cell embryos. It is widely believed 
that the complete hCG molecule is produced by the syncytial trophoblastic cells of 
the placenta and is secreted into the intervillous space (see Fig. 1.3.1 below) (Gabbe 
et a l, 1996; Cunningham et al., 1989 and Braunstein et al., 1976).
AMNIOTIC
FLUID
MATURATION OF PLACENTA
True villus-------
Ingrowth of 
cytolrophoblast
Fetal vessels
Amnion---------------
Cytotrophoblast
Syncytiotrophoblast
Villus
labyrinth
PLACENTA
-  Decidua
Ì  basal plate
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B
Figure 1.3.1: (A) Gross morphology o f the human placenta. The changes, which 
occur in the placental morphology as gestation advances, evolve from left to right. 
(B) Anatomic structure of early (left) and late (right) terminal villi. (Taken from Gabbe
et al., 1996, with permission).
Syncytiotrophoblast
Fetal 
Fetal 
Fetal blood
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It was demonstrated after implantation that mRNA for hormonal hCG is present in 
cytotrophoblasts and syncytiotrophoblasts in the outer syncytial layer, whereas 
mRNA for a-hCG is present primarily in cytotrophoblasts with none in the syncytial 
layer. hCG secretion is related to the mass of hCG-secreting trophoblastic tissues. 
Therefore, the release of hCG in vivo can be correlated with trophoblast layer widths 
from weeks 4 to 20 and with placental weights from 20 to 38 weeks. Proliferation of 
immature trophoblastic villi and an extensive syncytial layer occurs between weeks 3 
and 9. This coincides with rapidly rising hCG levels. Between 10 and 18 weeks 
gestation there is a decline in hCG which has been associated with a relative 
reduction in syncytiotrophoblasts and cytotrophoblasts at this time. From 20 weeks 
gestation to term there is a gradual increase in dimer hCG which corresponds with a 
gradual increase in placental weight and villus volume. In short, it is apparent that as 
the placenta begins to proliferate, the levels of hCG begin to rise and hCG levels 
decline as the placenta undergoes morphological changes which results in a reduction 
in trophoblasts, the source of hCG.
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1.4  Biosynthesis of KCG
The biosynthesis of hCG is a quite a complex process. The synthesis of the a  and p 
chains of hCG are regulated independently. A single gene, located on chromosome 
19, codes for the a-subunit of all of the glycoprotein hormones (Bischof et a l, 1997; 
Cunningham et al., 1989). There are eight separate genes that code for the P-subunit 
of hCG and LH. Seven genes code for p-hCG and one codes for p-LH. These genes 
are located on chromosome 7. It has been suggested that the seven P-hCG genes 
evolved from an ancestral gene for P-LH. Only two, possibly three of the genes for 
the p-subunit are expressed (Cunningham et a l, 1989). The rate at which the P- 
subunit of hCG is synthesised limits the rate of formation of the complete hCG 
molecule (Cunningham et a l, 1989). Intact hCG and a  and P-subunits of hCG are 
secreted by the trophoblasts of normal placenta, hydatidiform moles and 
choriocarcinoma tissues (Cunningham et a l, 1989). Generally, there is an excess of 
a-subunits detectable in the placenta and plasma of normal pregnant women, while 
the hCG P-subunit is usually present in small or even undetectable amounts. The 
signal sequences for both the a  and P-subunits are cleaved by microsomal 
endopeptidases since they are synthesised as larger molecular weight precursors.
It should be noted that eight different molecular forms of hCG have been identified: 
holo hCG, nicked hCG, holo hCG missing the C terminus, free p-hCG, free P-hCG 
missing the C terminus, nicked free P-hCG, free a-hCG and different glycosylation 
forms (Gabbe et al., 1996) (see Figure 1.4.1). Following translation of the hCG 
mature RNA (i.e.: any non-coding regions have been removed) into polypeptides, the 
peptides are further processed by glycosylation of the subunits. This is followed by 
cleavage of the signal peptide, folding of the subunits into their three-dimensional 
shape, formation of the ap  complex, attachment of the O-linked oligosaccharides 
and ‘trimming’ of the N-linked oligosaccharides (Cole and Kardana, 1992). This is a 
complex biosynthetic pathway which results in the secretion of biologically active 
hCG (holo hCG). This pathway is not ‘fixed’ so that besides holo hCG and free a  
and P-subunits, aberrant glycosylation products can appear in the circulation, some 
of which have clinical significance. In recent years, hCG or free P-subunits missing
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the peptide bonds 44-45, or 47-48 in ß-hCG, called nicked hCG (see Fig. 1.4.1) have 
been detected in serum and urine (Bischof et al., 1997; Kardana and Cole, 1994; 
Col ze ta l., 1991 andNishimura et al., 1988).
R i.  > -- A  A A A
Holo hCG Different Glycosylations
□ l? <m >
A A A
Nicked hCG Holo hCG missing C terminus
> -
A A A
Free ß-hCG Free ß-hCG missing 
C terminus
> .T d
A A A
Nicked free ß-hCG
HP
ß-hCG core fragment
D <
Free a-hCG
■<
■<
Represents a-subunit
Represents ß-subunit
Represent
glycosylated sites
Figure 1.4.1: Schematic representation o f the known isoforms o f the hCG 
molecule. Underneath each diagram is the relevant isoform name. A diagram key is 
included (see bottom right-hand comer). (Adapted from Cole et al., 1993b).
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1.5 Regulation of hCG Biosynthesis
hCG secretion exhibits a 24 hour rhythm in the first trimester of pregnancy during 
which the hCG levels are secreted in a pulsative m anner. A nadir is observed at 1400 
hours (12% below the 24 hour mean), followed by a progressive rise in the evening, 
reaching a peak at 0700 hours. hCG secretion is related to placental gonadotropin 
releasing hormone (GnRH). When an in vitro trophoblast perfusion system is used, 
hCG is released in 11 to 22 minute pulses where the pulse frequency and amplitude 
are linked to the release of placental GnRH (Gabbe et al., 1996).
1.5.1 cAMP
It has been demonstrated that hCG secretion can be stimulated in purified 
cytotrophoblasts in culture using 8-bromo-cAMP. This is followed by an increase in 
mRNA levels encoding for the a  and (3-subunits of the hormone. The demonstration 
that cytotrophoblasts possess adenylate cyclase activity identifies the adenylate 
cyclase-cAMP pathway in the activation of cellular responses to stimulatory agents 
in vitro. Stimulatory agents in vivo which may trigger cytotrophoblasts’ adenylate 
cyclase are not known.
1.5.2 Gonadotropin Releasing Hormone
The cytotrophoblasts of the placenta produce and secrete gonadotropin-releasing 
hormone (GnRH). Similar mechanisms of regulation act on placental and 
hypothalmic GnRH. It has been observed that circulating GnRH levels are higher in 
pregnant women than in non-pregnant women. Placental GnRH stimulates hCG 
release through a dose-dependent paracrine mechanism (see Figure 1.5.1, page 15). 
The time course and pattern of serum GnRH levels are parallel to those of hCG and 
are correlated with placental GnRH content, suggesting a placental origin for 
circulating GnRH and a regulatory role for GnRH in the secretion of hCG from the 
placenta. The addition of a GnRH antagonist reduces hCG secretion in placental cells 
in culture and reverses the stimulatory effect of GnRH. First trimester placental 
trophoblasts in culture appear to be more sensitive to GnRH stimulation of hCG 
secretion than those of late pregnancy; this is possibly due to the relative reduction of
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trophoblasts as the placenta transforms into an organ of transfer during gestation 
(Gabbe et al., 1996). There also appears to be a local regulatory loop between the 
secretion of GnRH, hCG and placental steroids (see Figure 1.5.1). Evidence for this 
theory is seen in the stimulation of progesterone production by hCG, while GnRH 
inhibits the formation of progesterones and oestrogens.
VIP
Insulin
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Prostaglandins
Progesterone
"N
Activin
Opioids
/
Cytokines
Syncytio- Cytotrophobiast
Trophoblast
Figure 1.5.1: The regulatory system o f GnRH and hCG between cytotrophoblasts 
and syncytiotrophoblasts. The autocrine and paracrine modes of regulation of 
GnRH by inhibin (inhibitory) and activin (stimulatory) are depicted (Adapted
from Chamberlain, 1995).
1.5.3 Inhibin and Activin
Inhibin and activin, which are synthesised in the cytotrophobiast, may also partake in 
the regulation of hCG secretion by modulating GnRH activity. Activin is a 
nonsteroidal regulator, which stimulates the secretion of FSH. The actions of activins 
are the opposite of those of inhibin. Inhibin contributes to the control of 
gametogenesis, embryonic and foetal development and haematopoiesis. The actions 
of inhibins are opposed by activins (Dorland, 1994). Adding inhibin antiserum to 
placental cell culture causes a significant increase in hCG secretion with a
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simultaneous rise in GnRH release. This suggests an inhibitory action by inhibin on 
hCG secretion. The suppressive effect of inhibin on hCG secretion only acts in the 
placenta in the later part of pregnancy and not in the first trimester. An important 
point to note is that addition of purified inhibin to cultured placental cells has no 
effect on either hCG or GnRH release. Thus, placental inhibin may function as both 
an autocrine and paracrine factor in regulating hCG via GnRH.
Activin has the reverse effect to inhibin (see Fig. 1.5.1). By adding purified activin to 
placental culture the GnRH-induced release of hCG is augmented. It has also been 
observed that this effect can be significantly reduced by the addition of inhibin. It 
thus appears that placental GnRH plays a fundamental role in the regulation of hCG 
secretion, but the functional activity of GnRH seems to be regulated by inhibin 
(inhibitory) and activin (stimulatory).
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1.6 Function of HCG
Biologically inactive, isolated hCG is present in normal and pathological states. 
Biologically active hCG is present normally only during pregnancy, secreted by the 
syncytial trophoblastic cells of the placenta (Braunstein et a l, 1976). The 
preimplantation embryo produces hCG and represents a signal of maternal-embryo 
dialogue at the time of implantation. The role of hCG is of importance in the 
endocrine control of early pregnancy in maintaining an ovarian source of steroid 
hormones until the placental endocrine activity is capable of replacing it (Reid et al, 
1972).
One of the functions of hCG is to stimulate the growth and action of the corpus 
luteum, thereby stimulating enhanced production of progesterone and relaxin by the 
ovaries. This luteotropic activity of hCG rescues corpus luteal function that 
otherwise would regress. Concomitantly, there appears to be a heightened production 
of inhibin by the corpus luteum of early pregnancy, thereby supressing pituitary FSH 
secretion. It has also been proposed that hCG may suppress LH secretion by the 
maternal hypothalamic-pituitary unit (Cunningham et a l, 1989). It is known that 
hCG possesses intrinsic thyrotropic activity, binding to the TSH receptor and 
stimulating iodide uptake and DNA synthesis in the thyroid gland (Gabbe et al, 
1996).
hCG enhances placental progesterone biosynthesis and provides gonadotropic and 
adrenotropic input to the foetus during the first trimester of pregnancy (Reid et al, 
1972). Of special interest is the stimulation of Leydig cells in the male foetus during 
organogenesis to produce testosterone, which, in turn, is instrumental in the 
development of the external genitalia. Foetal testicular testosterone secretion is 
maximum at the same time in gestation as the maximum levels of hCG secretion. 
Thus, at a critical time in male foetal development, hCG serves as an LH surrogate 
on foetal testes to promote testosterone synthesis and secretion and, thereby, male 
sexual differentiation. When testosterone is converted to dihydrotestosterone by 
5-a-reductase in the external genital tissue the development of male genitalia is 
determined (Gabbe et al, 1996) (see Figure 1.6.1).
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Adult human ovaries primed with FSH can be induced to ovulate by hCG. hCG is, 
therefore, often used therapeutically, in combination with FSH, as an LH surrogate in 
the treatment of infertility caused by anovulation due to hypogonadotropic 
hypogonadism (Cunningham et al., 1989).
Signal
Implantation to 10 weeks gestation
Figure 1.0.1: Diagrammatic representation of the functional role o f hCG in the 
maternal and foetal compartments during the first 10 weeks o f gestation. The 
GnRH/inhibin/activin system of the cytotrophoblast and the biosynthesis ofhCG in 
the syncytiotrophoblast are depicted by ovals (Gabbe et al., 1996).
i
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1.7 Levels of HCG
1.7.1 Normal Pregnancy
hCG appears in the maternal circulation soon after implantation, as early as 6-10 
days after conception (Cole, 1999b and Braunstein et a l, 1978) and its levels rise 
rapidly with a doubling time of 30.9 hours. This exponential rise reaches a peak of 
5,000-150,000 IU/L at the end of the first trimester, making hCG an ideal indicator 
for early confirmation of pregnancy (Cole, 1999b). This is followed by a fall to 
between 2,000-50,000 IU/L where it remains until the end of pregnancy (Cole, 
1999b). The levels of hCG in the second and third trimesters are approximately one 
third to one sixth of peak hCG levels (see Figure 1.7.1). There is a parallelism 
between values in serum and urine, there being an equivalent unitage per litre of 
serum and urine per 24 hours (Loraine and Bell, 1966). The levels of the a  and P- 
subunits of hCG are substantially different from those of the intact molecule (see 
1.7.4.2). The levels of the p-subunit are low or undetectable, while the a-subunit 
increases gradually until about 36 weeks gestation when a plateau is reached 
(Cunningham et a l, 1989). In twin pregnancies hCG levels 4-5 weeks after the last 
menstrual period (LMP) are more than two-fold higher than in singleton (one child) 
pregnancies. There are also significantly higher levels of hCG detectable in women 
with hydatidiform moles and choriocarcinoma (Reid et al, 1972).
1.7.2 Ectopic pregnancies
Abnormal pregnancies can be predicted by examination of hCG levels. In abnormal 
(ie: ectopic) pregnancies hCG may fall below 200 IU/L. A very high concentration of 
hCG is seen for molar pregnancies following surgery. Clinical observations have 
shown that tubal pregnancies develop individually different levels of P-hCG (Klein 
et a l, 1995). A pregnancy can be considered abnormal if two or more serum samples 
collected at two-week intervals show hCG levels above or below normal expected 
levels. Those with ectopic or those whose pregnancies are destined to terminate in a 
first or second trimester spontaneous abortion will have abnormally low serum hCG 
levels (Braunstein et a l, 1978).
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W eeks after last menstrual period
Figure 1.7.1: Graph o f mean serum hCG levels (IU/L) throughout normal 
pregnancy (i.e.: 39 weeks) (Braunstein etal., 1976).
1.7.3 Non-pregnant Levels
hCG is not unique during pregnancy. A remarkable characteristic of hCG is its broad 
distribution. It has been found in most, if not all, human tissues (Braunstein et al., 
1978 and Cunningham et al., 1989) and in the urine and serum of nonnal men and 
women and in many types of cancer cells. Free a  and P-subunits have been detected 
in the human pituitary gland. In normal nonpregnant women the median level of 
hCG increases more than tenfold from reproductive age (median 0.05 IU/1) to post­
menopausal age (median 1.1 IU/1).
1.7.4 Levels of various isoforms in normal pregnancy and disease
There are three groups of hCG configuration (refer to Figure 1.4.1, page 13) that 
effect the performance and interpretation of hCG assays.
1.7.4.1 Dimeric hCG
In the first trimester of pregnancy there is a sharp rise in the levels of dimeric hCG 
and both subunits, a-hCG and P-hCG. The dimeric hCG is usually measured for the 
diagnosis and monitoring of early pregnancy, either directly by sandwich-type assays
or indirectly by the detection of P-hCG (Gabbe et al, 1996). hCG is detectable in 
serum in approximately 5% of patients by 8 days after conception and in virtually all 
patients at day 11 (Cunningham et al, 1989). Ectopic pregnancies or spontaneous 
abortions are suspected if there is any deviation from the normal doubling pattern. 
Therefore, if the hCG levels fail to rise 66% in two days further investigation is 
required to determine if the patient is presenting with one of the above conditions.
1.7.4.2 Free a-hCG and P-hCG Subunits
Free a-hCG subunits are detectable at gestational week 6 and rise in sigmoid fashion 
to peak at gestational week 36 (Gabbe et al., 1996). The levels of free a-hCG 
subunits are rarely used for clinical interpretation; however, it should be noted that 
the levels of this subunit are elevated in persistent gestational trophoblastic neoplasia 
and appear to be significantly lower in women with insulin-dependent diabetes. Free 
P-hCG can be detected as early as 7 days after implantation. Persistently elevated 
levels of free P-hCG in patients with trophoblastic disease may be an indication of a 
poor prognosis.
1.7.4.3 Nicked hCG Subunits
Nicked hCG is a hCG subunit with deleted peptide linkages as outlined in section 
1.4. In the P-subunit these deleted linkages are between residues 47-48 and between 
44-45 or 46-47 (Hoermann, 1996). In the a-subunits they are found between 70-71. 
It has been observed that as nicking increases receptor binding decreases 
(Cunningham et al., 1989), making nicked hCG less biologically active. Much 
dissimilarity has been observed between the levels of hCG detected for the same 
samples on various assays, this is due to assays detecting subunits such as the free P- 
subunit, nicked hCG or the P core fragment. Many of these assays will give higher 
than expected readings by picking up these isoforms of hCG.
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1.7.5 hCG International Standards
The concentration of hCG may be measured in IU/L or ng/mL in urine or serum. 
The relationship between IU/L and ng/mL is expressed as:
1 ng/mL = 9 to 11 IU/L 
The International Unit (IU) is based on hCG bioassays, with the standard being the 
gonadotropin maintained at the WHO in London. (Flynn and Seifer, 1996). Two 
World Health Organisation (WHO) standards for hCG are commonly encountered 
while running hCG assays. These standards are utilised for reference, in order to 
ensure reproducibility and correlation between all of the various hCG assays on the 
market. The first of these standards is the Third International Standard (3rd IS) which 
is the same as the First International Standard (1st IS). Most assays are now 
calibrated against one of these two standards. Clinical specimens tested using the 
older, relatively impure Second International Standard (2nd IS) typically yield results 
that are about 50% lower. This is particularly important for assays which recognise 
the (3-subunit part of the molecule as the 2nd IS was quite highly contaminated with 
free a  and P-subunits.
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1.8 Clinical Applications of HCG Measurement
1.8.1 Pregnancy Diagnosis
Using very sensitive hCG assays, hCG is first detectable in the maternal blood and 
urine at approximately 8 to 11 days after conception. A sensitivity of approximately 
0.1 to 0.3 IU/L is required due to the low levels of hCG. The concentration of hCG 
increases exponentially approximately one week after conception. hCG levels rise 
rapidly with a doubling time of 1.5 to 2.5 days for the first 6 weeks of gestation 
(Klee, 1994 and Flynn and Seifer, 1996). Most of the current home use tests have a 
sensitivity of 25 IU/L and, therefore, would not show a positive result until 12-13 
days for most subjects (Gabbe et al., 1996). False positive results are common in the 
range 5-25 IU/L. Such false positive results can occur in perimenopausal and 
postmenopausal women because of endogenous pituitary hCG secretions. This 
phenomenon should, therefore, serve to discourage the current trend in rapid home 
tests to detect 10 IU/L. In practice, a level less than 5 IU/L can be confidently stated 
as negative and a level exceeding 25 IU/L can be confidently stated as positive. If 
any uncertainty arises, repeating the test 2 days later normally shows an increase in 
hCG levels, confirming a pregnancy.
1.8.2 Ectopic Pregnancy
Since 1970 the incidence of ectopic pregnancies has increased six fold in the United 
States (Flynn and Seifer, 1996). Approximately 10% of all maternal mortality can be 
attributed to ectopic pregnancies and only one third of women who have sustained an 
ectopic pregnancy will go on to deliver a live-born infant. The reported risk of 
sustaining a subsequent ectopic pregnancy ranges from 4% to 25% (Grimes, 1994). 
Up to day 10 after ovulation, the hCG levels in ectopic pregnancy are similar to those 
seen for a normal pregnancy. However, these levels then begin to decline to one fifth 
to one fiftieth of the median levels of hCG in a normal intrauterine pregnancy of 
comparable duration (Cole, 1999b). Direct information to diagnose ectopic 
pregnancy is available by comparing hCG concentrations with the results of 
transvaginal ultrasonography. Klee (1994) recommended that if an embryo is large
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enough to produce more than 1600 IU/L hCG, the gestational sac should be visible 
on transvaginal sonography. Therefore, if  the levels of hCG are >1600 IU/L and 
there is no evidence of a gestational sac in the uterus, the presence of an ectopic 
pregnancy should be suspected. This evidence combined with symptoms such as 
missed period, lower abdominal tenderness, or an adenexal mass and vaginal staining 
are good indicators of ectopic pregnancy.
1.8.3 Spontaneous Abortion
In patients with spontaneous abortion the serum hCG levels fall or fail to double. 
Serial quantitative titres of J3-hCG are indicative of an abnormal pregnancy if a 
plateauing or a decrease from the expected doubling time is displayed by a normal 
intrauterine pregnancy. The incidence of early pregnancy loss has been cited as high 
as 31% (Wilcox et al., 1988). HCG concentration reaches a peak two weeks after 
conception at 10-100 IU/L, then rapidly declines (Cole, 1999b). After spontaneous 
abortion the serum (3-hCG levels fall to near zero within 9 to 35 days, with a median 
of 19 days. This is much less than for induced abortion in which titres become non- 
detectable within 16 to 60 days, with a median of 30 days. This is attributed to the 
amount of residual vital trophoblastic tissue remaining after evacuation of the uterus 
(Steier, 1984).
1.8.4 Gestational Trophoblastic Disease
Gestational trophoblastic disease (GTD) (choriocarcinoma, hydatidiform mole) 
occurs in approximately 1 in 1000 pregnancies. Clinical presentation may include 
vaginal bleeding after a missed period, discrepancy between uterine size and 
gestational age, nausea, vomiting, pre-eclampsia, thyrotoxicosis and neurologic 
symptoms. A classic case of GTD would be a woman with an enlarged uterus and 
positive p-hCG, without foetal heartbeat (Flynn and Seifer, 1996). Generally, in 
GTD abnormally high levels of hCG are encountered, mostly intact hCG; however, 
one third of patients with GTD may have hCG titres that are below the sensitvity of 
the conventional pregnancy tests (Saxena, 1983). The concentration of hCG 
corresponds to the mass o f the viable tumour which is useful to monitor the effect of 
surgery or therapy (Klee, 1994). Patients with GTD also exhibit higher than normal 
levels of free (3-hCG (2-10% of intact hCG level); nicked hCG after therapy or
24
surgery (up to 100% of hCG molecules) and possibly higher proportions of 
hyperglycosylated hCG (up to -40% of hCG molecules) (Cole, 1999b).
1.8.5 Testicular Tumours
hCG levels in serum are useful in monitoring the efficacy of treatment for 
nonseminomatous germ cell testicular tumours. Serial measurement of both hCG and 
a-fetoprotein (AFP) is the most sensitive gauge for monitoring treatments. Both hCG 
and AFP should be measured as some tumours only produce one of these markers. It 
is also important to detect both intact hCG and (3-hCG as some tumours may only 
produce select forms (Klee, 1994).
1.8.6 Screening for Foetal Down’s Syndrome
hCG levels are elevated in women carrying a foetus affected by Down Syndrome. 
The median serum hCG and free (3-hCG level in a Down Syndrome pregnancy is 
twice the level in a normal pregnancy (Cole, 1999b). Generally these measurements 
are used in combination with maternal age, serum AFP, unconjugated estriol, 
pregnancy associated protein A and inhibin to provide a more accurate diagnosis 
(Cole, 1999b and Haddow et al., 1998). Using such serum analytes, two thirds of 
affected foetuses can be identified with a 6% false positive rate. It has been 
suggested that p-hCG is a superior marker for Down’s Syndrome (Gabbe et al., 
1996). Recently, a potentially more accurate indicator of Down’s Syndrome 
pregnancies in the second trimester has been reported. This marker is 
hyperglycosylated hCG, the levels of which are nine fold higher than seen for normal 
pregnancies (Cole, 1999b).
25
1.9 Pregnancy Diagnosis and Monitoring
The term ‘pregnancy test’ is actually a misnomer, since most of the assays described 
in this thesis measure the hormone hCG and not the presence of a foetus. There are a 
variety of techniques available for the both the qualitative and quantitative detection 
of hCG. Section 1.9.1-1.9.5 describes some of the assay methods, which have been 
used for the detection of hCG. One step rapid hCG assays are described in greater 
detail in section 1.10.
1.9.1 Precipitation Assays
Precipitation assays were the first immunoassays to be developed. Agglutination, 
nephelometric and turbidimetric immunoassays are examples of precipitation assays,
tilwhich are still in use today, albeit to a lesser extent than in the first half of the 20 
century. These assays all share a common endpoint, the direct detection of an 
insoluble immune complex. When a soluble antigen and its antibody are in contact in 
solution, the resultant antigen-antibody complexes may become insoluble and 
precipitate. Nephelometry, the measurement of scattered light, provides a means of 
quantifying immunoprécipitation reactions. A variation of this method, called 
nephelometric inhibition, is used for the measurement of haptens. Investigators are 
pursuing the use of this technique for the measurement of hormones (Albertson and 
Swanson, 1996).
Particle-enhanced immunoassays, employing inert solid phases such as covalently 
linked latex beads or erythrocytes are used to increase the sensitivity of these assays. 
The basis of these assays is the measurement of the agglutination of the antigen and 
its corresponding antibody as a function of the concentration of one of these 
components. Currently, there are commercially available kits and automated 
instrumentation systems for either the qualitative or semi-quantitative p-hCG assay 
(Albertson and Swanson, 1996). The haemagglutination inhibition (HAI) and latex 
particle agglutination inhibition assays belong to this group and are discussed since 
they represent commonly used pregnancy tests.
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In the HAI assay, erythrocytes coated with hCG are incubated with anti-hCG serum 
and the patient’s urine. In pregnancy, the hCG in the urine neutralises the hCG 
antibody and thus no agglutination occurs. Agglutination will occur in the absence of 
hCG in the urine which results in a uniform film at the bottom of the test tube. The 
assay time for HAI is approximately 2 hours. LAI is similar in principle to HAI, 
using hCG-coated latex particles instead of hCG-coated erythrocytes. Most of these 
assays are carried out on glass slides and take only a few minutes to perform (e.g.: 
pregnancy test from Cortez Diagnostics, refer to Table 1.10.1, page 37) (Flynn and
Seifer, 1996).
1.9.2 Radioimmunoassay (RlA)
Radioimmunoassays (RIA) were first developed for the detection of hormones and 
are known to be sensitive, specific and straightforward to perform. The basic 
principle of RIAs is the competitive inhibition of the binding of a labelled antigen to 
a ‘specific’ antibody by the same unlabelled antigen, which is contained within 
samples. A variation on this technique is the immunoradiometric assay (IRMA). 
These assays differ from the classic RIA in that the antibody is labelled instead of the 
antigen. The IRMA is generally of the ‘sandwich’ format. Despite the advantages of 
these assays there are concomitantly several drawbacks with these assays. These 
include the short shelf-life of the radioactive tracer component, long assay times 
(generally in the region of several hours), the cost of equipment for measuring the 
gamma or beta particles emitted, the exposure of users to radiation and the 
environmental problem of isotope disposal (Albertson and Swanson, 1996).
Traditionally this clinical laboratory technique has measured hCG through its P- 
subunit. RIA’s measure the combined concentrations of intact hCG and free P- 
subunits. hCG is labelled with a radioactive isotope and is displaced from binding 
sites on an anti-hCG antibody by unlabelled hCG in the patient’s serum. If all the 
labelled hCG is displaced, the patient’s serum contains a high concentration of hCG. 
These assays are quantitative and are useful in the diagnosis of ectopic pregnancy, 
spontaneous abortion or gestational trophoblastic neoplasia, as they are suitable for 
monitoring doubling times (Gabbe et al., 1996). Despite the disadvantages associated 
with these assays they continue to be relatively popular, particularly the IRMA tests, 
for the quantitative detection of hCG.
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1.9.3 Immunoradiometric Assay (IRMA)
In IRMAs the sandwich principle is used to detect dimeric hCG. These assays are 
quick to run, usually -30 minutes and are very sensitive. IRMAs utilise a radioactive 
antibody to detect hCG in the serum. Anti-hCG antibodies are bound to a test tube, 
the patient’s sample is added and a second labelled antibody binds to the hCG- 
antibody complex already bound to the test tube. The amount of hCG in the patient’s 
sample is therefore proportional to the amount of labelled antibody bound to the test 
tube. The hCG molecule is thus, ‘sandwiched’ between two antibodies. Some 
IRMAs are based on the use of antibodies against the a  and (3-subunits of hCG. 
These assays have been known to exhibit significant cross-reaction with both LH and 
FSH. Antisera against the (3-subunit result in an IRMA that is much more specific for 
hCG (Flynn and Seifer, 1996).
1.9.4 Enzyme-Linked Immunosorbent Assay (ELISA)
The evolution from radiometric to nonradiometric assays is best typified by the 
current widespread use of various enzyme immunoassays (EIA) or enzyme-linked 
immunosorbent assays (ELISA). This move from isotopic to nonisotopic 
methodologies is as a result of the factors outlined in section 1.9.2 with respect to the 
disadvantages involved in the use of radiometric assays.
The principle used in these assays is the same as for IRMAs. These use an enzyme- 
labelled second antibody instead of a radioisotope-labelled second antibody. This 
enzyme-labelled antibody can be detected by a colour change once binding has 
occurred and a substrate is added. The basic ELISA procedure first described by 
Engvall and Perlman (1971) has been subject to many modifications and 
refinements. An example of a heterogenous ELISA procedure is the ‘sandwich 
antigen format’, which entails ‘sandwiching’ the antigen between two specific and 
different antibodies (Albertson and Swanson, 1996). The primary or capture antibody 
is usually linked to a solid phase matrix, for example, a microtitre plate (96 wells) or 
a polystyrene tube. A separate secondary antibody is conjugated to the enzyme 
tracer. With respect to hCG EIAs or ELISAs, it is usual that the antibody attached to 
the solid phase (the microtitre plate) would be directed toward an epitope of the a-
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subunit of hCG and the secondary (labelled) antibody would be directed at an epitope 
of the P-subunit (Flynn and Seifer, 1996).
Although not as precise, these assays are sensitive and quick and are ideal for early 
diagnosis of pregnancy as they can detect concentrations as low as 10 IU/L. More 
rapid versions of such ‘sandwich’ assays are available as home pregnancy kits for the
qualitative or semi-quantitative detection of hCG. The principle of these assays,
colloidal gold-based in particular, will be described in more detail in section 1.10 and 
1. 11.
1.9.5 Fluoroimmunoassay (FIA)
Fluoroimmunoassays (FIA) and immunofluorometric assays (IFMA) are other 
examples of nonradiometric assays and were developed concurrently with EIAs and 
ELISAs. These particular assays are also known for possessing good sensitivity, 
being inexpensive, stable and safe for the end user. FIAs and IFMAs are based on the 
labelling of the immunoreactants with fluorescent probes. This is by no means a new 
technique, as early as 1941 Coons et al. described the immunological properties of 
antibodies containing fluorescent groups (Albertson and Swanson, 1996). This 
technique is also a ‘sandwich’ assay, using a fluorescent label on the secondary 
antibody. The amount of fluorescence emitted is proportional to the concentration of 
hCG in the sample. Levels as low as 1 IU/L can be detected using this method and it 
takes approximately 2 to 3 hours to complete.
1.9.6 Chemiluminescence assays
The chemiluminescent assay also consists of a similar format to that of the RIAs, 
EIAs and FIAs, utilising a chemiluminescence end point. Chemiluminescence differs 
from fluorescence in that it involves excited state formation as the product of an 
exoergic chemical reaction. The excited state product molecule relaxes to a ground 
state and in so doing emits photons. The photoefficiency of this reaction or the 
number of photons emitted per molecule of reactant is called the chemiluminescence 
quantum yield. Chemiluminescent molecules (e.g.: luminol) are covalently linked to 
either the assay antigen or antibody. The acridinium derivative labels are favoured 
for gonadotropin assays (Albertson and Swanson, 1996).
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1.10 Disposable immunoassay devices
The last decade has seen an enormous increase in the availability and range of point 
o f care (POC) and over the counter (OTC) products. One of the biggest success 
stories of this branch of immunodiagnostics is the pregnancy test. The current trend 
in immunodiagnostics is to develop less time consuming, cheaper and more user- 
friendly tests, which would be particularly suited for use in the home, doctor’s office 
or health clinic. Such assays also lend themselves to emergency situations, in 
ambulances and casualty departments where a quick diagnosis is often required. 
Similarly, these tests have application in third world countries where, ordinarily, 
neither the necessary finance nor equipment is available to carry out elaborate 
clinical assays. Additionally, many of these assays use unprocessed samples, which 
are then absorbed within the test device during testing. This requires less 
manipulation of potentially infectious samples and ensures a reduced risk of 
exposure to infectious diseases during disposal. This is of particular advantage to 
areas where the rate of infectious disease is high and/or the presence of proper 
disposal facilities for hazardous materials is negligible.
1.10.1 Classification of devices
Any immunoassay which is to be sold for the POC or OTC sector must incorporate 
the following design features: reproducibility, low cost, short assay time, an internal 
assay control, the use of unprocessed sample, no requirement for either specialised 
equipment or skilled operators, be user-friendly, no requirement for refrigeration and 
have as few steps as possible within the assay.
According to Price et al. (1997) there are four types of disposable devices:
© Encapsulated wet chemistry.
For this device all of the components of the test, including any diluents, are 
encapsulated in a complex disposable plastic unit, which only requires the addition of 
sample to run the assay. Basically, this assay format directly mimics the fluidics of a 
wet chemistry immunoassay. In general, these devices require an instrument for 
reading a photometric end point of the test reaction.
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© Simple immobilised analyte capture.
Typically, this format involves the immobilisation of a capture antibody to a solid 
porous matrix. The sample is added to this and additional reagents are added to 
detect captured antigen analyte. The liquid phase is trapped within the porous matrix. 
These assays are sometimes termed ‘flow-through’ or ‘cross-flow’ devices.
® Chromatographic and liquidic circuits.
With this assay format all reaction components are impregnated or immobilised on a 
porous solid phase and are brought into contact with the samples in sequence, 
sometimes after addition of a diluent. The impregnation/immobilisation of the test 
components obviates the need for the addition of any critical reagents. These assays 
may be termed ‘lateral-flow’ devices.
(D Immunosensors
Antigen is captured in these assays by addition of the sample to the surface of the 
biosensor. Upon binding of the antigen to the sensor, the antigen is directly detected 
by the change in the immediate environment of the surface of the sensor.
Devices of either class ® or ® are of most interest for the purposes of this thesis, 
since the majority of POC and OTC pregnancy tests fall within these categories. 
Immunosensor assays are still somewhat complex in comparison to the relatively 
straightforward ‘flow-through’ or ‘lateral-flow’ devices and do not lend themselves 
to the target sector of the market relevant to this thesis, due to their requirement for 
equipment. The wet chemistry devices are similarly unsuitable for this market due to 
the general prerequisite for a photometric reader for the assay end point.
Early disposable immunoassay devices for pregnancy testing were typically based on 
latex agglutination or colorimetrically monitored enzyme-labelled conjugates and 
occurred either on a slide or within a test tube (Flynn and Seifer, 1996). These assays 
were fraught with problems in that the interpretation of results was very ‘operator- 
dependent’. This problem is now eliminated with the new one-step devices, which 
are easy to interpret and contain their own in-built procedural control.
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1.10.2 ‘Lateral-flow’ and ‘Flow-through’ devices
The majority of current disposable devices rely on the binding of at least one reagent 
to a solid support. In general, a membrane (e.g.: nitrocellulose) is used. This is true 
for both the ‘lateral-flow’ and ‘flow-through’ devices.
‘Lateral-flow’ devices
Immunochromatographic or ‘lateral-flow’ devices involve the unidirectional flow of 
a pre-impregnated antibody-coated particle (e.g.: latex or colloidal gold particles) 
along a membrane. These coated particles capture the antigen of interest, if present, 
and subsequently are captured by an antibody, which is immobilised in certain 
defined areas of the membrane. Since the antigen/antibody-coated particle complex 
is concentrated in only defined areas of the membrane a signal is generated, which 
can be seen by the naked eye (see Figure 1.10.1). The construction of the ‘lateral- 
flow’ device is dependent on the end use of the test. These devices may be held 
directly in the sample without any plastic housing. They can also be constructed 
within plastic ‘cassette’ housing to which the sample is directly added. The ‘wick’ 
device is a combination of both of these formats in that the wick of the test is 
immersed directly in the sample but an outer plastic housing, which lends robustness 
to the assay, protects the device. The construction of a ‘lateral-flow’ test is described 
and illustrated in section 1.11.
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Y Immobilisedantibody Antigen/Antibody conjugate complex
Figure 1.10.1: (a) Sample addition to the test strip, (b) Antibody conjugate binds 
the antigen whilst progressing up the strip, (c) A ‘sandwich’ is formed with the 
antigen/conjugate complex and the antibody immobilised in the membrane.
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‘Flow-through’ devices
‘Flow-through’ devices are actually multi-step procedures, which have proven to be 
very successful in the laboratory and outpatient clinic. With these assays the capture 
antibody is immobilised onto a membrane, which is attached to an absorbent 
reservoir (see Figure 1.10.2 below). The sample is allowed to flow through the 
membrane and is followed at defined time intervals by the addition of set volumes of 
the test reagents. One of these reagents is an enzyme-labelled antibody conjugate. If 
the antigen is captured, which yields a colour change, the intensity of the colour is 
proportional to the concentration of the antigen being detected (Price et al, 1997). 
These devices supply a qualitative result when visually interpreted. A semi- 
quantitative result can also be achieved by using a calibrated colour comparison 
chart. ‘Flow-through’ devices have also been used to provide quantitative results by 
the use of a reflectance meter (Price et al, 1997).
f  ?  V 6 o o o
(a) (b) (c)
Y Capture antibody Antigen Enzyme conjugate
| Membrane [ ^ j  Absorbent reservoir
Figure 1.10.2: Schematic representation of a ‘flow-through’ device, (a) Addition of 
sample to the device, (b) An enzyme conjugate solution is added to the test and 
incubated fora defined period o f time, (c) Visualisation of the enzyme label is by 
addition of a substrate, which produces a coloured product (denoted by the arrow).
An example of a ‘flow-through’ device is the Cambridge Biotech recombigen HIV- 
1/HIV-2 test. This test can be used to simultaneously detect antibodies to both the 
HIV-1 and HIV-2 viruses. The test is made up of a small asymmetrical plastic 
chamber, which contains an absorbent reservoir to which glass fibre membrane is 
fused at the top. Coated on the surface of this membrane, in three discrete circular
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spots, are antigen or human IgG-coated latex beads. These spots are not visible to the 
user before addition of reagents. 7 drops o f human serum are added to the centre of 
the device, followed by 4 drops of conjugate solution. 800pl of wash buffer and 4 
drops of substrate solution are then added. This is incubated for 3 minutes and 400jil 
of stop solution is then added. The results are interpreted qualitatively, a negative 
result is indicated by the presence of the control spot only, which was coated with 
human IgG latex. A sample positive for HIV-1 will show 2 spots, one control and 
one which reacted with HIV-1 antigen-specific-coated latex beads. A similar result is 
obtained for HIV-2 positive samples, only with a different test spot, which had 
reacted with HIV-2 antigen-specific-coated latex beads, giving visible colour. Co­
infected or cross-reactive samples display 3 spots (see Figure 1.10.3) (Gosling, 
1996).
(a) (b) (c) (d)
Figure 1.10.3: Top view o f Cambridge Biotech HIV-1/HIV-2 ‘flow-through’ device.
Test and control spots are denoted by a blue spot, the shaded ring denotes the 
plastic housing of the device, (a) Negative result, showing the control spot, (b) HIV-1 
positive result, showing the control and HIV-1 spots, (c) HIV-2 positive result, 
showing the control and HIV-2 spots, (d) Co-infected or cross-reactive sample
result, showing all 3 spots.
The Trinity Biotech HIV-l/HIV-2 Serocard, while not a ‘flow-through’ device, does 
fall under the same category as ‘flow-through’ devices, i.e.: group ©, simple 
immobilised analyte capture. This test takes 7 minutes to run and serum, plasma or 
whole blood samples can all be used with this device. No sample pretreatment is 
necessary. Any anti-HIV-1 or anti-HIV-2 antibodies present in the sample are 
captured within 1 minute by the HIV-1 and HIV-2-specific peptides, which are 
immobilised on a discrete portion of the membrane. A goat anti-human IgG alkaline 
phosphatase conjugate solution is then incubated in the test and control ports of the
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device for 1 minute. The alkaline phosphatase then converts its substrate, BCIP, from 
a clear to a blue colour within 5 minutes. Results are interpreted semi-quantitatively.
1.10.3 Advantages and disadvantages of ‘lateral-flow’ and ‘flow- 
through’ devices
When choosing a format suitable for the development of a rapid pregnancy test, the 
advantages and disadvantages of both the ‘lateral-flow’ and ‘flow-through’ formats 
were examined.
1.10.3.1 ‘Flow-through’
One of the most important advantages of the ‘flow-through’ device is obviously, the 
ability to adapt these devices for qualitative, semi-quantitative or quantitative 
measurement of the analyte, while still maintaining a relatively ‘rapid’ assay time. 
However, this positive aspect of such assays is not amenable for use by the lay 
person at home in that the number of steps involved in running these assays are too 
great and would almost certainly lead to inaccurate results due to incorrect use of the 
device. It is no surprise to see from the list of pregnancy tests, currently on the 
market (see Table 1.10.1, page 37) that only three of the tests listed required four or 
more steps. Only one assay was described as a ‘flow-through’ device and this test is 
limited to use within the doctor’s office or in a laboratory situation.
1.10.3.2 ‘Lateral-flow’
From Table 1.10.1, page 37 it is clear that the majority of pregnancy tests on the 
market at the moment are ‘lateral-flow’ devices of either the cassette or wick 
formats. The popularity of these devices is due to the number of advantages this 
format possesses over the ‘flow-through’ device. With the ‘lateral-flow’ device the 
sample addition site is separate from the reactant surface. This allows for good 
separation of the sample, particularly for viscous samples such as serum, and also the 
antigen/antibody interaction is maximised as the entire sample volume comes in 
contact with the immobilised reactants. This is not so for vertical flow (‘flow- 
through’) devices where only some of the sample comes in contact with the 
immobilised reactants (see Figure 1.10.4). Typically, with ‘lateral-flow’ any 
contaminants within the sample are retained at the sample addition site, whereas for
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‘flow-through’ devices any contaminants remain on the membrane surface, this could 
potentially lead to non-specific reactivity with the reactants of the test.
(b)
Membrane
Figure 1.10.4: (a) Sample flow through a ‘lateral-flow’ device, (b) Sample flow
through a 'flow-through’ device
Sample
Discrete analyte spot
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Company Test
Name
Sample Format Assay
Time
Detection
Limit
Comments
Abbott
Laboratories
TestPack*  
+Plus™
Urine Cassette 5 min. >25 iU/L
ABI Surestep Urine/  
serum
Cassette 5 min. >20 IU/L
Aeon Biotech Pregnancy
test
Urine Strip 3-5
min.
> 25 IU/L
ANI Biotech Biocard
hCG
Urine Cassette &
Wick
5 min. > 25 IU/L
Chembio
Diagnostic Systems
HCG
STAT-PAK
Urine/
serum
Cassette 5 min. > 25 IU/L
Cortez Diagnostics 
Inc
Pregnancy
Test
Urine Indirect
Latex
3 min. 30-50 IU/L 2-8°C
storage
Direct
Pregnancy
Test
Urine Direct
Latex
3 min. > 30 IU/L 2-8°C
storage
Creschek Urine Cassette 5 min. > 25 IU/L
Serachek Serum Cassette 10 min. > 25 IU/L
Combichek Urine/
Serum
Cassette 3 min. > 25 IU/L 4step test
Hybritech' ICON®ll
hCG
Urine Flow
Through
Device
~5 min. > 20 IU/L 5 step 
test
Millenium Health
Resources Inc
i-hCG Test 
2000
Urine Cassette 3-5
mins
> 30 IU/L
Medlx Biotech 
Inc.
Contrast
hCG
Urine/
Serum
Cassette 4 min. > 20 IU/L
Mizuho USA Inc. Quick
Checker
Urine Wick 5 min. > 25 IU/L
Operon Stick hCG Urine Wick 5- 
10 mins
> 25 IU/L
Quldel Quickvue
hCG
Urine/
serum
Cassette 3 min. > 25 IU/L TL pink, CL 
blue
Randox Pregnancy 
Strip Test
Urine Cassette 5 min. > 25 IU/L
Rapid Diagnostic 
Technologies
Concise
PLUS
Urine Cassette 3-5
min.
>30
Savyon
Diagnostics
Quckstripe
hCG
Urine/
serum
Cassette 3-5
min.
> 25 IU/L
Syntron
Bioresearch
Quikpac II 
Onestep
Urine/
serum
Cassette 5 min. > 25 IU/L Latex
TECO
Diagnostics
One step Urine/
serum
Cassette &
Wick
2 min. > 25 IU/L
Unipath Clear Blue Urine Wick 1 min. Not given
Clearview 
hCG II
Urine Cassette 5 min. > 25 IU/L
Clearview 
hCG Duo
Urine/
serum
Cassette 5 min. >25 IU/L 
urine 
>50 IU/L 
serum
Vedalab Babycheck
-1
Urine/
serum
Strip 5- 
10 mins
> 10 IU/L
V-TECH Inc Target
hCG
Urine/
serum/
plasma
Cassette 3 min. > 50 IU/L 
urine.> 25 
IU/L serum/ 
plasma
6 step test
Wamer Lambert 1 step e.p.t Urine Wick 3 min. 1st day 
missed 
period
Table 1.10.1: List of OTC/POC pregnancy tests currently available. 
(TL = test line, CL = control line).
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1.11 Characteristics and manufacture of ‘lateral-flow ’ 
immunochromatographic assays
1.11.1 Feasibility of the development of a ‘lateral-flow’ hCG test
Section 1.10 illustrated the four different types of disposable immunoassays and 
provided reasons as to why a ‘lateral-flow’ assay was the most appropriate format for 
the development of a pregnancy test suitable for the POC/OTC sector of the 
immunodiagnostics market (see section 1.10.3). This sector is expected to be worth 
in excess of $6 billion by the year 2000, with 30% growth in POC diagnostics and 
25% growth for OTC products (Shine, 1998). Within Europe, there is a potential 
market value of £149 million available by 1999 if a test was to meet the criteria listed 
below (Kingshott, 1995).
1.11.2 Principles of the procedure
The test is based on the colloidal gold-linked immunosorbent assay technique and 
employs an anti-a-hCG antibody solution sprayed on the lower half of a 
nitrocellulose strip (test line) and a goat anti-mouse antibody solution sprayed on the 
upper half of the strip (control line) (See Figure 1.11.1, below).
Gold Conjugate Test Control
Membrane Pad
Figure 1.11.1: Schematic representation of a ‘lateral-flow’ test strip.
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The antibody lines are sprayed onto the nitrocellulose membrane during manufacture 
using an Acculine spraying machine, which is described in section 1.11.3.4. 
Nitrocellulose is a porous material, the properties of which are described in section 
1.11.3. The gold conjugate, which is dried onto a glass fibre pad (see Figure 1.11.1 
and 1.11.2), is pink/red in colour and each gold particle is coated with anti-(3-hCG 
antibodies. Once sample is added to the test strip it passes through the sample pad, 
some of the larger molecules present which might otherwise interfere with the assay 
remain on this pad, the resultant filtrate passes into the conjugate pad and rehydrates 
the gold conjugate. hCG present in the sample will bind to the gold anti-p-hCG 
conjugate forming a complex which laterally migrates up the test strip by capillary 
action (see Figure 1.11.2). These gold conjugate/hCG complexes will bind to the 
anti-hCG test line forming a sandwich (i.e.: a pink/red line is formed). Excess gold 
conjugate bound to hCG and any unbound conjugate continue to migrate up the test 
strip and deposition of these complexes appears in the form of a pink/red line at the 
control line site as they are bound by the anti-mouse IgG antibodies of the control 
line (see Figure 1.11.2). The visual formation of one or two pink/red lines allows for 
easy interpretation of results for negative (one line) or positive (two lines) specimens 
(see Figure 1.11.3). The control line should always appear and any test which does 
not possess a control line, should be considered invalid and should be repeated.
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Sprayed nitrocellulose 
membrane
(»)
Y Anti-hCG test line antibody Y Anti-mouse IgG control line antibody
<£ ° \ > °Anti-hCG gold conjugate hCG antigen Y  hCG/gold conjugate complex
Figure 1.11.2: (a) hCG test strip showing the gold conjugate impregnated pad and 
the nitrocellulose sprayed with anti-a-hCG antibody (test line) and anti-mouse IgG 
(control line), (b) Sample is added and the hCG antigen binds to the anti-fi-hCG gold 
conjugate and flows up the test strip, (c) The hCG antigen/gold conjugate complex 
binds to the test line antibody and any gold conjugate not bound to the hCG antigen 
binds to the anti-mouse IgG control line.
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Figure 1.11.3: Photograph showing the test device, which was developed for this 
thesis. The device on the left shows a negative result (one line) and the device on 
the right displays a low positive result (two lines).
1.11.3 Properties of the test components
1.11.3.1 Nitrocellulose Membrane
The type of solid phase chosen for use in a rapid immunoassay is critical. The solid 
phase should not be considered an inert part of the test as the surface and structure 
play an important part in the performance of the assay. The choice of the most 
suitable solid phase will ensure the desired flow of reagents (and, therefore, reaction 
time between the sample and test components) the mixing of constituents and the 
minimisation of non-specific binding. Additionally, the chemistry of the solid phase 
will determine the effectiveness of the immobilisation of capture reagents while also 
affecting the release rate of the impregnated (temporarily immobilised) mobile 
reagents (Price et al., 1997).
Typically, for rapid immunoassays the solid phase used is one of several different 
membranes. The binding of protein to the membrane is very much dependent on the 
polymer from which the membrane is made. Membranes can also be treated during 
manufacture sometimes with secondary polymers. These post-treatments can 
dramatically lower the ability of the membrane to bind protein. Table 1.11.1 shows 
the binding properties of three different types of membrane.
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Membrane Mechanism of binding
Nitrocellulose Electrostatic
Polyvinylidene Fluoride (PVDF) Hydrophobic
(Charge modified) Nylon (Ionic) Electrostatic
Table 1.11.1: Binding properties of three different membrane 
polymers (Millipore, 1996).
Nitrocellulose is the most suitable membrane for ‘lateral-flow’ immunoassays and is 
suitable for use with both colloidal gold and latex conjugates. It is used as the solid 
phase due to the following favourable characteristics which it possesses: © high 
protein binding, ® consistent ‘lateral-flow’ characteristics, ® in general, low non­
specific binding, © a smooth white surface for better visibility of results and © 
typically, uniform thickness.
Protein binding levels can be influenced by membrane formulation, the lateral flow 
rate of liquid up the membrane and the membrane pore structure. Performance varies 
with different proteins. As mentioned earlier, the polymer of a membrane affects its 
protein binding capacity, but this characteristic is also influenced by the porosity of 
the membrane (porosity is a measure of the amount of pores in a membrane). As the 
pore size of the membrane increases, the available polymer surface area declines and 
subsequently, the membrane binds less protein. Surface area decreases with 
increasing pore size (non-linearly), increases with increasing thickness (linearly) and 
increases with increasing porosity (non-linearly) (Millipore, 1996). Increasing pore 
size also has other effects, such as increased flow rates (Harvey, 1991). Slower flow 
rates in general increase the sensitivity of an assay since the test reagents are in 
contact with one another for longer periods of time. Faster flow rates allow a shorter 
assay time but typically at the expense of sensitivity. It is these pores which 
determine the flow rate of the assay.
Nitrocellulose membranes bind proteins by an electrostatic mechanism. The 
extemely strong dipole of the nitrocellulose ester interacts with the strong dipole of 
the peptide bonds of the protein (see Figure 1.11.4). Nitrocellulose membranes 
contain no acidic protons and are completely neutral. The binding of protein to the 
surface of the nitrocellulose is independent of the pH of the immobilisation solution 
for the capture antibody. However, it should be noted that the pH of this solution can
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have an effect on both the solubility and immobilisation efficiency of a particular 
protein (Millipore, 1996).
O Ö'
O
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Nitrocellulose ester Protein dipole
Figure 1.11.4: The structure o f nitrocellulose ester and 
protein dipoles (Millipore, 1996).
Another key area in protein binding to nitrocellulose is the actual application of the 
antibody solution to the membrane. If an efficient and optimised application process 
is not utilised, the intensity of the signal obtained will be diminished and hence the 
functionality of the test produced. There are four factors which influence the 
application of the antibody solution to the membrane: ® humidity effects, © wicking 
effects, ® the properties of the protein being applied and ® the drying conditions. 
For maximum reproducibility the humidity under which the membrane is being 
handled should be kept constant. The ideal humidity conditions for nitrocellulose 
membrane are between 45 and 55% RH. Wicking affects the application of protein in 
that depending on the membrane used, the width of the protein capture line is not 
necessarily as wide as the liquid line applied. The intensity of the result obtained for 
a given antibody concentration is inversely proportional to the line width (Jones, 
1999a). With regard to the protein being applied, the conditions that maximise the 
electrostatic interactions necessary for binding also lower the stability in solution of 
the protein. Generally, it is advised to avoid high salt content (although a certain 
amount is required) and the use of chaotropic detergents (e.g.: Tween® or Triton®) 
(Jones, 1999b). The ideal conditions to work at are around the isoelectric point of the 
protein. Finally, the drying of the sprayed membrane is critical. Failure to dry 
sufficiently could result in the capture antibody being removed from the membrane.
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1.11.3.2 Gold Conjugate
The 25 th anniversary of the introduction of colloidal gold as an immuno-specific 
probe in electron microscopy was celebrated in 1996. Due to its excellent detection 
qualities, colloidal gold has, since 1971, been used in immunoblotting, flow 
cytometry or to detect nitrocellulose-immobilised proteins. The use of colloidal gold 
in pregnancy tests and other rapid one-step assays is a relatively recent development. 
Colloidal gold conjugates are suitable for this type of test device as they are sensitive 
and specific, give good colour definition, are relatively inexpensive to use, easy to 
manufacture and have good stability on storage. The use of gold conjugates avoids 
the disadvantages involved in the use of radioactive labels, as gold probes are 
essentially non-toxic. Gold-based assays, as for all rapid one-step tests lend 
themselves to ‘on-site’ and ‘in-home’ use by virtue of their simplicity, speed and 
ease of use and interpretation. The properties and theory of colloidal gold use are 
discussed overleaf.
When viewed under a light or electron microscope colloidal gold sols are found to be 
made up of uniformly dispersed gold particles, which appear as solid spheres. It is 
possible to prepare suspensions of small particles of gold of known diameter 
(measured in nanometres). In general, gold particles of diameters of 15nm-40nm are 
used for nitrocellulose-based rapid assays. The processes involved in the interactions 
of gold particles with various macromolecules, which are exploited during gold 
conjugation procedures, are poorly understood. The surface of the gold particles in a 
stable sol is negatively charged due to overlap of the electrical double layer of each 
particle. This leads to gold-gold repulsion, thereby preventing aggregation of the 
particles. The preparation of a stable protein-gold complex is dependent on three 
interactions; ® the attraction which exists between the negatively charged gold 
particles and the protein molecule which in general possesses many positively 
charged sites, ® the adsorption of hydrophobic pockets on the protein to the metal 
surface and ® dative binding (i.e.: covalent binding) of the gold occurs if sulphydryl 
groups are present on the protein surface, (see Figure 1.11.5) (Hermanson, 1996). 
Another phenomenon, which comes into play during the labelling of macromolecules 
with gold, is the potential which exists for Van der Waals forces between the metal 
surface and other molecules.
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All gold conjugates are created by means of electrolyte-mediated coagulation. In a 
gold sol, coagulation of the gold particles is prevented as a result of the balance 
which exists between the attractive Van der Waals forces between gold particles and 
the gold-gold repulsive forces, which is caused by the negative charge which exists 
on each gold particle of a stable sol. For aggregation to occur this energy barrier, 
which prevents coagulation, must first be breached. This is possible by the addition 
o f electrolytes to the sol which mask the negative charge on the surface of each 
particle. The colloid will collapse with the aggregation of the gold particles in the 
absence of macromolecules, at a certain concentration of these electrolytes. 
However, if macromolecules are present when the negative repulsive forces are 
overcome the gold particles will adsorb to the protein molecules instead of one 
another, ie: the protein becomes labelled with gold (Hermanson, 1996). NaCl or 
other buffer salts are the most common electrolytes used. Aggregation within a sol 
minus macromolecules is accompanied by a colour change from orange/red or 
red/violet to blue (Roth and Binder, 1978).
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Figure 1.11.5: The various interactions involved in protein-gold binding.
1.11.3.3 Other important test components
There are several other components of the test, all of which play a very important 
role in the dynamics of the assay. These are © the sample pad, © the conjugate pad 
and ® the top pad.
The sample pad, as the first test component to come into contact with the sample, is 
critical for the progression of the assay. The function of the sample pad within the 
test is to remove any particulate matter that may be present in the sample and in 
some assays it may also be used to adjust either the pH or the viscosity of the sample.
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The pad, depending on its structural makeup can also be used if necessary to separate 
plasma or serum from whole blood samples. Since the sample pad is responsible for 
the even distribution of the sample to the rest of the test it is important to choose the 
most suitable material for this purpose. The sample being used for the test will 
determine which material is the most appropriate. The materials available are glass 
fibre, cellulosics (paper), woven fibres (meshes) and non-woven filters. In general, 
the cellulosics are selected for urine and serum assays (Weiss, 1997b). The glass 
fibre pads have a very large void volume and thus would release the sample far too 
quickly (Marsden, 1999). There is only a limited product range for the woven fibres 
and the non-woven fibres are not intrinsically wettable (Weiss, 1997b).
The conjugate release pad requires similar properties to that of the sample pad. It 
must be capable of transferring the sample volume efficiently and consistently to the 
membrane. In addition, it is required to take up and hold a consistent amount of the 
conjugate solution to be impregnated and to also maintain the stability of this 
conjugate. Most importantly, it must allow for good rehydration of the conjugate and 
deliver this conjugate consistently and quantitatively to the test strip (Weiss, 1997a). 
Similar materials to those listed above for the sample pad are also used for the 
conjugate release pad. Glass fibre is the chosen material for the test developed within 
this thesis as it releases a large volume of reagent quickly and evenly.
The absorbent top pad, despite having no direct involvement in the assay result, 
actually could significantly affect the result of the test were it absent. This pad 
ensures the attraction of liquid towards the top of the test strip due to its high fluid 
capacity. Its high absorbence rate can influence the speed of migration of the 
sample/reagents through the preceding substrates. The fact that no liquid waste is 
generated during the running of these assays highlights the advantage of the presence 
of a good quality absorbent top pad within the device, as it acts to draw the sample 
and reagents across the membrane and traps any waste liquid (Wells, 1997).
1.11.3.4 Equipment required for test manufacture
There are three main techniques involved in the manufacture of both test components 
and the test itself. These are (D spraying nitrocellulose, © assembling the test strips 
and © cutting the test strips to size.
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The Acculine sprayer is used for immobilising antibodies on nitrocellulose 
membrane. This machine dispenses the antibody solutions at relatively high speed by 
the use of air pressure, thus creating an aerosol of the test and control line, which can 
be controlled by changing the air jet opening width, by the use o f a moveable needle 
(see Figure 1.11.6). The test and control line antibody solutions bind by electrostatic 
adsorption to the nitrocellulose membrane, which is passing under the air jets via 
rollers at a fixed speed (see Figure 1.11.7).
Figure 1.11.6: Diagram of air je t needle similar to that used with the Acculine 
sprayer. Diagram shows test line reagent being sprayed through the needle opening 
onto the nitrocellulose membrane (Tisone, 1997).
For the assembly of a test laminate (i.e.: approximately 30 tests) an assembly device 
is required (see Figure 1.11.8). This device ensures that each of the test components 
is overlapping to the degree required to allow the test to proceed. It is vital that all of 
the porous media (membrane, sample pad, conjugate pad and top pad) used within 
the test are in intimate contact with one another in order to achieve an even transfer 
of the sample throughout the test. The BioDot cutter is used once the test laminates 
are manufactured to cut each laminate into approximately 30 x 8mm test strips. A 
photograph of this machine is shown in Figure 1.11.9.
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Figure 1.11.7: Photograph of the Acculine sprayer, showing a roll o f nitrocellulose
membrane in position for spraying.
Figure 1.11.8: Photograph displaying the assembly device, which shows a test 
laminate with the nitrocellulose membrane, gold conjugate and top and bottom pads 
in position. A section o f the bottom pad has been cut away to reveal the pink gold
conjugate impregnated strip.
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Figure 1.11.9: Photograph of the BioDot cutter, which is used to cut test laminates
into test strips (8mm wide).
1.11.4 Desired parameters of the test
There are several obvious advantages to developing a rapid POC/OTC hCG assay as 
opposed to an ELISA or IRMA for hCG, designed for use within the clinical 
laboratory. POC/OTC products give almost immediate results and are easy to use and 
interpret. They also provide confidentiality, in that customers can run the test in the 
privacy of their own home. The risk of the spread of disease is reduced, as there is 
little or no sample preparation required for these tests. They are relatively 
inexpensive to manufacture. Finally, and perhaps most importantly for the lay 
person, the cost of such tests is low.
Before the development process had begun the following test parameters were laid 
out based on studies, which examined competitor tests that were available for use in 
either the home or by the healthcare professional (refer to Table 1.10.1, page 37). 
The test parameters selected were © 3-5 minute assay time, © single step only (i.e.: 
sample addition), © no prerequisite for extra reagents, ® no necessity for equipment, 
© no technical skills required to run assay, © room temperature storage © low cost 
and ® user-friendly format. It was the aim of the work described within this thesis to 
meet all of these requirements.
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Section 2: 
Materials and Methods
2.1 M aterials
2.1.1 List of Suppliers
Abbott Laboratories
ABI Products 
Advanced Microdevices 
AFC American Filtrona 
Ahlstrom Filtration Inc.
Alex Mitchel Ltd.
Bio Sciences Ltd.
British Biocell 
Calbiochem
Coombe Women’s Hospital 
Cork Blood Bank 
Dako Ltd.
Dublin City University 
Gelman Science 
Genzyme/ Medix Biochemica
Gibco BRL.
G & L Precision Die Cutting 
International Enzymes
JBC Inc.
Maine Biotechnology
c/o Langanbach, Unit 4, Cedar Industrial Estate, 
Killamey Road, Bray, Co. Wicklow.
10237 Flanders St., San Diego, CA 92121, USA.
21 Industrial Area, Ambala, Cantt 133001, India.
8401 Jefferson Davis Highway, Richmond, USA. 
122W Butler St., P.O. Box A, Mount Holly Springs, 
PA 17065-0238, USA.
Unit 5, IDA East Wall Road, Dublin 3.
3 Charlemont Terrace, Crofton Road,
Dun Laoghaire, Co. Dublin.
Gold Gate, Tyglas Ave., Cardiff, CF4 5DX, UK. 
Boulevard Ind. Est., Padge Road, Beeston Nott.,
NE9 2JR, UK.
The Coombe, Dublin 8.
St. Finbar’s Hospital, Douglas Road, Cork.
16 Manor Court Yard, Hughendon Ave., High 
Wycombe, Bucks, HRP13 5RE, UK.
Collins Ave., Glasnevin, Dublin 9.
24 Kill Ave., Dun Laoghaire, Co. Dublin.
50 Gibson Drive, Kings Hill, W. Mailing, Kent, 
ME19 6HG, UK.
c/o Life Technologies, 3 Fountain Drive,
Inchinnan Business Park, Paisley, PA4 9RF, 
Scotland, UK.
1766 Junction Ave., San Jose, CA 95112, USA. 
c/o Aalto BioReagents Ltd., 14 Main St., 
Rathfamham, Co. Dublin.
147 Early Court, Elyria, Ohio, 44035, USA.
1037R Forest Ave., Portland, Maine 04103, USA.
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Medix Biochemica 
Millipore (UK) Ltd.
Nalge Europe
NIBSC
Pelican House 
Propak
Riedel de Haen
Rotunda Hospital 
Sarsteadt Ltd., 
Scantibodies 
Schleicher & Schuell
Sigma (Ireland)
St. James Hospital 
Trinity Biotech Pic.
Wyntek Inc.
See Genzyme/Medix Biochemica, page 50.
The Boulevard, Blackmoor Lane, Watford, Herts, 
WD1 8YN, UK.
Foxwood Court, Rotherwas, Hereford, HR2 6JQ, 
UK.
Blanche Lane, South Mimms, Potter’s Bar, 
Herfordshire, EN6 3QG, UK.
40 Mespil Road, Dublin 4.
Unit 4, Turnpike Ind. Est., Ballymount, Dublin 22. 
c/o Sigma (Ireland), Airton Road, Tallaght,
Dublin 24.
Parnell Square, Dublin 1.
Sinnotstown Lane, Drinagh, Co. Wexford.
9336 Abraham Way, Santee, CA 92091, USA. 
c/o Carl Stuart Ltd., Tallaght Business Park, 
Whitestown, Dublin 24.
Airton Road, Tallaght, Dublin 24.
No. 1 St. James Street, Dublin 8.
IDA Business Park, Southern Cross Route, Bray,
Co. Wicklow.
6146 Nancy Ridge Drive, Suite 101, San Diego, CA 
92121, USA.
2.1.2 Chemicals
Boric Acid, ACS Reagent 
Bovine Serum Albumin (BSA), 
minimum 98% purity 
EDTA, free acid, ACS Reagent 
DAB tablet set (Sigma Fast™)
Gold Chloride (Trihydrate), ACS Reagent 
Goldline
Sigma (Cat. No. B0394) 
Sigma (Cat. No. A7030)
Sigma (Cat. No. E9884) 
Sigma (Cat. No. D4418) 
Sigma (Cat. No. G4022) 
British Biocell (Cat. No. 
not available)
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Hydrochloric Acid, ACS Reagent 
Polyethylene Glycol Compound 200K 
Polyethylene Glycol Compound 1000K 
Polyethylene Glycol Compound 3350K 
Polyethylene Glycol Compound 8000K 
Polyethylene Glycol Compound 10000K 
Polyethylene Glycol Compound 15-20K 
Polyvinylpyrrolidone (PVP K-30),
ACS Reagent 
Potassium Phosphate, monobasic,
ACS Reagent 
Potassium Phosphate, dibasic,
ACS Reagent 
Sodium Azide, minimum 99.5% purity 
Sodium Borate, ACS Reagent 
Sodium Chloride, ACS Reagent 
Sodium citrate, Trisodium Salt Dihydrate, 
ACS Reagent 
Sodium Hydroxide, ACS Reagent 
Sucrose, D(+) -  saccharose, extra pure 
Trizma Base (Tris Base), Primary Standard 
& Buffer Reagent Grade 
Triton X-100®, Laboratory Grade.
Tween 20® (Polyoxyethylenesorbitan, 
Monolaurate), Protein Grade.
Sigma (Cat. No. H7020)
Sigma (Cat. No. P3015)
Sigma (Cat. No. P3515)
Sigma (Cat. No. P4338)
Sigma (Cat. No. P4463)
Sigma (Cat. No. P6667)
Sigma (Cat. No. P2263) 
Calbiochem (Cat. No. 9003-39-8)
Sigma (Cat. No. P0662)
Sigma (Cat. No. P3786)
Sigma (Cat. No. S2002)
Sigma (Cat. No. S9640)
Sigma (Cat. No. S9888)
Sigma (Cat. No. S4641)
Sigma (Cat. No. S0899) 
Riedel-de-Haen (Cat. No. 16104) 
Sigma (Cat. No. T1503)
Sigma (Cat No. X-100) 
Calbiochem (Cat. No. 655206)
2.1.3 Interference Study Reagents
Sigma (Cat. No. A5376) 
Sigma (Cat. No. A1653) 
Sigma (Cat. No. A1417) 
Sigma (Cat. No. C8960) 
Sigma (Cat. No. E1253)
Acetylsalicylic acid, minimum 99.5% purity 
Albumin, Human, Fraction V Powder 
Ascorbic acid, ACS Reagent 
Caffeine, SigmaUltra Grade 
Estriol, minimum 99% purity
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Gentisic acid, Free Acid 
Glucose, Anhydrous, ACS Reagent 
Haemoglobin, Human, Lyophilised Powder 
Phenothiazine, SigmaUltra grade
2.1.4 Sources of Serum
Goat Serum 
Rabbit Serum
Foetal Bovine Serum
2.1.5 Anti-hCG Antibodies
Anti-hCG (Intact) Monoclonal Antibody 
Anti-hCG (Beta) Monoclonal Antibody 
Anti-hCG (Beta) Monoclonal Antibody 
Anti-hCG (Beta) Monoclonal Antibody 
Anti-hCG (Beta) Monoclonal Antibody 
Anti-hCG (Intact) Monoclonal Antibody 
Anti-hCG (Beta) Monoclonal Antibody 
Anti-hCG (Intact) Monoclonal Antibody 
Purified Rabbit Anti-a-hCG  
Purified Anti-(3-hCG 
Anti-hCG Monoclonal Antibody
2.1.6 Miscellaneous Antibodies
Purified Goat Anti-Mouse, IgG fraction
Rabbit Anti-Mouse antibody 
Anti-Luteinising Hormone antibody
Sigma (Cat. No. G5254) 
Sigma (Cat. No. G5767) 
Sigma (Cat. No. H7379) 
Sigma (Cat. No. P4889)
Bio Sciences (Cat. No. 16210) 
Bio Sciences (Cat. No. 
16210/040)
Gibco BRL (Cat. No. 10108)
Maine Biotechnology, (No. 105) 
Maine Biotechnology, (No. 106) 
Maine Biotechnology, (No. 107) 
Maine Biotechnology, (No. 108) 
Medix Biochemica, (No.5006) 
Medix Biochemica, (No.5008) 
Medix Biochemica, (No.5009) 
Medix Biochemica, (No.6601) 
Wyntek Inc., (PN 210)
British Biocell (No. 1817) 
Genzyme (No.9812)
International Enzymes,
(Cat. No. 6405)
Dako Ltd., (Prod. No. Z0109) 
Genzyme (D11675)
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2.1.7 Hormone Standards
Human Chorionic Gonadotropin,
from human pregnancy urine 
Human Chorionic Gonadotropin,
WHO 3rd International Standard. 
Luteinizing Hormone,
Antigen grade
Follicle Stimulating Hormone,
Antigen grade 
Thyroid Stimulating Hormone,
Antigen grade
2.1.8 Gold Conjugates
Monoclonal Anti-hCG, 40nm gold conjugate 
Mouse Anti-HBsAg, 40nm gold conjugate
2.1.9 HRP Conjugates
Rabbit anti-mouse IgG-HRP conjugate 
Goat anti-rabbit IgG-HRP conjugate
2.1.10 Miscellaneous
Intact hCG ELISA Test Kit 
Unigold PT-hCG Test 
TestPack® +Plus™ hCG Test 
Gold Conjugate Dilution Buffer
Sigma (Cat. No. CG-10)
NIBSC (Cat No. 75/537),
International Enzymes, 
(Cat. No. 4207)
International Enzymes, 
(Cat. No. 4202) 
International Enzymes 
(Cat. No. 4221)
British Biocell (No Cat. No. 
available)
British Biocell (No Cat. No. 
available)
Sigma (Cat. No. A9044) 
Sigma (Cat. No. A6154)
Genzyme (Cat. No. KIF4013) 
ABI (Cat No. 3260)
Abbott (Cat. No. not available) 
Trinity Biotech, (Part No. 2979)
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2.1.11 Plastics/Filters
Pre cut filter wicks 
One step bottom pad 
One step top pad 
Laminated backing material
Glass Fibre Membrane 
Membranes
AE 105 8 i^m nitrocellulose membrane 
(Unbacked)
AE 98 5)j.m nitrocellulose membrane 
(Unbacked)
8p.ni nitrocellulose membrane (Backed)
lOpm nitrocellulose membrane (Backed)
General Plastics
Foil pouches 
Dessicants l.Og
C8 Maxi Breakapart Microtitre plate 
One Step cassette housing device (Top) 
One Step cassette housing device (Bottom) 
One Step wick housing device (Top)
One Step wick housing device (Bottom)
One Step wick splash guard
3.5ml graduated plastic transfer pipettes
2.1.12 Samples
hCG-free serum 
hCG-Negative Serum 
hCG-Negative Serum
AFC American Filtrona 
Gelman(No. 51334)
Ahlstrom (Grade 222)
G & L Precision Die 
Cutting Inc., (No. 187)
JBC Inc.
Schleicher & Schuell 
(Ref. No. 549909)
Schleicher & Schuell 
(Ref. No. 549916)
Advanced Microdevices Inc. 
(Cat. No. CNPF-Sj)
Millipore (Cat. No. SRHF 04)
Propak (Cat. No. VF58)
Propak (Cat. No. 40AG37) 
Nalge Europe (Cat. No. 473768) 
Alex Mitchel (Cat. No. 1295) 
Alex Mitchel (Cat. No. 1296) 
Alex Mitchel (Cat. No. 1295w) 
Alex Mitchel (Cat. No. 1296w) 
Alex Mitchel (Cat. No. 1297) 
Sarsteadt (Cat. No. 86.1172)
Scantibodies (Cat. No. T1503) 
Cork Blood Bank 
Rotunda Hospital
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HAMA-Positive samples 
Heterophilic Antibody positive samples
hCG-Negative Serum 
hCG-Positive Serum 
hCG-Positive Serum 
hCG-Positive Serum 
hCG-Negative Urines 
hCG-Negative Urines 
hCG-Negative Urines 
hCG-Positive Urines 
hCG-Positive Urines
Pelican House 
Rotunda Hospital 
In house samples 
The Coombe Hospital 
Collected in house 
St. James Hospital 
Dublin City University 
Rotunda Hospital 
The Coombe Hospital 
Scantibodies, Part No. 3PH498 
Scantibodies, Part No. 3PH498
2.1.13 Equipment
General Equipment
Mettler Toledo Analytical Balance.
Coming pH Meter 245 with calibration buffers at pH 4.0, pH 7.0 and pH 10.0. 
Mettler Toledo Magnetic Stir Plate & bars.
Stuart Scientific Vortex.
Jen way 6105 Spectrophotometer (UV Monitor).
Eppendorf single channel pipettes: 2-20(j.L, 10-100|uL, 50-250jjL and 200-1000|xL. 
Disposable pipettes, lOmL and 25 mL.
Pi-pump.
Dialysis Tubing.
Sterile plastic syringes, 5mL, lOmL, 20mL.
Syringe filters 0.2pm, 0.45j.im, 1.2(j.m.
Duran glass flasks, lOOmL, 500mL, 1L.
Glass universals.
Glass test tubes.
Sterile urine containers, 30mL and 60mL.
Latex gloves.
Face masks.
Safety glasses.
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Spraying/Conjugating Equipment
Acculine Sprayer.
Vacuum dryer.
Erlenmyer conical flasks, 500mL and 1L. 
Sorvall Centrifuge.
Centrifuge tubes, 50mL and 200mL. 
Disposable glass transfer pipettes.
Gauze Tray.
Stainless Steel Tray,
Flat tipped Tweezers.
Guillotine.
Calipers.
UniGold™ Test Assembly Device. 
Biodot Test Strip Cutter.
I
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2.2 Buffers and Solutions
2.2.1 Spraying Solutions
2.2.1.1 10mM EDTA Solution
EDTA 3.722g
Made up to 1L with deionised water.
2.2.1.2 1X Phosphate Buffered Saline (PBS), pH 7.2
Sodium chloride 8.7g
25x Phosphate Buffer 40mL
IN NaOH as required
IN HC1 as required
The pH was adjusted, if necessary, to 7.2+ 0.1 using either the IN HC1 
or the IN NaOH, and made up to 1L with deionised water.
Note: This IX phosphate buffer was 0.0008M with respect to the
potassium phosphate, monobasic and 0.0064M with respect to the
potassium phosphate, dibasic.
2.1.1.3 25X Phosphate Buffer
Potassium phosphate, monobasic 2.72g
Potassium phosphate, dibasic 27.9g
IN NaOH as required
IN HC1 as required
The pH was adjusted, if necessary, to 7.8+ 0.2 using either the IN HC1 
or the IN NaOH, and made up to 1L with deionised water.
Note: This 25X phosphate buffer was 0.02M with respect to the 
potassium phosphate, monobasic and 0.16M with respect to the 
potassium phosphate, dibasic.
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2 0 g
0.05g
2.2.1.5 Spraying solutions
Control Line spraying solution as per Method 2 3.2.1.
Test Line spraying solution as per Method 2.3.2.1.
2.2.2 Gold Conjugate solutions
All the solutions for the gold conjugate preparation were made up in cleaned boiled 
glassware using 0.2jj,m filtered RO water (For cleaning method, see Method 2.3.1.1).
2.2.2.1 10% (w/v) Gold Chloride (Trihydrate)
See Method 2.3.1.2.
2.2.1.4 20% (w/v) Sucrose/0.05% (w/v) Sodium Azide
Sucrose 
Sodium azide
Made up to lOOmL with deionised water.
2.2.2.2 1N Sodium Hydroxide (NaOH)
Sodium Hydroxide 40g
Made up to 1L with deionised water.
2.2.2.3 1N (M) Hydrochloric Acid (HCI)
Deionised water 917mL
Hydrochloric Acid 83mL
Note: Acid should always be added to water and never in the reverse 
order.
2.2.2.4 5% (w/v) BSA Solution
Dialysed BSA (65mg/mL) 38.5mL
Reverse Osmosis water (0.2pm filtered) 11. 5mL
Mix gently.
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2.2.2.S 10% (w/v) Sodium Chloride solution
Sodium chloride
Made up to 20mL with deionised water. 
Final solution was 0.2jj,m filtered.
2 g
2.2.2.6 0.25M Boric Acid
Boric acid
Made up to 500mL with deionised water. 
Final solution was 0.2fim filtered.
7.73g
2.2.2.7 0.1 M Sodium Borate
Sodium borate
Made up to 500mL with deionised water. 
Final solution was 0.2jum filtered.
19.07g
2.2.2.8 0.5M Tris Buffer, pH 7.5
TrizmaBase 60.55g
IN HC1 as required
IN NaOH as required
The pH was adjusted, if necessary, to 7.5+ 0.1 using either the IN HC1 
or the IN NaOH, and made up to 1L with deionised water.
2.2.2.9 Dialysed BSA (65mg/mL)
See Method 2.3.1.5.
2.2.2.10 Gold Conjugate Wash Buffer
0.25M Boric Acid, 0.2p.m filtered
0.1M Sodium Borate, 0.2(j.m filtered 
Polyethylene Glycol (PEG)
Sodium Azide
50mL
4mL
lg
0.5g
The pH was adjusted to pH 7.75 + 0.1 if necessary using 0.25M Boric 
Acid and 0.1M Sodium Borate and made to 1L with deionised water.
The GCWB was 0.2(im filtered and stored at 2-8 C for up to three 
months.
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2.2.2.11 12% (w/v) Sodium citrate
This solution was made up fresh for each manufacture of gold sol.
2.2 .2.12
2.2.2.13
2.2.2.14
2.2.3
2.2.3.1
2.2.3.2
Sodium citrate 1.2g
Made up to lOmL with 0.2(j,m filtered deionised water. The solution 
was then 0 .2 jiim filtered into a cleaned glass test tube and used on the 
same day.
0.25M Borate Buffer, pH 7.5
0.25M Boric Acid 10 parts
0.1M Sodium Borate 1 part
Note: a sterile lOmL pipette was used to make this solution.
The pH was adjusted, if necessary to 7.5 + 0.1 using 0.25M Boric acid
or 0.1M Sodium Borate. The buffer was 0.2^m filtered and stored at
0
2-27 C for up to one year.
1% (w/v) Polyethylene Glycol Solution
l.Og of PEG 15-20K was dissolved in lOOmL of distilled water.
Gold Conjugate Impregnation Solution
See Method 2.3.1.6.
Miscellaneous Buffers 
2% (w/v) Triton® X-100 Solution
Triton® X-100 20g
Made up to 1L with deionised water.
hCG Control Solutions
See Method 2.3.5.3.
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2.3 Methods
2.3.1 Gold Conjugation Methods
2.3.1.1 Preparation of Glassware for Gold Work
1. The presence of any particulate matter on equipment or in solutions used in 
the manufacture of gold sols and gold conjugates could potentially destabilise 
the gold binding. Therefore, glassware was kept especially for gold-labelling- 
related work. Half of the glassware was dedicated solely for the preparation 
of colloidal gold and the remainder for protein-gold conjugations.
2. The glassware was first cleaned with hot water and anti-microbial hand soap, 
then rinsed with distilled water and finally boiled for 10-15 minutes with
0.2|um filtered RO water.
3. Immediately before use the glassware was rinsed again with 0.2fj.m filtered 
RO water.
2.3.1.2 Formulation of 10% (w/v) Gold Chloride (Trihydrate)
lOmL of 0.2jj.m filtered distilled water was added to an amber glass container 
of l.Og of Gold Chloride. The bottle was swirled gently and the gold chloride 
was allowed to dissolve at room temperature. This was timed for 1 hour + 5 
minutes. The final homogenous solution was 0.2jj.m filtered into a glass
universal tube, which was covered in tin foil to exclude light.
2.3.1.3 Preparation of 0.01% (v/v) Colloidal Gold Sol, 40nm
1. 1L of 0.2p.m filtered RO water was added to an Erlenmyer glass flask, which 
had been cleaned according to method 2.3.1.1.
2. A stirring bar (used only for gold sol preparation) was added and the flask 
was placed on a heating stirring plate.
3. The water was heated while stirring to 85-90°C.
4. l.OmL of 10% (w/v) Gold Chloride solution (see 2.3.1.2) was added while
stirring.
62
5. The solution was heated to boiling temperature (until multiple bubbles were 
observed). The solution was boiled for a further 2 minutes.
6 . l.OmL of 12% (w/v) Sodium Citrate was added and the solution was allowed 
to boil for 6 minutes.
7. The flask was then removed from the stirring plate and placed in a dark place 
at room temperature for 12-18 hours.
8. The absorbance was read and recorded at 520nm using the 
spectrophotometer.
9. The gold sol was stored at 2-8°C in a dark place and given an expiry of one 
month.
2.3.1.4 Manufacture of Anti-hCG Gold conjugate
1. 20mL of 0.01% (w/v) Colloidal gold was added to 0.8mL of 0.25M Borate 
buffer and mixed by manual horizontal rotation.
2. lmL of the gold-borate buffer and 50mL of 1% (w/v) PEG solution was 
added to a glass test tube and mixed well. The pH was determined and should 
be within the range 7.3-7.6 .
3. The absorbance of the Anti-hCG antibody solution was read at 280nm to 
determine the concentration of antibody (Ig) in the solution by using the 
following equation:
mg of Ig = Absorbance 280nm of solution
ml 1.3 5 x dilution factor
Note: 1.35 = the absorption coefficient for Ig molecules at 280nm (Aslan 
and Dent, 1998). The dilution factor was only taken into account if it 
was necessary to dilute the stock antibody solution before reading at 
280nm.
4. The solution was diluted to lmg/mL using distilled water and any unused 
solution was stored at 2-8°C for up to 1 week.
Adsorption Isotherm
5. The anti-hCG antibody was diluted to lOOmg/mL using distilled water to give 
a volume of ~ 400mL.
6 . l.OmL of colloidal gold-borate buffer was added to each of six cleaned lOmL 
glass test tubes.
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7.
8 .
10.
11.
12.
13.
The specified volume of antibody solution was added to each tube as outlined 
in the example in Table 2.3.1.4 and each tube was mixed briefly and 
incubated for 5 minutes.
The colour change was observed and recorded in a table like that shown in 
2.3.1.4. lOOmL of 10% (w/v) NaCl was then added to each tube and mixed 
briefly.
The solutions were incubated for 5 minutes and the colour change, if  any was 
visually interpreted and then recorded in the same table as used for step 8 .
The tube containing the minimum amount of anti-hCG antibody solution 
without a colour change being observed was selected as the amount of 
antibody required to stabilise lmL of gold sol.
If none of the tubes were seen to be stable or all tubes remained the same 
colour the titration was repeated with higher/lower concentrations of the 
antibody.
300mL of 0.01% (v/v) gold sol was weighed into an Erlenmyer flask (it was 
assumed that lmL of gold sol weighed approximately lg).
12mL of 0.25M Borate buffer was added using a sterile lOmL pipette and 
mixed manually as the buffer was being added.
Tuba Gold Sol-Borate Anti-hCG Colour before Colour a fter NaCl
No. Buffer (mL) So»« (nL) NaCl a t 5  mlns a t 5 mins
1 1 5
2 1 10
3 1 20
4 1 30
5 1 40
Table 2.3.1.4: Example o f a plan for an adsorption isotherm showing examples of 
the amount o f gold sol-borate buffer and antibody which could be added to each 
tube is displayed. The volume of antibody required to stabilise the gold sol-borate 
buffer solution may vary depending on the antibody being conjugated. The 
respective colour for each tube before and after the addition o f NaC! would be 
recorded in the two right hand columns.
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14. From the adsorption isotherm, the volume of anti-hCG antibody (mL) 
required to stabilise 300mL of gold sol was calculated as follows:
{Vol. of antibody* (f^L)(step 10)}x{300mL (i.e.: vol. of gold sol)}
*volume added to the selected tube from step 10 .
15. The volume calculated in step 14 was multiplied by 1.1 to allow for a 10% 
excess of antibody solution to be added to the gold sol. This volume was 
added to the flask as one aliquot while manually mixing horizontally.
16. The solution was incubated for 10 minutes at room temperature and the 
colour was recorded.
17. ImL of the solution was removed and lOOmL of 10% (w/v) NaCl was added 
to the aliquot and was allowed to incubate for 5 minutes and the colour was 
recorded.
18. The above electrolyte test was repeated and if the aliquot retained its 
pink/purple colour, the conjugation was allowed to proceed.
19. 12mL of 5% (w/v) BSA was added to the flask and mixed by manual 
horizontal rotation and incubated for 60-90 minutes in a dark place.
20. lOOmL of this solution was transferred to a 250mL centrifuge tube and 
centrifuged at 10,000 rpm for 60 minutes at 2-8°C.
21. The supernatants were aspirated and discarded and the pellets resuspended in 
~100mL of GCWB and centrifuged as above.
22. Steps 20-21 were repeated once more and the supernatants aspirated the
pellets were combined and reconstituted with GCDB to a final volume of 
30mL.
23. The absorbance at 520nm was recorded and the conjugate solution was
further diluted if necessary, with GCDB until an absorbance at 520nm of 3 .0
was acheived.
24. The conjugate was stored at 2-8°C in a dark place.
i
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2.3.1.5 Manufacture of a 65mg/mL diaiysed BSA solution
1. A 65mg/mL solution of BSA was made up in distilled water as follows:
Note: The total amount of BSA required was initially added to 60% of the 
total amount of distilled water required to make up the 65mg/mL solution. 
The BSA was added slowly and allowed to dissolve without stirring, as this 
would cause frothing. Once the BSA had dissolved, the solution was made up 
to its required volume using distilled water.
2. Some dialysis tubing was pre-wet in distilled water for a minimum of 10 
minutes. One end of the tubing was knotted tightly several times as close to 
the end as possible and the BSA solution was transferred to the tubing using a 
pasteur pipette. The other end of the tubing was then knotted several times to 
form a tight seal, keeping the air space above the liquid to a minimum. Note: 
gloves were worn at all times while handling the dialysis tubing.
3. The dialysis tubing was placed in 2.0L of deionised water. This deionised 
water was replaced three times a day for two days, keeping the dialysis tubing 
in the replacement buffer for a minimum of two hours.
4. The diaiysed solution was removed from the tubing and first 1.2)im filtered 
into a sterile container. The resulting solution was then 0.2(j.m filtered in the 
laminar hood into a sterile container. The volume was noted.
5. A 1 in 20 dilution of the diaiysed BSA was carried out using IX PBS, pH 7.2.
6 . A dilution series was prepared using a BSA protein standard and IX PBS, pH
7.2 as shown in Table 2.3.1.5.
The absorbance at 280nm was recorded for each BSA solution.
Tube
No.
BSA Cone. 
(mg/mL) par tu b *
Volume of BSA 
added to tuba
Volume of PBS, 
pH 7.2, added to tuba
1 0.700 1.0mL of 1.400 mg/mL standard 1.0 mL
2 0.350 1. OmL of 0.700 mg/mL standard 1.0 mL
3 0.175 1.0mL of 0.350 mg/mL standard 1.0 mL
4 0.087 1. OmL of 0.175 mg/mL standard 1.0 mL
Table 2.3.1.5: BSA Protein Standard Dilutions
7. The absorbance at 280nm for each BSA solution was plotted against the BSA 
concentration (mg/mL) to create a standard curve.
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8. The 1 in 20 dilution of the dialysed BSA was serially diluted to give the
following dilutions: 1 in 40,
1 in 80,
1 in 160,
1 in 320,
1 in 640,
1 in 1280.
9. The absorbance at 280nm was read and the concentration of BSA was 
calculated for the 1 in 320-1 in 1280 dilutions. The mean of these 
concentrations was used to dilute the original undiluted dialysed BSA 
solution to obtain a concentration of 65mg/mL, using 0.2|nm filtered water in 
the laminar flow hood.
10. This readjusted solution was serially diluted as previously outlined in step 9
and the absorbance values used to determine if the solution was within the 
range 65 + lmg/mL. If not, the dilution step was repeated.
11. The 65mg/mL dialysed BSA was aliquotted into 1. lmL lots into 2mL 
polypropylene vials and stored at -20°C for up to 1 year.
2.3.1.6 Impregnation of Gold Conjugate Strips
1. In order to manufacture gold conjugate strips, it was necessary to impregnate 
glass fibre strips with a gold conjugate solution of a specified A520nm with 
respect to the gold conjugate component. The absorbance of the stock Anti- 
hCG gold conjugate was read at 520nm. Using the desired A520nm of the gold 
conjugate the volume of this stock conjugate required was calculated as 
follows:
Required A520nm of gold conjugate x Vol. of Gold Conjugate Solution required*
A520nm of stock gold conjugate
* 1.5mL of gold conjugate solution required per gold conjugate strip.
2. The volume of stock conjugate required was added to a clean test tube and 
the solution was made up to volume using gold conjugate dilution buffer 
(GCDB).
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3. Strips of glass fibre membrane were cut to measure 8mm x 28mm using a 
paper guillotine. Their widths were checked using a measuring calipers.
4. The glass fibre strips were placed on a cleaned stainless steel tray and 
numbered with a ball point pen.
5 750|uL of the diluted gold conjugate solution was added in drops along the
length of each strip and allowed to absorb. A further 75Oja.L was added per 
strip and the solution was spread evenly along the strip using the tip of the 
Eppendorf.
6 . The impregnated strips were placed on a cleaned gauze tray using a flat 
tipped tweezers and placed in the vacuum dryer overnight (see 2.3.5.1).
7. Once dried, all strips were stored with indicating desiccants at 20-25°C in an 
airtight container until required for test assembly.
2.3.2 Spraying of Nitrocellulose Membrane
2.3.2.1 Formulation of Spraying Solutions
Test Line
1. The volume of the stock anti-hCG solution required for the test line was 
calculated as follows:
Concentration required x Volume of spraying solution required
Concentration of stock solution
Note: The volume of spraying solution required is calculated by assuming 
that 1 ml of solution is required per test.
2. The amount of lOmM EDTA required was calculated as follows:
Spraying volume required x 0.03 = Vol. of lOmM EDTA required.
3. The volume of 20% (w/v) sucrose required was calculated by using the
following formula:
Spraying volume required x 0.1 = Vol. of 20% (w/v) Sucrose required.
4. These three reagents were added to a clean test tube and the solution was
made up to the required volume using IX PBS, pH 7.2.
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Control Line
5. The formulation of the control line solution was carried out exactly as for the
test line solution apart from the use of different antibody solutions.
2.3.2.2 Spraying of Nitrocellulose
1. The starting temperature and humidity were recorded.
2. The nitrocellulose membrane and airbrushes were mounted on the Acculine 
Sprayer according to the instructions outlined in the Acculine Manual,
Section 5, pages 12 and 13.
3. The parameters of the sprayer were set as follows:
Membrane Speed: 4 cm/sec
Airbrush Pressure: 24 psi 
Airbrush Position:
Test Line: 12mm (Cassette) 9.75mm (Wick)
Control Line: 19mm (Cassette) 20mm (Wick)
12mm
19mm
Figure 2.3.2.2: Diagram showing the distance (mm) o f the sprayed test & control 
lines from the bottom o f the nitrocellulose membrane. Spraying positions shown are 
for the cassette device. The relevant distances for the wick device are shown above.
Airbrush Opening for spraying needle:
Test Line: Began with 6mm
Control Line: Began with 6mm
4. The relevant reagents were connected to their airbrushes and the brushes were 
primed as outlined in the Acculine Manual.
5. The test and control line solutions were sprayed until the solutions ran out, 
maintaining a mean line thickness of 1 - 1 .2 mm.
69
6 . The membrane was vacuum dried for 2-16 hours as per method 2.3.5.1
depending on the length of membrane sprayed.
2.3.3 Assembly of Test Strips and Devices (Cassette & Wick)
1. The following were required to assemble test strips:
Laminated Backing Material 
Top and Bottom pads 
Sprayed Nitrocellulose 
Impregnated Conjugate Pad 
Assembly Device
2. The laminated backing material was placed between the guide rails of the 
assembly device and the larger top cover strip removed to reveal the adhesive 
surface.
3. A section of sprayed membrane was measured and cut to fit the length of the
laminated strip and was applied as evenly as possible to the adhesive surface, 
ensuring that the sprayed side was orientated correctly (i.e.: with the sprayed 
control line to the top side).
4. The larger cover strip (just removed) was used to press down the membrane
thus avoiding direct contact with the sprayed surface.
5. The centre guide rail was placed in the device and the top pad was placed on
top of the membrane meeting the top edge of the centre guide rail and 
overlapping the membrane.
6 . The lower cover strip was removed from the laminated backing and the
conjugate strip (pink) was placed overlapping the membrane (by at least 
2 mm) against the bottom edge of the centre guide rail.
7. The bottom pad was placed over the conjugate strip keeping its bottom edge
against the top edge of the bottom guide rail of the assembly device.
8 . The resulting ~30cm strip was cut into 8mm test strips using a Biodot Cutter
(see section 1.0, Introduction, Figure 1.11.8.)
2.3.3.1 Device Assembly (Cassette)
9. An 8mm test strip was placed in a bottom housing device, ensuring that the
conjugate (pink) strip was at the bottom.
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10. The top housing device was placed carefully over the bottom piece with the 
sample port at the bottom.
11. The pieces were snapped closed, ensuring a tight fit.
2.3.3.2 Device Assembly (Wick)
12. The wick test was assembled as above in step 9 and an impregnated wick was 
placed within the wick guide walls of the wick housing device leaving 
~20 mm of the wick outside the housing device.
13. The top housing piece was placed over this and snapped shut, ensuring all 
pins are closed down firmly.
2.3.4 Assay Formats
2.3.4.1 Test format for the ‘in-house’ assay
Cassette Assay
1. The test was removed from its foil pouch and was allowed to come to room 
temperature along with the sample being run.
2. Four drops of urine/serum were added to the sample port and the timer was 
started.
3. The test was read at 3 minutes for urine and 5 minutes for serum and results 
interpreted as per 2 .3.4.2 .
Wick Assay
1. The test was removed from its foil pouch and was allowed to come to room 
temperature along with the sample being run.
2. The splash guard was pushed back and the 2/3 of the wick was immersed in 
the urine/serum until the sample flow was seen at the bottom of the test 
window.
3. The test was read at 3 minutes for urine and 5 minutes for serum and results 
interpreted as per 2 .3.4.2 .
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2.3.4.2 Results Interpretation
Unl-Gold
hCG
Control
Tost
Sample
TRINITY
BIOTECH
Uni-Gold
hCG
-L
Control m  
T e s t “
Sample (
TRINITY
BIOTECH
f  Unl-Gold
hCG
Control
Test
CZ'J
Sample
TRINITY
BIOTECH
Negative
A line is 
visible only 
at the 
Control Line
Positive
A line is 
visible at 
both the Test 
& Control Line
Inconclusive
No line is 
visible at 
either the Test 
or Control Line
Figure 2.3.4.1: Interpretation o f Assay results
2.3.4.3 ABI Assay Format
Cassette Device
1. Four drops of urine/serum were added to the sample port of the device.
2. Once the required assay time had elapsed (3 minutes for urine, 5 minutes for
serum), the device was interpreted in a manner identical to that
described for the ‘in-house’ assay in Figure 2.3.4.1, shown above.
2.3.4.4 Assay Format for the Genzyme hCG ELISA
1. 50/j.L of each serum sample to be run and each of the following kit standards 
were dispensed in duplicate 0, 5, 25, 50, 100 and 200 IU/L to the required 
number of coated wells. The plate was gently shaken for 30 seconds.
2 . lOOf^L of the supplied sample/standard dilution buffer was added to each well 
and the plate was shaken thoroughly for 10 seconds and incubated for 30 
minutes at room temperature.
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3. The plate was hand washed x 5 with running tap water and tapped dry.
4. 150f.iL of the enzyme conjugate solution was then added to each well of the
plate and the plate was shaken gently for 5 seconds and incubated at 15 
minutes at room temperature.
5. The washing step was repeated as in step 3.
6 . 200fiL of TMB substrate was dispensed into each well and gently shaken for
5 seconds. The plate was incubated for 15 minutes at room temperature.
7. The reaction was stopped with 50jiL of 4N H2SO4 solution per well and the 
absorbance was read at 450nm.
8. A standard curve was plotted using the absorbance reading at 450nm for the 
kit standards and a value was calculated for each sample using this curve.
2.3.5 Miscellaneous Methods
2.3.5.1 Vacuum Drying Procedure
1. The vacuum dryer refrigeration unit was turned on approximately 15 minutes 
before use to ensure that the temperature had reached -56°C.
2. Once the temperature had reached -56°C the gold conjugate strips/sprayed 
membrane were placed on cleaned gauze trays in the vacuum dryer.
3. The door of the vacuum dryer was sealed and the vacuum pump was switched 
on. The opening of the outlet tube was covered until a sufficient vacuum was 
pulled.
4. The strips/membrane were left vacuum drying overnight under these 
conditions.
2.3.5.2 Impregnation Prodedure for Wicks
1. The wicks were placed in a large container and covered completely with a 2% 
(w/v) Triton X-100® solution and allowed to soak for lhour + 1 0  minutes at 
room temperature or overnight at 2-8°C.
2. Once the required time had elapsed the solution was drained off and the 
wicks were placed in a single layer on a gauze tray specifically set aside for 
this purpose and placed in the vacuum dryer overnight.
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2.3.5.3 Manufacture of hCG controls
The hCG used was a lyophilised sample of the WHO 3rd International Standard. This 
standard contained 650 IU of hCG/ampoule. The contents of each ampoule were 
diluted in 6.5mL of deionised water to give a concentration of lx  IO5 IU/L. A 1 in 
100 dilution was made of this stock to give a solution of 1000 IU/L. This was then 
diluted as follows in either serum or urine to give the required concentration of hCG.
Volume of 1000 IU/L required =
Required hCG Concn. (IU/L) x Vol. required 
1000 IU/L (i.e.: Stock Concn.)
The volume of 1000 IU/L stock calculated above was added to a sterile container and 
the solution was made up to the desired volume with either hCG negative urine or 
serum and mixed gently.
Prozone Solutions
These solutions were known as ‘Prozone Solutions’ as a result of their high hCG 
concentrations and the subsequent potential prozone effect (false negative result, see 
Discussion, section 4.9.4) that would most likely be observed for the test due to these 
high concentrations of hCG.
The solutions were manufactured using the 1 x 105 IU/L hCG stock as described 
above. This stock was diluted as shown overleaf to give the required concentration:
Volume of 1 x 105 IU/L required =
Required hCG Concn. (IU/L) x Vol. required 
1 x 105(IU/L)(i.e.: Stock Concn.)
The volume of 1 x 105 IU/L stock calculated above was added to a sterile container 
and the solution was made up to the desired volume, with either hCG-negative urine 
or serum, and mixed gently.
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2.3.5.4 Testing of Sample Pads
Absorbance Test for sample pads
Distilled water was added in 20|xL increments to each square until the maximum 
amount that the pad could absorb was reached. This was observed as being the point 
where the water was seen to leach from the edges of the pad and to form a film on 
the surface of the pad.
Flow Test for sample pads
Distilled water was placed in a weigh boat and each pad was held vertically and the 
edge of its short side dipped into the liquid. The time taken for the water to travel to 
the top of the strip of absorbent pad was recorded and used as a crude method for 
determining the flowrate of the pad.
2.3.5.5 Analysis of Clinical Trial Results (Hart, 1980)
For all calculations using the sample results from clinical trials the following apply:
% Sensitivity = _________ Number of True positives______________ x 100
Number of True positives + Number of false negatives
% Specificity = Number of True negatives x 100
Number of True negatives + Number of false positives
2.3.5.6 Dot Blot for comparison of various antibody affinities for 
the hCG antigen
1. hCG solutions were manufactured as per Method 2.3.5.3 to ensure that hCG 
was titered out from 100 IU/dot to 5 IU/dot (Each dot consisted of 10p.L of 
solution).
2. Each dot was added carefully to membrane no. 1 (see Materials, section 2.1) 
to ensure that each dot was of the same size and the membrane was dried at 
37°C for 10 minutes.
3. Each membrane strip was blocked for 30 minutes at room temperature on a 
shaker in a solution of 5% (w/v) BSA in IX PBS, pH 7.2.
4. The strips were repeatedly washed in IX PBS, pH 7.2.
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5. Each of the antibodies being examined for their affinity to hCG were diluted 
to 5(ig/rnL in 1% (w/v) BSA in IX PBS, pH 7.2 and incubated with the 
relevant membrane strip for 30 minutes on a shaker at room temperature. This 
was to allow an accurate comparison to be made between results.
6. The strips were repeatedly washed in IX PBS, pH 7.2.
7. The rabbit anti-mouse-HRP conjugate at l^g/mL in 1% (w/v) BSA in IX
PBS was added to all the strips which had been incubated with mouse 
monoclonal antibodies. Only one rabbit polyclonal antibody was examined 
and therefore this was incubated with goat anti-rabbit-HRP also at ljig/mL in 
1% (w/v) BSA in IX PBS, pH 7.2. All strips were incubated for 30 minutes at 
room temperature on a shaker.
8. The strips were repeatedly washed in IX PBS, pH 7.2.
9. All strips were incubated with a DAB solution for 10 minutes to provide
colour. The DAB solutions were disposed of safely and the strips were 
washed in deionised water and examined for colour intensity.
2.3.5.7 Formulation of Variations of the Gold Conjugate Dilution Buffer
The following applied for Section 3.8.5 of the Results section, entitled ‘Buffer
evaluations’:
1. 10% (w/v) Tween 20® and Triton X-100® were added into the GCDB to a 
final concentration of 0.001% (v/v).
2. Each of the different sized Polyethylene glycols (PEGs) to a final 
concentration of 5mg/mL in the GCDB.
The following applied for Section 3.8.5i of the results section, entitled ‘Further
buffer evaluation’:
1. GCDB was supplemented individually with each of Triton X-100® and 
Tween 20® to give a final concentration of 50g/L. Each of these solutions was 
serially diluted 1 in 2 to give 6 solutions, with the lowest concentration being 
1.25g/L.
2. Similarly, a 60g/L stock of PVP K-30, a 50g/L stock of PEG 15-20K, a 
250g/L stock of sucrose and a 40g/L stock of BSA were made up in the 
GCDB. Each of these stock solutions were also serially diluted 1 in 2 as
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described in step 1, to give 6 solutions, with the lowest concentrations of each 
stock solution as follows: 1.5g/L PVP K-30, 1.25g/L PEG 15-20K, 12.5g/L 
sucrose and lg/L BSA.
2.3.5.8 ‘Comb’ Method
1. The nitrocellulose membrane was sprayed in the usual manner with test line 
and control line antibodies (see method 2.3.2).
2. This membrane was placed on the laminate plastic backing but no gold 
conjugate strip, top or sample pads were stuck down with this membrane. 
This laminated membrane was then cut into 4mm strips.
3. Any excess laminate was trimmed from these strips at the test line bottom 
edge so that the membrane exactly reached this edge.
4. The laminate cover was removed from the top edge and each 4mm strip was
arranged on a piece of card using the now exposed adhesive. This formed a 
‘comb’ of strips with enough space between each strip so that the ‘comb’ 
could fit into the wells of a blank microtitre plate (See Figure 2.3.5.8).
5. The following was placed in each well:
40|aL of Gold conjugate
80|aL of the relevant GCDB (1-16)
40jj.L of sample*
* Both negative and spiked positive samples were used.
6. The plate was shaken for 1 minute to allow mixing of the solutions.
7. The ‘comb’ was dipped into the wells and the flow characteristics were
observed over time.
Control Line 
Test Line
Plate
Gold Conjugate/Buffer 
& Sample Solution
Figure 2.3.5.8: The Microtitre ‘Comb’ Method. Schematic representation o f the 
‘comb’ made up of several test strips being inserted into the microtitre plate wells, 
which contain liquid components to run a test.
77
2.3.5.9 Stability Study Method
Accelerated stability studies were carried out to determine an expected shelf-life of 
both the cassette and wick ‘in-house’ tests. This was carried out by placing tests at 
37°C for the periods of time specified in Table 2.3.5.9 and testing these against 
devices, which were stored at 20-25°C (control devices) to decipher how stable the 
tests were (Anderson and Scott, 1991). A shelf-life equivalency table is shown in 
Appendix II. Devices were tested on day 0, 7, 14, 28 and month 2, 3, 4, 5, 6 and 7 
where applicable.
Weeks a t 37°C Equivalent tim e at 20-2S°C
14 12 months
21 18 months
28 24 months
Table 2.3.5.9: Accelerated time stability study: reference table used 
for calculating approximate shelf life o f the ‘in-house’ tests,
1. The number of devices to be placed at 37°C was calculated for each 
individual study. These devices were then manufactured in one lot using 
identical components for both the control devices and the devices to be 
placed on stability study (test devices). All devices were pouched to ensure 
they remained dry throughout the study.
2. The required number of test devices was placed at 37°C for the required 
length of time. The required number of control devices was placed at 20- 
25°C.
3. The test and control devices were tested in duplicate on day 0 with a negative 
urine and/or serum control and low and high hCG-positive urine and/or serum 
controls.
4. The same lot of hCG controls were run on the test and control devices on the 
subsequent testing days to ensure minimum variability. The results for the 
test devices were compared to those for the control devices. The shelf-life 
was calculated for the test based on the shelf-life equivalency table (see Table
2.3.5.9 above and Appendix II) and on the length of time taken for the test 
devices to deteriorate in comparison to the control devices.
5. The shelf-life calculated by this accelerated time stability method was 
confirmed by ‘real-time’ studies in a similar manner.
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Section 3: 
Results
3.1 Summary of common param eters throughout the  
development and evaluation of the ‘in-house’ hCG assay
This section outlines methods, which were used throughout the development of 
the assay. These methods did not change and were common for all experiments 
during the course of this project unless otherwise specified in the relevant 
sections. Various parameters of the assay, such as sample volume, assay time, 
etc., evolved with the development of the test. These changes are recorded in the 
relevant sections of the results and also in the summary tables (see 3.6, 3.10 and 
3.13).
(A) The Manufacture of Assay Components
o Nitrocellulose membrane spraying: Methods 2.3.2.1 -2.3.2.2.
e Gold conjugate manufacture: Methods 2.3.1.1-2.3.1.5.
e Gold Conjugate impregnation: Method 2.3.1.6.
© Membrane and conjugate strip drying: Method 2.3.5.1.
6 Assembly of test devices; Methods 2.3.3.1 -  2.3.3.2.
® Manufacture of hCG controls: Method 2.3.5.3.
(B) Assay Format
The assay format for the initial developmental process is laid out in Table 3.1.1.
Sample Volume 200jul (4 drops, using transfer pipette)
Assay Time 5 minutes
Assey Tem perature Room Temperature
Table 3.1.1: ‘ In-house’ assay parameters during early development
Note: In some cases the assay time was varied from 3 to 15 minutes for 
observation purposes. Any deviation from the assay time stated in Table 3.1.1 is 
noted in the relevant results section. The final assay formats are shown in method 
2.3.4.1.
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(C) Interpretation of Results
All results for the duration of the development and evaluation of the assay were 
interpreted as follows:
O The assay result was deemed negative, positive and/or inconclusive as per
Method 2.3.4.2.
© The intensity of the test and/or control line (where relevant) was then read
against a chart similar to that shown below (see Figure 3.1.1).
Line
Intensity Result Score
Negative 0
Positive 0.5
Positive 1
Positive 2
Positive 3
Positive 4
——■ Positive 5
Positive 6
Positive 7
— Positive a
Positive 9
Positive 10
Figure 3.1.1: Example of a Colour Interpretation Chart
© Use of P-N Value
In an attempt to facilitate more straightforward comparisons it was decided to 
employ a ‘P-N value', which was essentially the positive result minus the negative 
result obtained for a particular test combination.
(D) Miscellaneous Common Components
O Reference hCG Assay: ABI Unigold PT-hCG assay (see Materials, section
2 .1.10)
© Sample Pad B (see Appendix I): used throughout the initial development
to Section 3.11.2.
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3.2 Initial Selection of Suitable Test Line Antibodies
3.2.1 Assessment of the performance of nine anti-hCG antibodies 
when sprayed as the test line antibody.
Nine anti-hCG antibodies (one polyclonal and eight monoclonals) were selected 
initially for examination as suitable capture antibodies for the test line. Each antibody 
solution was sprayed on membrane no.2 (see Appendix I) at the concentrations 
outlined in Table 3.2.1.
A monoclonal anti-f3hCG antibody (antibody no.5, Appendix I) was conjugated to 
40nm colloidal gold (conjugate C, see Appendix I) and conjugate strips were made 
up at an A52onm of 0.6. Test strips were then manufactured using each of the sprayed 
nitrocellulose strips with the 40nm gold conjugate strip. Each test combination was 
assayed, as described in section 3.1, and the results interpreted accordingly. The 
results are shown below in Table 3.2.1.
T«»t Lin* 
Antibody No.
Test Lin* 
Cone. (rngfmL)
0 IU/L hCG Urin« (C.l.) 50 IU/L hCG Urin« (C.l.)
3 min S min 3 min 5 min
1 4mg/mL (undiluted) 0 0 1 2
1mg/mL 0 0 1 1
2 4mg/mL (undiluted) 0 0 0 1
1mg/mL 0 0 0 1
3 4mg/mL (undiluted) 1 1 1 2
1mg/mL 1 1 1 2
4 4mg/mL (undiluted) 0 0 0 1
1mg/mL 0 0 0 1
5 1mg/mL (undiluted) 1 1 1 2
6 1mg/mL (undiluted) 2 2 1 2
7 1mg/mL (undiluted) 2 2 0 1
6 1mg/mL (undiluted) 0 1 1 2
9 6mg/mL (undiluted) 0 1 1 2
1mg/mL 0 0 1 2
Table 3.2.1: Results for Test Line Antibody Comparison Study ~ Evaluation o f nine 
test line antibodies with 40nm gold conjugate (C). Colour intensity results at three 
and five minutes for positive and negative samples.
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In examining the results shown in Table 3.2.1, it is apparent that three of the sprayed 
antibodies, no.l, no.8 and no.9 exhibited satisfactory colour intensity (C.I.) results 
for both the positive and negative samples. No colour was observed for the negative 
sample at 3 minutes for each of the devices assembled using nitrocellulose sprayed 
with these three antibodies. At five minutes antibody no. 1 was still clear of colour for 
both the 4mg/mL and lmg/mL concentrations with this negative sample. Antibody 
no.8 demonstrated a C.I of 1 at five minutes for a sprayed concentration of lmg/mL, 
as did antibody no.9 at the 6mg/mL concentration. This positive C.I. result was 
deemed acceptable, despite its presence for a negative sample since the C.I of 1 was 
very faint and was only apparent outside the proposed assay time of 3 minutes for 
urine samples. It was also noted that for antibody no.9 this positive result was only 
observed for the 6mg/mL spraying concentration and not for the lmg/mL 
concentration, i.e.: it was proposed that further titering of the test line concentrations 
would eliminate the false positive C.I. result.
Antibodies no.l, no.8 and no.9 all provided a C.I. of 1 at 3 minutes and a C.I. of 2 at 
five minutes for the 50 IU/L hCG urine sample. These results, although faint, gave 
satisfactory positive results, with a distinct difference observed in the C.I’s obtained 
for the positive and negative samples using these three antibodies as the test line.
No positive/negative distinction was apparent for the remaining test line antibodies. 
Antibody no.2 and no.4 demonstrated poor sensitivity while antibodies no.3, no.5, 
no.6 and no.7 exhibited poor specificity.
•  Conclusion
As a result of these observations antibodies no.l, no.8 and no.9 were selected for 
further examination as the test line antibody.
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3.2.2 Further Evaluation of Three Test Line Antibodies.
Antibodies no.l, no.8 and no.9 were sprayed as described in Table 3.2.2 on 
nitrocellulose membrane no. 2 with gold conjugate C (see Appendix I).
Male urine was collected in house, pooled into different lots (A, B and C) and used 
as hCG negative controls. 50 IU/L hCG positive controls were manufactured using 
each of these three hCG negative controls. Each lot of controls was run on each 
device. The results are shown below in Table 3.2.2.
Tm I  Lin« 
ID No.
Test Lin* 
Concentration 
(mg/mL)
Pooled 
Sample 
ID No.
Colour Intensity (C.I.) Results
Negative Pool Positive Pool
5 min 10 min 5 min 10 min
1 4mg/mL (Undiluted) A 0 0 0 1
1 mg/mL 0 0 0 1
8 1 mg/mL (Undiluted) 0 0 1 1
9 6.2mg/mL (Undiluted) 0 0 1 2
1 mg/mL 0 0 0 1
1 4mg/mL (Undiluted) B 0 0 0 0
1 mg/mL 0 0 0 0
8 1 mg/mL (Undiluted) 0 0 0 1
9 6.2mg/mL (Undiluted) 0 1 1 2
1mg/mL 0 0 1 2
1 4mg/mL (Undiluted) C 0 0 1 2
1 mg/mL 0 0 0 1
3 lmg/mL (Undiluted) 0 0 2 2
9 6.2mg/mL (Undiluted) 0 0 3 3
1 mg/mL 0 0 2 2
Table 3.2.2: Comparison o f three Test Line Antibodies ~ Colour intensity results for 
three 0 IU/L & 50 IU/L hCG sample pools at five and ten minutes.
Negative Sample Results:
Each of the three test line antibodies showed no colour (C.I. of 0) for all three 
negative sample pools, apart from a C.I. of 1 which was noted at ten minutes for 
antibody no.9 sprayed at 6.2 mg/mL, with pool B. This false positive result was 
therefore considered non-applicable since no colour was observed with the same 
antibody no.9 at the lower concentration of lmg/mL. The positive sample for pool B 
gave a C.I. result of 2 with the test line antibody no.9 at 1 mg/mL.
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Positive Sample Results:
Antibody no. 8 and no.9 demonstrated good C.I results for each of the positive 
sample pools with antibody no.9 exhibiting the higher C.I. results. Antibody no.l 
showed only faint C.I. results at 10 minutes for two out of three of the sample pools. 
For the positive sample pool A the highest C.I. (C.I. of 2) was observed for antibody 
no.9 at a concentration of 6.2 mg/mL at 10 minutes, a C.I. of 1 was seen for antibody 
no.8 at 5 and 10 minutes. Similarly, C.I. results of 2 were seen for antibody no.9 at 
10 minutes with positive sample pool B, a C.I. of 1 was only detected at 10 minutes 
for antibody no. 8, while no colour was noted for antibody no. 1. Positive sample pool 
C provided C.I.’s of 2 at 5 and 10 minutes for both antibody no.8 and the lmg/mL 
concentration of antibody no.9. The devices manufactured with nitrocellulose 
sprayed with undiluted antibody no.9 gave C.I.’s of 3 at both 5 and 10 minutes. Once 
again the lowest results were obtained with antibody no.l with a C.I. of only 1 noted 
at 5 minutes for the undiluted test line. It should be noted that antibody no. 1 did not 
perform as well as observed in Table 3.2.1. Therefore, due to inconsistent 
performance with different samples this antibody was eliminated from inclusion into 
further test line antibody studies.
•  Conclusion
Antibodies no.8 and no.9, at 1 mg/mL, were selected for further examination with six 
different gold conjugates to determine the optimum test line/gold conjugate antibody 
pair (see section 3.3).
84
Test Line Combinations
3.3 Combined Evaluation of Various Gold Conjugate and
3.3.1 Assessment of six gold conjugates with two test line antibodies
Selection of an antibody for conjugation to a 40nm gold colloid was initially based 
on six monoclonal antibodies A, B, C, D, E and F (see Appendix I). Each gold 
conjugate was impregnated at the A520nm readings as outlined in Table 3.3.1 below, 
which were formerly shown to be optimal from previous studies (results not shown). 
Test devices were manufactured and evaluated using these gold conjugate strips and 
membrane no.2 was sprayed with antibodies no.8 and no.9 in an attempt to choose 
the most suitable test line/gold conjugate antibody pair.
Gold Conjugate Antibodies Test Line Antibodies
Gold Conjugate I.D. AjïOnm Test Line I.D. Concentration
A 0.3 no. 8 1mg/mL
B 0.3 no. 9 1mg/mL
C 1.0 - —
D 0.43 - —
E 0.3 - -
F 1.0 - —
Table 3.3.1: List of six 40nm gold conjugate and two test line antibodies evaluated 
in combination. The A 520nm at which the gold conjugates were impregnated and the 
test line spraying concentrations are included.
The results are shown in Table 3.3.2, 3.3.3 and 3.3.4 and graphed on pages 87-88 
(Figure 3.3.1 and 3.3.2).
The results from these tables reveal that the gold conjugates C and D performed best 
with both of the test lines no. 8 and no. 9 and exhibited comparable results to those 
observed for the ABI reference test. Gold conjugates A and B in combination with 
test line no. 8 manifested little differentiation between positive and negative samples. 
The same conjugates with test line no. 9 provided acceptable results (P-N value of 
0.5 for both conjugates, see Table 3.3.4, page 87) but exhibited slight false positives 
for the negative sample (C.I. of 0.5 for both conjugates at 5 minutes). The C.I. results
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for the positive samples were also slightly lower than those noted for conjugate C 
and D (C.I. of 1 for both, see Figure 3.3.2).
Teat Line 
I.D. No.
Test Lina 
Cone, (mg/ml)
Conjugate
£  &tMnm
Result (C.I.)
at 5 min at 10 min
8 1 mg/ml A at 0.3 1 1
B a t 0.3 1 1
Cat 1.0 0 0.5
D at 0.43 0 0
E a t 0.6 2 2
F a t 1.0 2 2
9 1 mg/ml A at 0.3 0.5 1
B at 0.3 0.5 1
Cat 1.0 0 0.5
D at 0.43 0 0
E at 0.6 1 2
F a t 1.0 2 2
ABI 0 0.5
Table 3.3.2: C.I. results for the gold conjugate/test line combinations outlined in 
Table 3.2.1, using a negative (0 IU/L hCG) urine sample.
Teat Lina
I.D. No.
Test Lina 
Cone, (mg/ml)
Conjugate Result (C.I.)
*  "MOmti at 9 min at 10 min
8 1 mg/ml A at 0.3 1 1
B at 0.3 1 2
C at 1.0 2 2
D at 0.43 2 2
E at 0.6 2 2
F a t 1.0 2 2
9 1 mg/ml A at 0.3 1 2
B at 0.3 1 1
C at 1.0 3 3
D at 0.43 4 4
E a t 0.6 2 2
F a t 1.0 2 2
ABI 2 2
Table 3.3.3: C.I. results for the gold conjugate/test line combinations outlined in 
Table 3.2.1, using a positive (5 0 IUA. hCG) urine sample.
Conjugate E and F were eliminated from further study since strong false positives 
were a factor for these two conjugates with both test lines. No differentiation was
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apparent between positive and negative samples for these combinations (all samples 
provided a C.I. result of 2).
Test Lin« 
I.O. No.
Tost Lino 
Cone, (mg/ml)
Conjugate
® A-uonm
P-N Vatu«
at 5 min
a 1 mg/ml A at 0.3 0
B at 0.3 0
Cat l .O 2
D at 0.43 2
E a t 0.6 0
Fat 1.0 0
9 1 mg/ml A at 0.3 0.5
B a t 0.3 0.5
Cat 1.0 3
D at 0.43 4
E at 0.6 1
Fat 1.0 0
ABI 2
Table 3.3.4: Comparison ofP-N  values for the gold conjugate/test line 
combinations outlined in Table 3.3.1, using the negative and positive C.I. results
from Tables 3.3.2 and 3.3.3
Figure 3.3.1: Comparison of C.I. values for six gold conjugates & two test 
lines using a hCG negative urine at 5 minutes
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Figure 3.3.2: Comparison o f C. I. values for six gold conjugates & two
a hCG positive sample at 5 minutes
8  @ 0.3
0.43C @  1.0 E @ 0.6 
C onjugate (A520n J
0
A @ 0.3
■  Test Line No. 8 
□  Test Line No.9
Based on these results the test line chosen for further evaluation was no. 9 as this test 
line gave stronger positive C.I. results for conjugate C and D compared to the ABI 
test. No. 9 also demonstrated cleaner negative results than no. 8, with those for 
conjugate C and D matching those for the ABI reference test.
The gold conjugates selected as the most applicable for further use within this assay 
were C and D, based upon the P-N values which pertained to their positive and 
negative C.I. results. Peaks for P-N values were seen with both conjugates C and D 
from Table 3.3.4. This result confirms their suitability as conjugates.
• Conclusion
Test line no.9 was chosen as the test line antibody at this point. Two monoclonal 
anti-(3-hCG antibody-gold conjugates (C and D) were selected for further testing with 
the new test line based on the above results.
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3.3.2 Direct Comparison of Conjugate C and Conjugate D
The performance of the two selected gold conjugates, C and D, were assessed with 
varying concentrations of the test line antibody (results not shown). Consequently, 
two test combinations were chosen:
O Conjugate C at an A520nm of 1.0 with the test line antibody at l.Omg/mL.
© Conjugate D at an A520nm of 0.6 with the test line antibody at 2.0mg/mL.
Both of these combinations were compared using the same urine samples to 
determine the most suitable final format for the test. The results are presented in 
Figure 3.3.3 overleaf.
As observed from Figure 3.3.3 conjugate D did not perform as expected. None of the 
25 IU/L samples were detected and the 50 IU/L samples resulted in quite low colour 
intensity. The C.I. results for the 50 IU/L samples were, however, of similar intensity 
as the ABI reference test. The conjugate C combination gave the most satisfactory 
results, giving better results than the ABI test, particularly for the 50 IU/L samples.
Conjugate D was re-evaluated at an A520nm of 0.75, 1.0 and 1.5 with a test line 
antibody concentration of 2.0 mg/mL (results not shown). Even at the A520nm of 1.5 
the colour intensity of these positive samples was very faint. It appeared that the 
conjugate became unstable over time.
• Conclusion
Conjugate C at an A520nm of 1.0, with the test line antibody at 1.0 mg/mL, was 
selected for use as the format for the in house assay at this stage in the development 
of the test.
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Figure 3 .3.3: Comparison of C.l. values for Conjugate C & D vs the ABI test using 3 urines , each tested at
OIU/L hCG and spiked with 25 IU/L and 5 0 IU/L hCG.
□  OIU/L, ABI
■  25 IU/L, ABI
■  50 IU/L, ABI
@ OIU/L, C at 1.0 
® 25 IU/L, C at 1.0
■  50 IU/L, C at 1.0
■  0 IU/L, D at 0.6
■  25 IU/L, D at 0.6
■  50 IU/L, D at 0.6
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3.4 The discovery of specificity problems w ith fem ale urines &
methods to resolve this issue
3.4.1 Initial evaluation of in house test combination using male and 
female urine samples
The previous experimentation with gold conjugates had been carried out using male 
urine samples for evaluation. It was, however, noted at a later date that negative female 
urine samples gave a higher proportion of false positives than that observed for male 
urines. A summary of these results is shown below in Table 3.4.1. Since the assay was 
being developed for use as a rapid pregnancy test (i.e.: the projected market was 100% 
female) it was vital to re-examine the gold conjugate/test line antibody combination 
again using female urine samples.
Samples Assayed
Total num btr of Samples 25 25
Number of negative results 25 12
Number of false positive results 0 13
% Specificity 100% 48%
Table 3.4.1: Summary o f evaluation o f the in house test combination with
male & female urine samples.
Conjugate C was impregnated at the A520nm readings outlined below and tested with 
membrane no. 2 sprayed at lmg/mL with test line antibody no. 9. Each conjugate/test 
line antibody combination was re-evaluated with positive and negative male and female 
urines (obtained in-house), some of the results of which are shown overleaf in Table 
3.4.2 and illustrated in Figure 3.4.1 - 3.4.3.
The problem of false positives with female samples was apparent from the results shown 
in Table 3.4.2 and Figures 3.4.1, 3.4.2 and 3.4.3. The results for the ‘in-house’
Conjugate
AsWnm
C.I. Results a t S minutes
Male Samples Female Samples.
gt i f ^ irZ^ q sr ^ 77-;
K g F g
[flf at [ I Vjplw
W m
Cat 1.0 0 2 2 2 2 0
C at 0.6 0 2 2 1 1 0
Cat 0.3 0 1 1 0.5 1 0.5
C at 0.15 0 1 1 0 0.5 0.5
AB I 0 2 2 0 2 2
(Reference)
Table 3.4.2: Comparison o f C. I. results and P-N values with both male and 
female negative (0 IU/L) and positive (50 IU/L) using four dilutions o f the same 
gold conjugate (c). Results read at 5 minutes.
assay with female samples vary substantially from those detected when a male urine 
pool was used (see Table 3.4.2 and Figure 3.4.1 and 3.4.2). Figure 3.4.3 clearly 
demonstrates these different reactivities of conjugate C with male and female urines. 
The P-N value dropped considerably from 2 (with male samples) to 0 (with female 
samples) with an A520nm of 1.0 for this conjugate. At an A52onm of 1.0 conjugate C gave 
equal results for both the positive and negative female samples (C.I. of 2, see Table 
3.4.2) and consequently a poor P-N value of 0. It was necessary to dilute out conjugate C 
to an A520nm of 0.15 before the false positive was eliminated (C.I. of 0), however, the 
colour intensity of the positive result was also reduced to a C.I. of 0.5. This elimination 
of the false positive result provided an improved P-N value of 0.5 (see Figure 3.4.3).
While conjugate C at an A520nm of 0.15 was the only combination to supply a negative 
C.I result for the female negative sample, the C.I. results with positive female samples 
were too low to be deemed useful. The positive C.I. of 0.5 for the female positive 
sample compared poorly with that recorded for the ABI assay. The ABI test provided a 
C.I. of 2 for the same sample while maintaining a C.I. of 0 for the hCG-negative sample. 
It was noted from Figure 3.4.3, that the best P-N value obtained for the female samples 
was only half of the worst P-N value calculated for the male samples. It was, as a result, 
necessary to determine a method of eliminating the false positive result with negative 
female samples without jeopardising the positive C.I. result.
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Figure 3.4*1: Comparison of C.l. results at 5 minutes using male and female 
hCG-negative (0 lil/L) urine samples on tests with four dilutions of the gold
conjugate C
2. 1.5 
&
(A
Ca>
o 0.5 
o
hi
0
C@1.0 C @ 0.6 C @ 0.3 C@0.15 ABI
■ Male Samples 0 0 0 0 0
□ Female Samples 2 1 0.5 0 0
Conjugate (AszonJ
Figure 3.4.2.: Comparison of C.l.results at 5 mins using male and 
female hCG-positive (50 IU/L) urines with tests manufactured with 
four dilutions of Conjugate C
C@ 1.0 C @ 0.6 C  @  0-3 C @ 0 .1 5 ABI
■ Male Samples 2 2 1 1 2
□ Female Samples 2 1 1 0.5 2
Conjugate (A520nm)
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Figure 3 .4 .3  : Comparison o f P-N Values for four gold 
conjugates using male and female test samples
□  F em ale  Sam p les  
■  M ale Sam p les
C@1.0
C @  0.6
C @  0.3
Conjugate
C @ 0 .1 5
•  Conclusion
It was concluded that, in an attempt to eliminate false positives with conjugate C, it was 
necessary to examine the use of various non-specific serums in the conjugate. It was 
hoped that the inclusion of such serums would absorb the non-specific component in the 
female urine, which was binding to the test line antibody (see Discussion, section 4.5.2).
3.4.2 Assessment of the inclusion of various serums in the gold 
conjugate strip to reduce non-specific results.
Outlined overleaf in Table 3.4.3 are five different serums and the relevant percentages to 
which they were supplemented into the gold conjugate solution. Each gold conjugate 
solution was manufactured using conjugate C at an A52onm of 1.0 in GCDB (see 
Materials, section 2.1). A control conjugate strip was manufactured by impregnating 
conjugate C at the same A520nm but without the inclusion of any non-specific serums. 
The test line antibody no. 9 was sprayed at lmg/ml on membrane no. 2.
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The test combinations were tested with both a negative and positive female urine 
sample. The results are outlined in Table 3.4.3 below and compared in Figure 3.4.4.
Conjugats/Sarum C.I. Results P-N
ValueNegative  
(0 IU/L)
Positive 
(50 IU/L)
C  at 1 .0 /N o  added serum 2 2 0
C a t  1 .0 /1 5 %  (v/v) Goat Serum 1 2 1
C at 1 .0 /2 0 %  (v/v) Goat Serum 0 2 2
C a t  1 .0 /5 %  (v/v) Human Serum 1 2 1
C at 1 .0 /1 0 %  (v/v) Human Serum 1 2 1
C a t  1 .0 /1 5 %  (v/v) Rabbit Serum 1 2 1
C  at 1 .0 /2 0 %  (v/v) Rabbit Serum 0.5 2 1.5
C a t  1 .0 /5 %  (v/v) Mouse IgG 0.5 2 1.5
C at 1 .0 /1 0 %  (v/v) Mouse IgG 0 1 1
C a t  1 .0 /1 5 %  (v/v) FBS 1 1 0
C a t  1 .0 /2 0 %  (v/v) FBS 2 2 0
Table 3.4.3: Evaluation o f the addition o f non-specific serums to gold 
conjugate C -  Colour intensity results for a 0 IU/L and a 5 0 IU/L hCG 
female urine sample at an assay time o f 5 minutes.
The inclusion of all of the non-specific serums, with the exception of FBS, to the 
impregnation solution for Conjugate C (A520nm 1-0) reduced non-specific binding when 
compared to the control strip. This is clearly demonstrated in Figure 3.4.4 and by the P- 
N values illustrated in Table 3.4.3.
The greatest improvement in the P-N value and in the reduction of the C.I. for the 
negative sample was noted for the strip supplemented with 20% (v/v) goat serum. This 
combination appeared to be the most effective in reducing the false positive result (from 
a C.I. of 2 to a C.I. of 0). This lowering of the negative C.I. was achieved without 
diminishing the positive C.I. result of 2 (see Figure 3.4.4). The P-N value for this 
combination was therefore seen to increase from 0 to 2 (see Table 3.4.3).
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The performance of the 20% (v/v) goat serum combination was followed closely by that 
of the 20% (v/v) rabbit serum combination and the 5% (v/v) mouse IgG. Both of these 
combinations displayed only a very faint positive line (C.I. of 0.5) for the negative urine 
while maintaining the positive sample C.I. at 2 (see Figure 3.4.4). This allowed for a 
satisfactory P-N value of 1.5 (see Table 3.4.2). 10% (v/v) mouse IgG eliminated the 
false positive result, however, the C.I. for the 50 IU/L positive sample was reduced by 
50% (v/v) from 2 down to 1. This decrease, thereby, negated any expected positive 
effect that the reduction in the negative sample C.I. may have had on the P-N value (see 
Table 3.4.2).
The supplementation of the gold conjugate strip with human serum reduced the false 
positive result seen for the negative sample by 50% (v/v) (i.e. : the C.I. dropped from 2 to 
1). As for the other two serums the positive result remained the same, at a C.I. of 2. It is 
important to note, however, that the inclusion of 10% (v/v) human serum did not reduce 
the false positive result any further than that seen for the addition of 5% (v/v) human 
serum (i.e.: both displayed a negative sample C.I. of 1). Therefore, the incorporation of 
twice as much human serum in the 10% (v/v) human serum strip as was added to the 5% 
(v/v) strip, did not have any effect on the negative sample result. Since the addition of 
greater amounts of human serum did not produce the desired negative result (i.e.: a C.I. 
of 0) it was decided to reject the use of human serum as a ‘blocker’ in the gold conjugate 
strip for this assay.
Both percentages of FBS produced poor results, showing no differentiation between 
positive and negative samples. This is clearly illustrated in Table 3.4.2 since both 
percentage solutions yielded a P-N value of 0. For this reason FBS was also rejected for 
inclusion in the gold conjugate impregnation solution.
Despite their satisfactory results, rabbit serum and mouse IgG were excluded for use as 
blockers. Rabbit serum was removed from further use since the 20% (v/v) solution did 
not completely eliminate the specificity problem and it was not feasible to add a higher 
percentage of serum to the conjugate strip. Mouse IgG was eliminated due to the effect 
observed on the C.I of the positive sample. These results combined with the results
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outlined on the previous page and the knowledge that purified mouse IgG would prove 
to be an expensive blocker at high percentages, ensured the selection of goat serum for 
addition to the gold conjugate solution to eliminate non-specific binding.
•  Conclusion
A substantial difference was noted in the results achieved with male and female urine 
samples using the chosen format of the in house assay.
The inclusion of 20% (v/v) goat serum to the gold conjugate C, impregnation solution 
was found to reduce the non-specific binding seen with the use of female samples.
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Figure 3.4.4 : Comparison of C.l. results for hCG-negative and hCG-positive urines using tests 
with five different sera included in the conjugate strip at concentrations ranging from 0-20% (v/v)
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As outlined in Section 1.11.3, Introduction, the control line is an intrinsic part of the 
rapid assay. The necessary properties for a suitable control line are described in 
section 4.5.1, Discussion. Three potential control lines were selected for comparison 
with the in house assay:
O Rabbit anti-mouse IgG (RAM)
© Goat anti-mouse IgG (GAM)
© Goldline (GL)
Membrane no. 2 was sprayed with each of the above antibodies at the required 
control line position (see Method 2.2.2.2). The test line antibody (no. 9) was sprayed 
at the test line position (see Method 2.2.2.2) and gold conjugate C was used at an 
A520nm of 1.0. Spraying concentrations for the test and control lines are outlined in 
Table 3.5.1 along with the corresponding results.
From the results shown in Table 3.5.1 it is apparent that the colour intensity for each 
of the control line combinations were affected by the strongly positive hCG sample. 
The intensity of the GL control line was almost diminished completely by this 
sample, giving a reading of only 1 at five minutes and a C.I. of 2 at the same assay 
time for the negative sample. The C.I. results for control line with the negative and 
low positive (50IU/L) samples were far too low for this control line to be considered 
acceptable. The GL solution had been applied to the membrane undiluted, i.e.: the 
maximum amount of GL possible was available to bind any unbound gold conjugate 
in each test. Therefore, it would have been expected that this GL control line would 
have given stronger colour intensities than those observed. GL was thus eliminated 
from any further evaluation for use as a control line.
Both the RAM and GAM gave excellent control lines for the negative and 50 IU/L 
hCG positive samples, giving colour intensities of 10 with each sample. There was, 
however, a marked decrease in intensity when the strongly positive (100,000 IU/L) 
sample was run. For the RAM at 0.5 mg/mL an intensity of 4 was observed at 3 
minutes, less than half the intensity observed for the negative and 50 IU/L hCG 
samples at the same assay time. The colour intensity increased to 6 at 3 minutes with
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Control Cone, of Control Sample C.l. Result for Control Line
Lino Line (mg/ml) (IU /L) 3 mine 5 mlns
RAM 0.5 0 10 10
50 10 10
100,000 4 6
1.0 0 10 10
50 10 10
100,000 6 6
1.5 0 10 10
50 10 10
100,000 6 6
GAM 0.5 0 10 10
50 10 10
100,000 6 6
1.0 0 10 10
50 10 10
100,000 8 8
1.5 0 10 10
50 10 10
100,000 8 8
Goldline* Undiluted 0 2 2
50 2 2
100,000 0 1
Table 3.5.1: Comparison o f three control lines, rabbit anti-mouse (RAM), goat anti­
mouse (GAM) and Goldline* at various concentrations using negative (0 IU/L hCG), 
positive (5 0 IUA. hCG) and strongly positive (100,000 IUA hCG) urine samples. C.l. 
results at 3 and 5 minutes. *Reacts with the gold particle on the gold conjugate
the 1.0 and 1.5mg/mL concentrations of RAM. These lines were quite distinct but 
were not as intense in colour as those observed with the GAM at concentrations of
1.0 and 1.5 mg/mL. These control lines both gave colour intensities of 8 when the 
strongly positive hCG sample was used, which was only slightly less intense than 
that noted for the same GAM concentrations using the negative and 50 IU/L hCG 
samples.
•  Conclusion
Goat anti-mouse antibody at 1 mg/mL was selected for use as the control line for the 
in house assay format.
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3.6  Format of the Prototype ‘In-House’ Assay following Initial
Development Work
Outlined below in Table 3.6.1 is a summary of all the test components and the 
amounts o f each of these that are utilised for the manufacture of the ‘in-house’ assay 
at this point in the development of the test. The aim of this section is to clarify, in 
one table, the format of the assay which was used for the first clinical trial (see 
following section, 3.7). Further on in this results section similar tables will be 
presented to exhibit the changes that occur in the test format as the development 
progresses (see sections 3.10 and 3.13).
Component Component Details Used at:
Test Line Antibody Antibody no. 9 1 mg/mL
Control Line Antibody Goat Anti-Mouse Antibody 1 mg/mL
Nitrocellulose Membrane Membrane no. 2 n/a
Gold Conjugate Antibody Anti fi-hCG Monoclonal 
(Conjugate C)
As20nm 1 0
Gold Conjugate GCDB Goat Serum at
Impregnation Buffer With Goat Serum 20% (v/v)
Sample Pad Sample Pad B n/a
Sample Volume n/a 200jul (4 drops)
Assay Time n/a 5 minutes
Table 3.6.1: Format o f Prototype Assay: List of test components, relevant 
quantities and test parameters. Full details o f components are found in Appendix I
and Materials, section 2.1.
3.7 First Internal Clinical Trial
The first clinical trial was carried out internally using 116 female urine samples from 
the Rotunda Hospital, Dublin. All samples were assayed using the ABI assay 
(reference test) and the ‘in-house’ assay. The ‘in-house’ hCG test format utilised 
during this trial is outlined in Section 3.6.
An analysis (see Method 2.2.5.5) of the results obtained is shown below in Table
3.7.1 and 3.7.2. The frequency of various C.I. results obtained with each test is 
plotted overleaf in Figure 3.7.1.
Test ‘In-house' HCG assay Total
Positive Negative
Rotunda Positive 95 1 96
Hospital
Negative 6 14 20
Total 101 15 118
Table 3.7.1: Comparison o f the ‘in-house’ assay versus the 
Rotunda Hospital results
Test ABI Assay Total
Positive Negative
Rotunda Positive 95 1 96
Hospital
Negative 1 19 20
Total 96 20 116
Table 3.7.2: Comparison o f the ABI assay versus the 
Rotunda Hospital results
The results obtained for the ‘in-house’ hCG assay were satisfactory in comparison to 
those observed for the ABI assay. As demonstrated in Table 3.7.1 the ‘in-house’ 
assay detected all but one of the positive samples which matched the results obtained 
with the ABI assay for the same samples (see Table 3.7.2) i.e.: both displayed a 
sensitivity of 98.9% (see Method 2.2.5.5). However, six of the twenty negative 
samples read as positive on the ‘in-house’ assay giving a specificity of only 70% (see 
Figure 3.7.1). This was in contrast to a specificity of 95% for the ABI test since only
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one of these samples resulted in a false positive C.I. result. For some of the samples 
run, the ‘in-house’ assay demonstrated quite an uneven release of gold conjugate 
from the glass fibre pad. It was, therefore, deemed necessary to examine different 
methods of improving the release of the gold conjugate from the pad. It was also 
decided to examine other methods of optimising the assay parameters in an attempt 
to reduce the number of false positive results thereby improving the specificity of the 
assay.
Another issue, which was noted for the in-house assay was that 24 of the 116 tests 
run, gave faint control lines. It was concluded that further work was necessary to 
obtain a control line giving good colour intensities for strong positive samples.
Flgur« 3.7.1: Plot of the frequency of various positive and negative C.I. results for 
and ABI A ssa y s  with 1 1 6  Rotunda Hospital sam ples
In-House
‘In-House
ABIColour Intensity
•  Conclusion
It was decided to evaluate the components of the Gold Conjugate Dilution Buffer 
(GCDB), which was used for the impregnation of the gold conjugate, in an attempt to 
improve the flow of gold conjugate from the glass fibre pad.
Based on the poor specificity of the ‘in-house’ assay it was also concluded that 
further optimisation was necessary to alleviate the problem of false positives which 
was observed for this trial and that the control line required further optimisation.
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3.8 Optimisation of Prototype test based on first 
clinical trial results
3.8.1 Improvement of the Control Line
Following the observation of faint control lines for the in house assay during the 
clinical trial (Section 3.7) it was decided to supply excess gold conjugate within the 
assay to improve the intensity of the control line. This was carried out by adding a 
non-specific gold conjugate to the conjugate pad. The ideal non-specific gold 
conjugate was one which would bind only to the control line and would have little or 
no affinity for the test line antibody.
A commercially available anti-hepatitis B antibody (see Materials, section 2.0) was 
conjugated to 40nm gold. This gold conjugate was impregnated to give a solution of 
A520nm 1.0 (i.e.: the same A520nm as used for the anti-p-hCG gold conjugate in the ‘in- 
house’ assay). This conjugate was also impregnated at the A520nm readings as 
outlined in Table 3.8.1 with conjugate C at an A520nm of 1.0. An anti-phCG gold 
conjugate strip was manufactured without any anti-hepatitis B gold conjugate for use 
as the negative control strip. Each of these gold conjugate strips were assembled 
using membrane sprayed with GAM IgG control line and the test line antibody no. 9 
at 1 mg/mL. The results are shown in Table 3.8.1.
It is clear from Table 3.8.1 that the addition of a non-specific gold conjugate to the 
conjugate strip improved the intensity of the control line, especially when a strongly 
positive sample was used. The test strip devoid of the non-specific gold conjugate 
gave a colour intensity of only 6 at three minutes assay time for the 100,000 IU/L 
sample.
As can be seen from the results this colour intensity was improved upon for all of the 
conjugate strips containing the anti-Hepatitis B gold conjugate up to an A52onm of 
0.075. The conjugate strips that possessed the anti-Hepatitis B gold conjugate at an 
A520nm of 0.15 and 0.1 each gave a colour intensity of 10 for each of the samples run. 
The strips manufactured at an As20nm of 0.08 and 0.06 gave lower C.I. results for the
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100,000 IU/L sample. Since a C.I. result of 10 was the maximum colour intensity 
attainable, according to the colour interpretation chart (see section 3.1), the anti- 
Hepatitis B gold conjugate at A520nm 0.1 was selected for inclusion into the gold 
conjugate impregnation solution. This A520nm was also chosen for cost reasons, as 
less anti-Hepatitis B gold conjugate would be required at this dilution.
Conjugate Strip (AsMnm) Sample (IU/L) C .I. Result for Control Line
3 mlns 5 mlns
No anti-HepB Au 0 10 10
& anti-hCG Au at 1.0 50 10 10
100,000 6 6
No anti-hCG Au & 0 10 10
anti-HepB Au at 1.0 50 10 10
100,000 10 10
Anti-HepB Au at 0.15 0 10 10
& anti-hCG Au at 1.0 50 10 10
100,000 10 10
Anti-HepB Au at 0.1 0 10 10
& anti-hCG Au at 1.0 50 10 10
100,000 10 10
Anti-HepB Au at 0.08 0 10 10
& anti-hCG Au at 1.0 50 10 10
100,000 8 10
Anti-HepB Au at 0.06 0 10 10
& anti-hCG Au at 1.0 50 10 10
100,000 6 8
Table 3.8.1: Comparison o f the controlline (CL) colour intensity for gold conjugate 
strips with varying levels o f a non-specific gold conjugate. Colour intensity results for 
the CL with 0, 50 & 100,000 IUA. hCG urines at 3 and 5 mins.
It should be noted that the conjugate strip which only contained anti-Hepatitis B gold 
conjugate did not interfere with the test line for any of the samples, i.e.: a colour 
intensity of 0 was obtained for each sample (results not shown). This indicated that 
the anti-Hepatitis B gold conjugate did not have an affinity for hCG and would, 
therefore, not interfere in the assay.
• Conclusion
Anti-hepatitis B gold conjugate was selected for inclusion in the conjugate strip at an 
A520nm Of 0.1.
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3.8.2 Determination of the affinity of various Anti-hCG antibodies for 
the hCG antigen and confirmation that an Anti-LH antibody has 
no affinity for hCG, by the employment of a Dot Blot Method.
It was decided to examine the affinity of the antibodies used in the current format of 
the ‘in-house’ assay for the hCG antigen as a consequence of the poor specificity of 
the assay as observed during the first clinical trial. The following antibodies were 
evaluated using the dot blot method (see method 2.3.5.6) to determine their affinity, 
if any, for the hCG antigen: test line antibodies nos. 1, 8 and 9 and gold conjugate 
antibody C (see Appendix I for further details). An anti-LH antibody was also 
examined for its affinity for the hCG antigen as it was planned (see section 3.8.3) to 
determine whether its inclusion in the assay would have an effect on the false 
positive results seen during the first clinical trial (see section 3.7). Each antibody was 
incubated with membrane, which had been ‘dotted’ with hCG concentrations ranging 
from 5-100 IU/dot (see Method 2.3.5.6). Two negative control blots were performed 
in combination with the antibodies being examined for affinity. These negative 
control blots used the goat anti-rabbit HRP and rabbit anti-mouse-HRP conjugates, 
which were used to detect the other antibodies. The results are shown overleaf in 
Figure 3.8.1.
From the results shown in Figure 3.8.1 it is evident that the antibody no. 9 possessed 
the highest affinity for the hCG antigen at all levels of hCG. The dots for this 
antibody were several times more intense in colour than those observed for any of 
the other antibodies tested. From their dot blots it could be seen that antibodies no. 8, 
no. 1 and C all have similar affinities for the hCG antigen but none as strong as that 
observed for antibody no. 9. The colour intensities for the blots of these antibodies 
were much fainter than those achieved with antibody no. 9, but were similar in 
intensity to one another. From this it can be concluded that the test line antibody used 
for the clinical trial was indeed the most suitable, as it possesses the highest affinity 
for the antigen being detected.
106
Test Dot Blots
100 100 © 100
75 75 a 75
50
50 \  <y 50
30 30
r.”
30
20
20
20
10
10 /
n
10
5
5
5
100
50
20
© '
#
Control Dot Blots
100
50
20
100
75
50
30
20
100
75
50
PN
30
20 
10
5
No. 1 No. 8 No. 9 C
Anti-Mouse Ab Anti-Rabbit Ab 10
HRP conjugate HRP conjugate
Anti-LH
Figure 3.8.1: Dot blot results demonstrating the affinities o f the antibodies listed on 
page 106, for the hCG antigen at levels varying from 100IU hCG per dot to 
5 IU hCG per dot (shown by the numbers to the left o f the blots). The blue writing 
beneath each blot indicates the antibody, which was incubated with that particular 
blot. All antibodies were examined at a concentration o f 5/jg/mL using HRP 
conjugates and probed with a DAB substrate.
Based on these results the spraying concentration of the test line antibody (no. 9) was 
re-evaluated, as was the A520nm of the gold conjugate C, both of which had been 
selected for use in the ‘in-house’ assay format during previous studies. The re- 
evaluations demonstrated that the chosen test line concentration of 1 mg/mL and the 
A520nm of 1.0 for the gold conjugate provided the most acceptable, sensitive and 
specific results (results not shown).
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Minimal cross-reactivity was detected for the anti-LH, anti-mouse-HRP and anti- 
rabbit-HRP antibodies. It can be concluded, therefore, that the colour intensity seen 
for antibodies no. 9, no. 8, no. 1 and C was due to these antibodies only binding to 
the hCG on the membrane and not through non-specific binding of the conjugates. It 
was also decided that the anti-LH could be used in the assay without interfering in 
the binding of hCG to the test line (see section 3.8.3 and Discussion, section 4.5.2).
• Conclusion
Antibody no. 9 was proven to be the most suitable test line antibody and was thus 
retained for use as the test line. The anti-LH antibody was shown to have minimal 
interaction with the hCG antigen and was deemed suitable for inclusion in the assay.
3.8.3 Examination of the inclusion of an Anti-Luteinising Hormone 
(LH) line below the test line
Also as a result of the disappointing % specificity noted during the first clinical trial 
it was postulated that LH may have been binding to the test line (see Discussion, 
section 4.5.2). An anti-LH antibody was received from Genzyme and was sprayed at 
a concentration of lmg/mL 3mm beneath the test line with the intention that this 
antibody could bind any LH in the urine, thereby reducing the specificity problem. 
Negative urine, which resulted in a false positive C.I. in the clinical trial, was 
assayed, along with a 50 IU/L and 100,000 IU/L-positive urine sample on strips 
assembled using the membrane sprayed with and without the anti-LH line. The 
results were read at 3, 5, 10 and 15 minutes and are shown in Table 3.8.2.
The results obtained from this study were not as expected, as both the specificity and 
sensitivity worsened with the inclusion of an anti-LH line below the test line (see 
Discussion, section 4.5.2). Without the anti-LH line, only faint colour was beginning 
to appear at 10 minutes for the negative urine. On the other hand, with the anti-LH 
line colour appeared by 3 minutes for the same sample, which increased to a C.I. of 2 
by 15 minutes. It is interesting to note that for the tests sprayed with the anti-LH line 
the 50 IU/L and 100,000 IU/L samples displayed lower colour intensities than that of 
the tests devoid of an anti-LH line.
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Teet Sample Anti-hCG Line Anti-LH Line
(IU/L) 3 mln 3 mln 10 min 15 mln 3 mln 5 mln 10 min 15 mln
Without 0 0 0 0.5 0.5 n/a n/a n/a n/a
LH Line 50 0 2 4 4 n/a n/a n/a n/a
100,000 2 2 4 4 n/a n/a n/a n/a
With LH 0 0.5 0.5 1 2 0 4 6 6
Line 50 0 1 2 2 4 6 6 6
100,000 1 1 2 2 6 6 6 a
Table 3.8.2: Colour intensity results for the test line (anti-hCG) and where 
applicable, the anti-LH line for tests manufactured with and without an Anti-LH line 
sprayed below the test line. Colour intensity results are shown for a negative (0 
IU/L), a positive (5 0 IU/L) and a strongly positive (100,000 IU/L) hCG urine.
Quite intense colour was seen for the anti-LH line on tests which possessed such a 
line (see Table 3.8.2 above, C.I. results ranging from 4 -  8). Reasons as to why this 
line was visible and as to why the colour intensity increased for the negative sample 
and decreased for the positive samples are discussed section 4.5.2, Discussion.
•  Conclusion
It was decided not to carry out further studies using the anti-LH line due to the 
worsening of sensitivity and specificity levels as a result of the presence of this line 
below the anti-hCG test line. It was concluded that further work would be necessary 
examining various agents capable of blocking non-specific binding (i.e.: ‘blockers’) 
in an attempt to alleviate the false positive problem.
3.8.4 Evaluation of Gold Conjugate Release Pads
The importance of the characteristics of the gold conjugate release material are 
outlined on section 4.5.3, Discussion. In this study it was decided to examine six 
different release pads for their release qualities and their volume capacity. These 
were the release pad, which had been in use up until this point (no. 1) and five
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release pads of various grades supplied by Millipore (pads 2-6) (see Materials, 
section 2.1 and Appendix I).
An 8mm x 30cm strip was cut from each of the release materials. Each strip was 
impregnated with conjugate C at an A520nm of 1.0 and the volume of gold absorbed 
was recorded in Table 3.8.3 below for each pad. The strips were dried and assembled 
into test devices, keeping all other components common. The results are outlined in 
Table 3.8.4.
Pad ID no. Volum« 
Absorbed (mL)
Ease of 
Absorption
1 1.35 Quick Absorption
2 0.35 Uneven, patchy
3 0.40 Very slow
4 0.50 Poor, hydrophobic
5 0.40 Good
6 0.45 Poor
Table 3.8.3: Comparison of various release pads nos. 1-6 (see Appendix I and 
Materials, section 2.1) for the gold conjugate strip: volume of gold conjugate 
absorbed and absorption characteristics for each release pad are recorded.
Pad I.D
no.
Negativ» Sample Positive Sample
Test Line Control Line Test Line Control Line
1 0 8 4 8
2 2 4 4 4
3 2 4 4 4
4 2 4 4 4
5 2 4 4 4
6 4 4 4 4
Tabla 3.8.4; Comparison of release pads nos. 1-6 (see Appendix I and Materials, 
section 2.1) for the gold conjugate strip: Colour intensity results for the test and 
control lines using a positive (5 0 IU/L hCG) and negative (0 IUÆ. hCG) urine sample.
The results shown in Table 3.8.3 and Table 3.8.4 illustrated that pad no. 1 possessed 
the most satisfactory characteristics required for a gold release pad. Good absorption, 
release and good positive/negative discrimination were properties of this pad. The 
remaining pads demonstrated inconsistent absorption (see Table 3.8.3) and poor
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release of the gold conjugate, which resulted in poor specificity for negative samples 
(see Table 3.8.4).
•  Conclusion
Pad no. 1 was confirmed as the most suitable gold conjugate release material due to 
its satisfactory absorption traits, sensitivity and specificity. Pads no. 2-6 were 
disregarded based on the results outlined above.
3.8.5 Buffer Evaluations
Polyethylene glycol (PEG) (size range 0.2-20.OK), Triton® X-100 and Tween® 20 
were added to the Gold Conjugate Dilution Buffer (GCDB) (see Materials, section 
2.1) in the combinations listed overleaf in Table 3.8.5. The purpose of the addition of 
these reagents was to examine their effect on the reactivity, release and flow of the 
anti-hCG gold conjugate from the vacuum-dried glass fibre strip. The reasons why 
these particular components were selected for inclusion in the GCDB are outlined in 
the Discussion, section 4.5.3. Initially, due to the large number of buffers (i.e.: 16, 
see Table 3.8.5) these 16 buffers were examined in liquid form, i.e. the gold 
conjugate and sample were added to the buffer and the test strip was ‘dipped’ into the 
solution. The effect if any, of the reagent on the test result was thereby monitored 
and the selected buffers were examined in greater detail (see 3.8.5i and 3.8.5ii).
The Triton® X-100, Tween® 20 and PEG’s were added to the relevant buffers (See 
Table 3.8.5) at the concentrations outlined in Method 22.5.1 (i.e.: 0.001% (w/v) for 
Triton® X-100 and Tween® 20 and 5mg/mL for each of the PEG’s). All of the above 
buffers were evaluated by employing the ELISA plate ‘Comb’ Method (see Method 
2.3.5.8). Each buffer was assessed using both a negative and positive (25 IU/L) urine 
sample. The intensity of both the control and test lines were recorded along with the 
flow rates for the samples. The results are recorded in Table 3.8.6.
It was observed from this study that the addition of PEG (15-20K) in combination 
with either of the detergents (Tween® 20 or Triton® X-100) exhibited the best test 
and control lines. Both of these buffers (no. 15 and no. 16 overleaf) gave control
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lines of a colour intensity of 10 and test lines of colour intensity 0.5 for the positive 
urine sample. Buffers no. 1-no. 4, which did not contain any detergent but contained 
the smaller sized PEG’s (0.2 -  8K) demonstrated faint control lines of colour 
intensity ranging from 2 to 4. This was due to their faster flow rates, the average flow 
rate being 1 minute 7 seconds. An uneven release of gold was also observed for these 
four buffers and significant amounts of gold conjugate remained at the bottom of 
these strips. The amount of residual gold, which remained at the bottom of the strip 
decreased with the addition of Tween® 20 (buffers no. 10-no. 13). It was, therefore, 
concluded that the addition of detergent assisted the even flow and release of the 
gold conjugate up the strip.
Identification no. Buffer
1 GCDB with PEG 0.20 K
2 GCDB with PEG 1.0 K
3 GCDB with PEG 3.35 K
4 GCDB with PEG 8.0 K
5 GCDB with PEG 10.0 K
6 GCDB with PEG 15.0- 20.0 K
7 GCDB with Triton® X-100
8 GCDB with Tween® 20
9 GCDB no additives
10 GCDB with PEG 0.2 K and Tween® 20
11 GCDB with PEG 1.0 K and Tween® 20
12 GCDB with PEG 3.35 K and Tween® 20
13 GCDB with PEG 8.0 Kand Tween® 20
14 GCDB with PEG 10.0 Kand Tween® 20
15 GCDB with PEG 15.0 -2 0 .0 K  and Tween® 20
16 GCDB with PEG 15.0- 20.0 K and Triton® X-100
Table 3.8.5: Description of sixteen gold conjugate buffers examined for their 
effect on the gold conjugate. The amount o f each component added to the 
GCDB is given in Method 2.3.5.7, section 2.2.
No false positive result was observed for any of the 16 buffers. It was also noted that 
the GCDB without additives (buffer no. 9) had high background colour and did not 
detect the 25 IUZL hCG-containing urine sample.
Fast flow rates were also seen for buffers no. 9-no. 14. It was, therefore, deduced that 
the best test and control lines were only observed with the buffers, which were
supplemented with PEG of sizes greater than 10K and with either Tween® 20 and 
Triton® X -100.
• Conclusion
It was decided to further examine the effects on the assay of the use of the gold 
conjugate dilution buffer (GCDB) supplemented with PEG (15-20K), Tween® 20 
and Triton® X-100.
Buffer
Negative Urine Positive Urine
C.l.
Result
Flow
Time
Comments C.l.
Result
Flow
Time
Comments
T l CL (min,sec) L__ _ _ _ _ :l--- ,--- !------—!
1 0 2 1,02 Flow too fast & 0 2 1,05 Uneven flow of
2 0 2 1,07 poor flow of Au. 0 2 1,01 gold. Residual
3 0 4 1,09 Residual Au at bottom 0 2 1,10 Au at bottom of strip.
4 0 4 1,12 *’ 0 4 1,06
5 0 8 1,30 Good flow 0.5 8 1,27 Good flow
6 0 8 1,36 Good flow 0.5 8 1,32 Good flow
7 0 8 1,06 Flow too fast 0 8 1,09 Flow too fast
8 0 8 1,39 Good flow 0.5 8 1,26 Good flow
9 0 6 1,10 High Background 0 4 1,13 Flow too fast
10 0 6 1,20 Uniform Flow, some 0 4 1,23 Even flow, some
11 0 4 1,23 residual Au left. 0.5 6 1,21 residual Au observed.
12 0 6 1,25 0 6 1,19
13 0 8 1,26 0 8 1,27
14 0 8 1,29 0 8 1,26
**
15 0 10 1,41 Cleanest 0 10 1,40 Best test <£ control
16 0 10 1,38 backgrounds. 0 10 1,39 lines. Good flow
Table 3.8.6: The comparison o f sixteen different gold conjugate buffers. Colour 
intensity results for the test line (TL) and control line (CL) and flow rates for each 
buffer using a negative (0 IU/L hCG) and positive (50 IUA.) urine sample.
3.8.5 i Further Buffer Evaluation
From the results of the previous study carried out in relation to buffers (see section 
3.8.5) it was decided to further examine the effect o f Triton® X-100 and Tween® 20 
on the assay. It was also postulated that the addition of BSA and sucrose should 
confer stability on the gold conjugate in its dried state and thus might possibly 
benefit the GCDB. This topic is discussed further in section 4.5.3 of the Discussion.
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Thus, BSA and sucrose were also examined along with PEG 15-20K and PVP K-30 
to determine their effect on the test and control lines.
Each of the components listed below was added to a Tris-based buffer (see Method 
2.3.5.7) at a range of concentrations, with the higher concentrations providing an 
excess of the component, thereby forcing an effect on the assay. The GCDB was 
used as the reference diluent. Each buffer, including the GCDB was spiked to a level 
of 5 0 IU/L hCG to give a hCG positive solution. Each unspiked buffer was used as a 
negative sample. 200\xL (4 drops) of each buffer were added per test unless stated 
otherwise. All buffers were run on the same test combination. Each test was 
examined for C.I. result, flow rate, overall visual impression as to how the test ran 
(e.g.: release of gold conjugate, intensity of control lines) and buffer front. The buffer 
front is defined as the distance observed between the ‘top’ of the liquid sample flow 
and the ‘top’ of the gold conjugate flow as both components travel up the sprayed 
membrane (see section 4.5.3, Discussion). The ideal buffer front is one where both 
the sample and gold conjugate flow together thereby allowing an optimum of 
conjugate binding to the antigen. It is important to note that the chemicals and 
biologicals contained within the GCDB play a significant role in determining the size 
of the fronts for this type of assay (see Discussion, section 4.5.3).
The results are shown in Table 3.8.7 (pg 118) and Table 3.8.8 (pg 119). These results 
are further examined in section 4.5.3, Discussion, the conclusions drawn from the 
results shown in tables 3.8.7 and 3.8.8 are presented below:
The inclusion of Triton® X-100 in the Tris-based buffer improved the release of gold 
conjugate from the pad. The buffer front improved with increasing concentrations of 
Triton® X-100. However, the flow was too slow at the higher concentrations of 
Triton® X-100, which resulted in weak control lines. Positive results were observed 
(C.I. o f 0.5) for the hCG-positive solution on those strips, which were run with 
Triton® X-100 at concentrations higher than 2.4 g/L. It was decided to include 
Triton® X-100 at a concentration of 2.4 g/L in the current GCDB since this 
concentration gave a positive result for the positive sample, provided good buffer 
fronts and the flow was not as slow as that seen for the higher concentrations.
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Tween® 20 produced similar results to Triton® X-100. The release of the gold 
conjugate from the glass fibre pad improved with the addition of increasing amounts 
of Tween® 20 to the Tris-based buffer. Even flow was noted for the strips run with 
Tween® 20-containing buffers, which further improved with the higher 
concentrations of Tween® 20. These higher concentrations in turn slowed the flow 
from the glass fibre pad. The intensity of the control line was proportional to the 
concentration of Tween® 20 in the Tris-based buffer run on the strip. It was, 
therefore, concluded that the inclusion of Tween® 20 at 5 g/1 would provide the best 
release of gold conjugate from the pad with good fronts and acceptable flow rates 
(slower flow rates were observed for 10 g/L and higher concentrations). Since no 
positive result was noted with the Tween® 20 buffers it was anticipated that the 
addition of other components from this study would allow the detection of the hCG. 
This assumption was based on the previous buffer study (see section 3.8.5) in which 
C.I.’s of 0.5 were observed for the positive solution of buffers containing Tween
With regard to PVP K-30, false positive results were noted for all of the negative 
solutions. However, it was hoped that, in its dried state in the impregnated gold 
conjugate strip, the PVP K-30 would not react with the test line to such an extent. 
This was assumed since the function of the PVP K-30 is to form a protective coating 
around the gold conjugate as the liquid is evaporated off the glass fibre strip during 
the drying procedure. In liquid form, as in this case, the PVP K-30 is not forced to 
form such a coating due to the abundance of water molecules surrounding the gold 
conjugate. Thus, the PVP K-30 is free in solution to bind non-specifically to the test 
line of the membrane strip.
The gold conjugate front was very good for all concentrations of PVP K-30 (i.e.: 
there was minimal distance between the top of the liquid sample flow and the gold 
conjugate flow. Flow rates were also good and similar for each buffer, i.e.: no effect 
was observed on flow rate with increasing levels of PVP K-30. PVP K-30 appeared 
to play a more significant role in the release of gold conjugate from the glass fibre 
strip since it was apparent that the addition of greater amounts of PVP K-30 allowed 
for cleaner background with more distinct test lines. However, this phenomenon may 
have partly been as a result of the interaction of the PVP K-30 with the test line and
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gold conjugate as viewed for the negative solution which demonstrated false positive 
results at all concentrations of PVP K-30. As a consequence of the occurrence of this 
non-specific interaction with the test antibodies it was decided that the PVP K-30 
should be added to the GCDB at the lowest concentration examined in this study, 
i.e.: 1.5 g/L. It was unnecessary to include the PVP K-30 at a higher concentration 
because, as noted earlier from the results, the most important effect of the addition of 
this component was in providing a good release of the conjugate. As all of the 
concentrations of PVP K-30 demonstrated a similar gold conjugate release, there was 
no apparent benefit in adding more than 1.5g/L PVP K-30 to the GCDB.
In examining the results for the Tris-based buffers supplemented with PEG 15-20K it 
was clear that the concentration of PEG 15-20K was inversely proportional to the 
width of the gold conjugate front observed, i.e.: the gold front was seen to improve 
as higher concentrations of PEG 15-20k were added. False positive results were also 
observed for the negative solutions containing PEG 15-20K. The flow rate decreased 
with higher concentrations of PEG 15-20K and no effect was apparent on the 
intensity of the control line. Therefore, it was concluded that the PEG 15-20K served 
only to decrease the gold conjugate front and had no bearing on the release of gold. 
Due to the false positive results noted for concentrations higher than 2,5g/L and 
because the flow rate of the test was too slow at the same concentrations of PEG 15- 
20K, 1.25 g/L of PEG 15-20K was chosen as the most suitable concentration for 
addition to the GCDB. The fronts observed at this concentration were as good as 
those seen for higher concentrations but without the slower flow rates and higher 
false positive C.I. results.
Poor fronts and fast flow featured for the strips run with buffers containing various 
levels of sucrose. Since the sucrose was included in the buffer as a stabilising agent 
in the dried gold conjugate strip and not to improve flow or release of gold conjugate 
only the positive /negative result was important in this case. No false positives were 
apparent and a concentration of 12.5 g/L of sucrose was selected because high 
concentrations would be required to confer stability in the dried state. A higher 
concentration was not selected because the flow slowed considerably as the amount 
of sucrose increased. More significantly, as a gold conjugate strip was dried the
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removal of liquid from the strip would, as a result, cause an increase in the 
concentration of the chemicals present in the strip.
No false positives were detected for the BSA containing buffers and the gold 
conjugate front was not affected by increasing amounts of BSA. The release of gold 
conjugate from the pad was, nevertheless reduced with the addition of high 
concentrations of BSA. This poor release could be assumed to be a consequence of 
the very slow flow rate noted with these buffers. Due to the diminished release of 
gold conjugate and slow flow rates, the addition of 2 g/L of BSA to the GCDB was 
deemed the most appropriate concentration for this constituent.
• Conclusion
The following components were selected for inclusion in the GCDB formulation at 
the concentrations specified below in Table 3.8.9:
Component Concentration
Triton® X-100 2.4 g/L
Tween*  20 5.0 g/L
PVPK-30 1.5 g/L
PEG 15-20K 1.25 g/L
Sucrose 12.5 g/L
BSA 2.0 g/L
Table 3.8.9: Concentrations o f 6 components for addition to the gold 
conjugate dilution buffer (GCDB)
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Cone.
<8'M
hCG
Status
C.l. Result Buffer
Component
3 min 5 min
front Flow Visual
Triton'31 X-100 0.3 Negative 0 0 Fronts quite Had to add 2 Good release o f
0.6 0 0 pronounced drops extra to gold, improves
1.2 0 0 release gold with increasing
2.4 0 0 Good fronts from pad for Triton X-1009
6 0 0
t*
concns o f
12 0 0 " 2.4 g/L and
GCDB 0 0 ” upwards
Triton® X-100 0.3 Positive 0 0 Good control Very slow
0.6 0 0 lines. flow. Extra Release o f gold
1.2 0 0 ** drops o f sample increases with
2.4 0 0.5 Faint control required above increasing
6 0 0.5 lines due to 2.4 g,1. Triton X-100*
12 0 0.5 slower flow
GCDB 0 0.5
Tween® 20 1.25 Negative 0 0 Good fronts Good flow but Good release of
2.5 0 0 observed slightly slower gold. C.l o f
5 0 0 for all than GCDB. control line higher
10 0 0 combinations. The flow for with more T-20®.
25 0 0 50g/L was too 25 & 50g/L had
50 0 0 slow. background
GCDB 0 0 problems.
Tween® 20 1.25 Positive 0 0 Good fronts. Good Flow
2.5 0 0 Fronts Increasing 
Tween®
5 0 0 decreased increases release
10 0 0 with higher o f gold from pad.
25 0 0 levels of Slow Flow
50 0 0.5 Tween 20® Slow Flow
GCDB 0 0
PVP K-30 1.5 Negative 0.5 0.5 good front Similar to False
3 0.5 0.5 H GCDB positives
6 2 2 n apart from appeared
12 2 2 IT 60g/L on high conc.
30 2 4 W buffers
60 2 4 n immediately
GCDB 0 0
PVP K-30 1.5 Positive 0.5 1 v.good front Similar to Background
3 0.5 1 ■ GCDB clears up as
6 1 1 w apart from more PVP is
12 2 2 ■ 60gL. added. Test lines
30 2 2 w more distinct as
60 2 2 It PVP increases.
GCDB 0.5 0.5
Table 3.8.7: Examination o f the inclusion of two different detergents (Triton X-100 
and Tween® 20) and PVP K-30 in the GCDB. Best results are highlighted in red.
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Component Cone.
hCG C.l. Result Buffer Flow Visual(g/L) Status 3 min 5 min front
PEG 15-20K 1.25 Negative 0 0.5 Front Strong false
2.5 0.5 0.5 decreases Flow slows positives
5 1 2 as conc of as PEG is on all except
10 2 2 PEG is Increased. 1.25&2.5g/L
25 4 4 increased. No control line
50 4 4 seen for 50g/L.
GCDB 0 0
PEG 15-20K 1.2 5 Positive 0.5 0.5 As above As above No control tine
2.5 0.5 0.5 for PEG for PEG seen for 50g/L.
5 2 2 negative negative
10 2 2 solution solution
25 4 4
50 4 6
GCDB 4 4
Sucrose 12.5 Negative 0 0 Front Fast flow Control line
25 0 0 decreases as Flow slows faint for all.
50 0 0 sucrose conc as sucrose is Needs to be used
100 0 0 is increased. Increased in combination
250 0 0 Best front with Good release with other
GCDB 0 0 GCDB. components
Sucrose 12.5 Positive 0 0 As above As above As above
25 0 0 for sucrose for sucrose for sucrose
50 0 0 negative negative negative
100 0 0 solution solution solution
250 0 0.5
GCDB 2 2
BSA 1 Negative 0 0 V. good front Extremely
2 0 0 It slow flow
4 0 0 ■
8 0 0 It'-
20 0 0 It
40 0 0.5 ■
GCDB 0 0.5 Woref front
BSA 1 Positive 0 0 Appears to Very slow
2 0 0 be very flow No control lines
4 0 0 poor release Very slow to visllble except
8 0 0 o f gold adsorb off pad for GCDB
20 0 0 2 drops extra
40 0 0 required
GCDB 40 0..5 0.5
Table 3.8.8: Examination o f the inclusion o f PEG 15-20K, Sucrose & BSA in the 
GCDB. Best results are highlighted in red.
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3.8.5ii Evaluation of the performance of gold conjugate strips 
manufactured using the GCDB substituted with various 
components
Gold conjugate strips were manufactured using the GCDB with and without the 
substitution of the components selected in section 3.8.5 and 3.8.5i (see Table 3.8.9). 
These components were supplemented, where relevant, into the GCDB at their 
optimum concentrations as determined in section 3.8.5i. All devices were tested with 
samples from the Rotunda Hospital to determine if any differences were apparent in 
the C.I. result for both the test and control line. The results are shown in Table 3.8.10 
and overleaf in Figure 3.8.2.
Sample
No.
Sample
Status
C .I. R esult®  5 mln
-------------------------
Comments
n a ) jj.) ■ 1 H 3 I'TtrlW
18
53
84
negative
negative
negative
0
0
0
0
0
0
27* negative 0.5 0
29* negative 2 0.5
58* negative 0.5 0
11 positive 4 6
47 positive 6 6
68 positive 6 8
1 strong positive 10 8 Stronger C. lines
39 strong positive 8 10 on GCDB with
49 strong positive 10 10 substitutions
Table 3.8.10: Comparison o f the performance o f conjugates with & without 
chemical substitutions as decided in section 3.8.5 & 3.8.5 i. Evaluation o f 6 negative 
& 6 positive samples from the Rotunda Hospital. Colour intensity results at 5 
minutes. * = Previously gave false positive results with the ‘in-house’ assay.
As observed from Figure 3.8.2, the gold conjugate strip made up with GCDB 
including substitutions gave superior results to those obtained for the strip using 
GCDB without any chemical additions. The GCDB with substitutions demonstrated 
only one false positive for sample no. 29, which was of a low C.I. of 0.5. Conversely, 
the GCDB without substitutions exhibited three false positives, for samples no. 27, 
no. 29 and no. 58. These three samples were selected for testing as they had 
demonstrated false positive C.I. results with the prototype ‘in-house’ assay during the 
clinical trial described in section 3.7. The results obtained for the positive samples 
were also better for the strips using the GCDB with substitutions. Higher C.I. results
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were noted for three of the positive samples (no. 11, no. 58 and no. 39) with this strip 
in comparison to those obtained with strips manufactured with unsupplemented 
GCDB. Only one positive sample gave lower results with the supplemented GCDB 
strip (no. 1).
Figure 3.8.2: Comparison o f conjugate strips with and without chem ical
substitutions. C.l. results at 5 m inutes
□  (w  fth s u b s t i tu t io n s )
The aim of the inclusion of additional components to the GCDB was to reduce the 
false positive problem seen during the first clinical trial. Samples no. 27, 29 and 58 
had demonstrated the worst false positive C.I. results from this trial. Strips containing 
the GCDB with substitutions were tested with 30 negative urines and 30 negative 
serums from the Cork Blood Bank. 100% specificity was observed with these strips 
(results not shown). Therefore, it was decided that the GCDB could be supplemented 
with the chosen chemicals since the worst false positive results were eliminated in 
two cases and much reduced in the third. Also, no detrimental effect was observed on 
the other negative samples tested and an improvement in C.l. results was observed 
for three of the positive samples. It should be noted that all of the samples examined 
were run in triplicate, each sample giving the same C.l. result on each occasion and 
thereby strengthening the decision to favour the ‘new’ GCDB.
• Conclusion
The addition of the chemicals outlined in section 3.8.5i was approved based on the 
above results.
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3.9 Assessment of the Effect on Specificity of the Position 
and Thickness of the Test Line
Considerable success was achieved in improving the specificity of the assay by the 
addition of various components to the GCDB (see sections 3.8.5-3.8.5ii). However, 
from section 3.8.5ii it was observed that the specificity could be improved further as 
one of the negative urines still exhibited a positive C.I. result, albeit a low one. It was 
decided to examine the effect o f varying the thickness and position of the sprayed 
test line on the sensitivity and specificity of the assay in preparation for further 
clinical trials.
Test lines were sprayed at 8, 9, 10, 11 and 12 mm on membrane no. 2. The C.I. 
results for three samples with each of these sprayed membranes are recorded in Table 
3.9.1 below.
Test L in* 
Position (mm)
Sample
(IU/L)
C.I. Result @ 9 mln
8 0 1
25 2
50 4
9 0 0.5
25 2
50 4
10 0 0.5
25 1
50 3
11 0 0
25 1
50 2
12 0 0
25 1
50 2
Table 3.9.1: Determination o f the effect o f varying the position o f the test line. 
Colour intensity results fo ra  0, 25 and 5 0 IU/L hCG urine sample at 5 minutes, using 
conjugate C at A520nm o f 1.0 and test line antibody no. 9 at 1.0 mg/ml.
From Table 3.9.1 it can be seen that the closer the test line was to the bottom edge of 
the nitrocellulose membrane the higher the C.I. result for each of the three samples
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due to the extension of the reaction time (see Discussion, section 4.6). Consequently, 
positive C.I. results were noted for the negative sample on membrane sprayed at 8, 9 
and 10 mm. The C.I. results for the positive samples were approximately two-fold 
greater with test lines sprayed at 8, 9 and 10mm, than the C.I. results for the same 
samples with membrane sprayed at 11 and 12 mm. Membrane sprayed at both 11 and 
12 mm gave good positive-negative differentiation with both membranes exhibiting 
the same C.I. results for all three samples assayed. Since, from this experiment, the 
closer the test line was sprayed to the edge of the membrane the more likely the 
occurrence of false positive results, it was decided to select a spraying position of 12 
mm for use in the ‘in-house’ assay.
Membrane no. 2 was then sprayed at 12 mm with a lmg/mL solution of antibody no. 
9 at the thicknesses described in Table 3.9.2. The results are presented in Table 3.9.2.
Test Line Sample C.I. Result @ 5 mln
Thickness (mm) (IU/L)
0.5 0 0
25 0
50 1
1.0 0 0
25 1
50 2
1.5 0 0.5
25 2
50 3
2.0 0 2
25 2
50 4
Table 3.9.2: The effect o f test line thickness on the sensitivity & specificity of the 
‘in-house’ assay. Colour intensity results at 5 minutes for 0, 25 and 50 lUA. hCG 
urine samples, with conjugate C at an A52onm of 1.0 & test line no. 9 
at 1 mg/ml at a position of 11 mm.
From Table 3.9.2 it is evident that the only line thickness which supplied the required 
sensitivity and specificity was that at 1 mm. The 0.5 mm thick test line was not 
sensitive enough as exhibited by the poor C.I. result obtained for the 25 and 50 IU/L 
samples (C.I. result of 0 for 25 IU/L and 1 for the 50 IU/L). The 1.5 and 2 mm thick 
test lines presented specificity problems with the appearance of a C.I of 0.5 for the 0
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IU/L sample with the 1.5 mm test line and a C.I. of 2 for the same sample with the 
line of 2 mm thickness. Conversely, the test line sprayed at a thickness of 1 mm gave 
a C.I. o f 0 for the negative sample and a C.I. of 1 for the 25 IU/L sample and 2 for 
the 50 IU/L sample.
•  Conclusion
A line position of 12 mm from the bottom edge of the membrane and a line thickness 
of 1 mm was selected for use in the in-house assay.
124
3.10 Format of the ‘In-House’ Assay following adjustments 
to solve specificity problems
Table 3.10.1 and 3.10.2 are presented in this section in order to summarise the 
changes made to the ‘in-house’ assay format during the optimisation of the original 
assay format (see 3.6) to improve the test’s specificity. As for section 3.6 the tables 
outline the test components and the quantities of each component used for the 
manufacture of the ‘in-house’ assay at this stage in the test development.
Component Component Details Used at
Test Line Antibody Antibody no. 9 1 mg/mL
Test Line Position n/a 12 m m
Test Line Thickness n/a 1 mm
Control Line Antibody Goat Anti-Mouse Antibody 1 mg/mL
Control Line Position n/a 19 mm
Nitrocellulose Membrane M em brane no. 2 n/a
Gold Conjugate Antibody Anti /3-hCG Monoclonal ~ 
Conjugate C
As20nm 1 0
Gold Conjugate 
Impregnation Buffer
Trinity Biotech ~ GCDB  
With Goat Serum, Anti-Hep B gold 
conjugate, Triton X -100, Tween 20, P V P  
K-30, P E G  15-20K, Sucrose & BSA
* see overleaf 
for amounts 
added per 
constituent
Sample Pad Sample Pad B n/a
Sample Volume n/a 200¡J (4 drops)
Assay Time n/a 5  minutes
Table 3.10.1: Format o f Assay following improvements on specificity. List o f test 
components, relevant quantities and test parameters. For further component details 
see Appendix I and Materials, section 2.1.
# Added to the GCDB as follows:
Component Concentration
Triton x-100 2 .4  g/L
Tween 20 5 .0  g/L
P V P  K-30 1.5 g/L
PEG  15-20K 1.25 g/L
Sucrose 12.5 g/L
BSA 2 .0  g/L
Goat Serum 20%
Anti Hep B gold conjugate AsiOnm @ 0.1
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urine and serum samples
3.11 Methods to increase the flow  rate of the assay with both
This area in the development of the ‘in-house’ assay was concerned with the 
introduction of the use o f serum samples and the improvement of the flow rate for 
both urine and serum samples. Therefore the aim of this section was to increase the 
sample flow rate while maintaining the sensitivity and specificity inherent to the in 
house assay.
This was carried out by examining the flow rate of the sample with the following:
CD Three nitrocellulose membranes of various pore sizes.
® Different sample pads, 
d) Two different sample volumes
These studies are described in this section.
It should be clarified that throughout the assay development that follows, the flow 
rate was defined as the distance travelled (cm) per second by the urine/serum sample 
(unit: cm/sec). The flow time was defined as the length of time taken (unit: min,sec) 
for the sample to travel from the bottom edge of the test window to the top edge of 
the test window (see Figure 3.11.1).
Control
T est
Sample
TRINITY
BIOTECH
Figure 3.11.1: Device showing test window, 
used for the calculation o f flow times.
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3.11.1 Examination of the flow rates of urine and serum sample 
with various membranes.
The flow rates of several membranes were examined initially with deionised water 
(to mimic urine samples) and a 5% (w/v) BSA solution (to mimic serum samples) to 
aid in the selection of an appropriate nitrocellulose membrane for further flow rate 
studies (results not shown). As the assay time was required to be within 3 minutes for 
urine samples and 5 minutes for serum samples, large pore size membranes were 
examined. These membranes were expected to have intrinsically faster flow rates.
From this study the nitrocellulose membranes, as described for the combinations in 
Table 3.11.1, were selected for evaluation with urine and serum samples. Because 
membranes no. 1 and no. 3 possessed different pore sizes and protein binding 
capacities (see Discussion, section 4.7) to membrane no. 2 it was necessary to 
optimise the test line concentration and gold conjugate A520nm for each of these 
membranes (results not shown). Membrane no. 2 had been used throughout the 
development of the test to this point. These new test line and gold conjugate 
combinations for the two membranes to be tested are outlined in Table 3.11.1 below 
along with the combination used to date.
T e *t Combination 
Identification no.
Membrane
No.
Optimised Test 
Line Cone.
Optimised Gold 
Conjugate
1 No. 2 1mg/mL As20nm 10
2 No. 1 1mg/mL As20nm 10
3 No. 3 1.5mg/mL A520nm 0.9
Table 3.11.1: List o f test combinations assayed using 31 urine samples & 30 serum
samples from the Rotunda Hospital.
Each of the above test combinations were assayed with 31 urine and 30 serum 
samples from the Rotunda Hospital, Dublin. The sample flow time was recorded for 
each of the urine and serum samples with each of the three test combinations. The 
C.I. result was read for each combination at 3 minutes for urine samples and at 5 
minutes for serum samples as these were the assay times for the competitor kits 
being run in parallel with the in-house assay. The C.I. result was also recorded for
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the competitor kit (ABI) to ensure that the sensitivity and specificity characteristics 
of the in-house assay did not decline with the faster flow rates.
The results are illustrated overleaf in Tables 3.11.3 and 3.11.4. A summary of the 
average flow time results is outlined in Table 3.11.2 below.
Sampla
Urine
Serum
Avoraga Flow Tima (min,sec)
Combination no.
2,12
3,22
Combination no. 2
1,62
2,55
Combination no. 3
1,57
3,03
Table 3.11.2: Summary o f Average Flow Time results for the three test 
combinations assayed to evaluate three different nitrocellulose membranes.
From the summary table above it is clear that Combination no. 2 possesses the fastest 
average flow times for both urine and serum samples. Each of the three ‘in-house’ 
test combinations performed well in comparison to the ABI assay with regard to C.I. 
results. Despite the faster flow times for test combination no. 2 it is important to note 
that 9 out of 31 urine samples evaluated had a flow time of 2 minutes or greater 
while 13 out of the 30 serum samples demonstrated a flow time of 3 minutes or 
more. It was the aim of this section to reduce the sample flow time for urines to a 
maximum of 2 minutes since the assay was to be read at 3 minutes. Likewise, it was 
the intention to establish a maximum flow time of 3 minutes for serum samples since 
these samples were read at 5 minutes. These flow times would ensure that all 
samples could run to completion within the specified assay time and allow good 
sample clearance from the membrane.
As quite a large percentage of both the urine and serum samples fell outside these 
maximum flow times it was concluded that it was necessary to examine the effect of 
changing the sample pad and sample volume to bring the majority of samples within 
these assay time zones.
•  Conclusion
Membrane no. 1 was selected for use in the assay due to its more favourable flow 
characteristics with both urine and serum samples.
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In
house
no.
C.l. Result at 3 mine & Flow time for urine samples on 3 combinations A ll
TestCombination no. 1 Combination no. 2 Combination no. 3
Result (m in.sec) Result
Flowrate  
(min,sec) Result
Flowrate  
(m in,sec) Resuit
4 2,14 7 1,59 6 2,01 8
3 8 1,58 8 1,48 6 1,45 6
4 7 1,42 8 1,35 6 1,42 6
5 8 2,31 8 2,12 7 2,14 8
6 8 2,10 5 1,52 6 2,03 4
7 6 2,06 8 1,47 6 1,45 8
8 8 2,19 6 2,01 7 1,58 6
9 5 1,43 6 1,27 6 1,36 5
10a 8 2,37 7 2,08 6 2,10 6
11 8 1,54 6 1,39 5 1,42 7
12 7 1,39 8 1,24 6 1,33 6
13 8 2,22 6 2,03 8 2,13 5
14 8 1,48 4 1,32 7 1,27 4
15 8 2,16 7 1,54 6 2,05 6
16 8 2,27 6 1,59 7 2,14 4
17 8 2,05 8 1,42 8 1,35 8
18 8 2,17 6 2,00 5 2,06 6
19 9 1,52 6 1,26 6 1,37 3
20 8 1,59 6 1,41 8 1,49 5
21 8 1,45 6 1,22 6 1,20 6
22 7 2,03 4 1,50 8 1,56 4
23 8 1,58 8 1,33 8 1,42 2
24 8 2,34 8 2,07 6 2,11 8
25 5 2,13 4 1,59 4 1,54 2
' 2f> 8 2,24 8 2,04 8 2,15 6
27 8 2,11 8 1,57 6 2,01 8
S’ 28 8 2,36 9 2,09 6 2,03 8.
29 7 1,41 8 1,21 6 1,38 6
' 30 8 1,50 8 1,35 6 1,44 6
E l 6 2,27 6 2,02 6 2,10 6-
Average
Fiowrate 2,12 1,52 1,57
Table 3.11.3: Comparison o f colour intensity results at 3 minutes and flow rates
(min.sec) for 31 urine samples from the Rotunda Hospital using three ‘in-house’ 
assay formats (Combination no. 1, no. 2 and no. 3). The average flow rate (min,sec) 
for the 31 samples is shown for each test combination.
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In
house
no.
C.l. Rasuit a t 5 m in t & Flow tim a for urine samples on 3 combinations ABI
TestCombination no. 1 Combination no. 2 Combination no. 3
C... S 
Result
Flowrate
(mln,sec)__j
C.l.
Result Result
Flowrate
( m ln .E e c ) Result
a 2,57 8 2,20 6 2,15 8
2 6 3,56 8 2,59 7 3,06 8
3 8 4,24 7 3,44 8 3,57 8
4 8 3,22 9 2,54 9 2,44 10
5 6 3,09 9 2,36 6 2,45 10
6 6 2,59 6 2,22 8 2,51 8
7 6 3,35 7 3,01 6 3,15 8
8 7 3,29 8 3,06 8 3,22 8
9 8 3,47 8 3,12 8 3,32 8
10 6 4,18 6 3,56 6 4,01 8
I 11 8 2,54 8 2,33 8 2,47 8
12 8 3,36 6 3,05 6 2,59 7
13 8 3,12 6 2,52 6 3,11 8
14 8 2,45 8 2,27 8 2,34 8
13 8 2,59 6 2,31 8 2,28 8
16 8 2,19 8 2,06 8 2,14 81
17 8 3,42 6 3,15 8 3,26 8
18 8 3,18 7 3,04 6 3,07 8
19 6 3,06 6 2,54 6 3,01 8
20 6 2,47 6 2,23 6 2,33 8
21 8 3,44 6 3,21 6 3,24 8
22 6 3,16 6 2,45 6 3,02 8
23 6 2,34 6 2,12 6 2,25 8
24 8 2,56 6 2,55 8 2,48 8
25 8 3,54 6 3,34 6 3,42 8
26 6 4,01 6 3,57 6 4,00 8
27 8 3,22 9 2,41 9 2,52 10
28 8 3,52 8 3,18 8 3,20 10
29 6 3,41 7 3,02 6 3,16 8
30 8 2,58 6 2,38 8 2,41 8
Average
Flowrate 3,22 2,55 3,03
Table 3.11.4: Comparison o f colour intensity results at 5 minutes and flow rates 
(min.sec) for 30 serum samples from the Rotunda Hospital using three ‘in-house’ 
assay fomnats (Combination no. 1, no. 2 and no. 3). The average flow rate (min.sec) 
for the 30 samples is shown for each test combination.
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3.11.2 Evaluation of the effect of the sample volume and Sample 
Pad on the assay flow time.
From 3.11.1 it was noted that an increase in the sample flow rates was achieved by 
changing the nitrocellulose membrane to one of a larger pore size, i.e.: membrane no. 
1 replaced membrane no. 2. However, this new membrane did not sufficiently reduce 
the sample flow time for all samples and accordingly it was decided to attempt to 
increase the flow time by the addition of more sample per test. The ABI assay 
employed a sample volume of 250jj.1 whereas up until this point a sample volume of 
200|al was added to each in house test. A comparison of these two sample volumes 
using urine and serum samples with the ‘in-house’ assay was carried out and the 
results are recorded below in Table 3.11.4. The ‘in-house’ assay flow times were 
compared to those obtained with the ABI test.
S am p le F lo w  T im e  (m in e , s ec )
p i[  Vjvÿ! *
Urine: no. 1
no. 2 
no. 3 
no. 4 
no. 5
1,50
1,38
1,44
1,29
1,32
2,20
2,30
2,10
2,00
1,50
1,58
1,50
1,33
1,47
1,38
Seram: no. 1 1,40 3,10 2,20
no. 2 1,42 2,30 2,10
no. 3 1,53 2,50 1,56
no. 4 1,50 2,23 1,41
no. 5 1,52 2,14 1,52
Table 3.11.4: Evaluation comparing sample volumes of 200jA & 250j.il 
against the ABI reference test (sample volume ~ 250/ul)
From the above results there is a significant difference noted for the urine and serum 
samples run with a sample volume of 200|al as opposed to 250^1. Excellent flow 
rates were achieved with a sample volume of 250jj,l. The flow times noted for the 
250^1 volume on the in-house assay were very similar to those seen for the ABI 
assay for all of the urine samples and for 3 out of the 5 serum samples. Much slower 
flow times were recorded for both urine and serum samples with the sample volume 
of 200(4,1.
The selected sample volume (i.e.: 250p.l) was used below in combination with 
various sample pads to further improve the flow time for all the serum samples.
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Sample pads B, D, E, F and G (see Appendix I) were examined for their effect on 
assay flow with the sample volume of 250jal. The function of the sample pad is to 
absorb and uniformly deliver the sample to the test membrane at a flow rate that is 
consistent with the flow time required for the assay being developed. The sample 
pads examined here possessed varying absorbancies and sample release rates. This 
study aimed to choose the pad most suited to the required assay times of 3 minutes 
for urine and 5 minutes for serum samples. Note: sample pad B had been used in the 
‘in-house’ assay format up until this point. Devices were assembled using the same 
sprayed membrane (membrane no. 1) and gold conjugate strips. Only the sample pad 
varied in each case. The same five urine and serum samples as used to evaluate 
sample volume were used in this instance also. The flow times for each pad are laid 
out in Table 3.11.5 below.
Sam ple Flow Tim e (mins, sec)
l - ;
Urino: no. 1
no. 2 
no. 3 
no. 4 
no. 5 
Avg Flow Time
1,34
1.30 
1,27
1.30 
1,44 
1,33
1,40
1,26
1.32
1.33 
1,53 
1,37
1,40
1,29
1,10
1,27
1,24
1,26
2,23
1,57
1,30
2,07
2,26
2,05
1,40
2,14
2,21
2,20
1,55
2,06
Serum: no. 1 4,00 4,24 1,56 3,29 3,03
no. 2 4,11 3,22 2,05 3,43 3,14
no. 3 5,00 3,07 1,52 4,20 1,58
no. 4 3,23 2,42 1,59 2,42 2,01
no. 5 4,36 3,58 2,02 3,24 1,54
Avg Flow Time 4,14 3,31 1,59 3,32 2,26
Table 3.11.5: Flow times o f 5 urine and serum samples with 5 different sample 
pads. Average flow times are shown for each pad with both urine and serum.
The results illustrated in Table 3.11.5 show that the fastest flow times for the ‘in- 
house’ assay were seen when devices were assembled using sample pad F. The flow 
times recorded with this sample pad were in line with those seen in Table 3.11.4 for 
the ABI assay. Pad B, which was the sample pad utilised with the ‘in-house’ assay 
throughout the development of the test until this point, gave results similar to those 
seen in Table 3.11.4. Sample pad F and B were directly compared as outlined in 
Table 3.11.6 overleaf.
It was necessary to evaluate the effect, if  any that the increased flow rate may have 
had on the sensitivity and specificity of the ‘in-house’ assay. As demonstrated in 
Table 3.11.6, no adverse effect was apparent on the specificity or sensitivity of the
assay by the reduced flow times observed when sample pad F was used. While the 
flow times for the urine and serum samples were acceptable with sample pad B also, 
it was necessary to select sample pad F with faster flow times. This was in order to 
meet the projected assay times for both urine and serum samples.
Device
Description
Sample Flow Time 
(min,sec)
C .l. Result 
(TImCL)*
with sample pad B 0 IUÆ urine 2,25 0,6
with sample pad F 0 IU/L urine 1,42 0,6
with sample pad B 25 IU/L urine 2,16 0.5,5
with sample pad F 25 IU/L urine 1,37 0.5,6
with sample pad B 50 IU/L urine 2,19 2,6
with sample pad F 50 IU/L urine 1,39 3,8
with sample pad B Serum no. 4 4,19 0,6
with sample pad F Serum no. 4 3,25 0,8
with sample pad B Serum no. 6 4,44 0,6
with sample pad F Serum no. 6 3,13 0,8
with sample pad B Serum no. 8 4,59 0,6
with sample pad F Serum no. 8 2,45 0,8
with sample pad B Serum no. 11 4,33 0,5
with sample pad F Serum no. 11 3,10 0,7
with sample pad B Serum no. 12 3,58 0,5
with sample pad F Serum no. 12 2,37 0,8
Table 3.11.6: Evaluation o f sample pad F in the ‘in-house’ assay in comparison 
with sample pad B which had been previously used. Colour intensity results for the 
test line (*TL) and control line (*CL) at 3 minutes for urine and 5 minutes for semm.
•  Conclusion
Sample pad F and a sample volume of 250(41 were selected to increase the flow rate 
for both urine and serum samples.
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3.12 Evaluation of the In House Assay W ick Format
The home-use test was to consist of a test format as pictured below in Figure 3.12.1. 
The test strip employed for the wick assay was the same as used for the cassette 
device apart from a test line position of 9.75mm and a control line position of 20mm 
to facilitate the structure of the plastic housing devices. The only significant 
difference between the two assays was, therefore, the wick itself, which served to 
deliver the sample to the test strip.
Wick Test Window Control Window
Figure 3.12.1: Wick Format o f In House Assay
3.12.1 Selection of a suitable detergent for wick impregnation
It was deemed necessary to examine the performance of the wick assay using several 
detergents impregnated on the wick (see Method 2.2.5.2) to allow for an even and 
fast delivery of the sample to the test strip within the device housing.
Wicks were impregnated with varying levels of Triton® X-405, Triton® X-100 and 
Tween® 20 and compared with the unimpregnated wick and wicks taken from the 
ABI wick assay and assembled into the in house assay. The test strip for each of the 
wick devices tested was identical. Both positive and negative urine samples were 
assayed on each wick combination. The results are described overleaf in Table 3.12.1 
and Table 3.12.2.
As illustrated in Table 3.12.1, the ‘in-house’ wicks which provided the most uniform 
flow, with clean negative results and control lines of strong intensity, were those 
impregnated with Triton® X-100 and Triton® X-405 at concentrations of 2% (w/v).
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Wick
C.I. Recult *TL, *C t)
Flow Comments
At 3 mfn At 5 mln
ABI wick 0,6 0,8 Fastest Flow
Unimpregnated 0,5 0,5 Fastest Flow Flow observed for 2%
(w/V) Triton® X-100
2%(w/v) Triton® X-100 0,6 0.5,8 Fastest Flow equal to that seen with
5%(w/v) Triton19 X-100 1,6 1,6 ABI wick
10%(w/v) Triton0 X-100 1,5 2,6
Cleanest test & control
2%(w/v) Triton9 X-405 0,6 0,8 Fast Flow line seen for 2% (w/v)
5%(w/v) Triton® X-405 1,4 2,6 Triton® X-100 & 2%
10%(wN) Triton® X-405 2,3 2,4 (w/v) Triton® X-405
2%(w/v) Tween® 20 0,5 0,6 Slow Flow 2% (w/v) Triton® X-100
5%(w/v) Tween® 20 0,4 0,5 Still negative at 40
10%(w/v) Tween® 20 0,4 0,5 Faster than 2% 
(w/v) Tween® 20
minutes
Table 3.12.1: Comparison o f wicks impregnated with various detergents. Colour 
intensity results for the test line (*TL) and control line (*CL) at 3 and 5 minutes and 
flow observations with negative urine no. 27 (Rotunda Hospital).
A slight false positive result (C.I. of 0.5) was noted for the negative urine sample 
using the wick impregnated with 2% (w/v) Triton® X-405. However, this false 
positive result was not present at three minutes and was of a much less colour 
intensity than those observed for the higher concentrations of both Triton® X-100 
and Triton® X-405. The unimpregnated wick developed control lines of low colour 
intensity (C.I. of 5) due to slow transfer of the sample from the wick onto the sample 
pad of the test strip. All of the wicks impregnated with Tween® 20 yielded similarly 
low intensity control lines also as a result of slow sample flow. The flow was much 
slower for the wicks impregnated with Tween® 20 than observed for the wicks 
impregnated with either Triton® X-100 and Triton® X-405.
Likewise, it can be seen from Table 3.12.2 that similar results were obtained for the 
positive sample with the unimpregnated wick. In contrast, 2% (w/v) Triton® X-100 
and 2% (w/v) Triton® X-405 demonstrated uniform flow arising in C.I. results 
similar to those recorded with the ABI wick. The flow of the gold conjugate for all 
concentrations of Tween® 20 and for the higher concentrations of both of the
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Tritons® was too fast and subsequently the test line gave low C.I. readings. It was 
most likely that some of the sprayed test line was being washed away by this rapid 
flow, resulting in diminished binding and, therefore, lower C.I results.
W ick
C.I. Result *TL, *CL)
Flow Comments
A t 3 mln A t 5 m ln
ABI wick 8,8 8,8 Fastest Flow
Unimpregnated 2,5 2,5 Fastest Flow Best test line seen 
for 2% (w/v)
2%(wN) Triton® X-100 8,8 8,8 Fastest Flow Triton* X-100 & 2%
5%(w/v) Triton®X-100 6,7 6,8 (w/v) Triton® X-405
10%(w/v) Triton® X-100 6,7 6,8
Flow decreases
2%(wN) Triton® X-405 8,8 8,10 Fast Flow with higher % (w/v)
5%(w/v) Triton® X-405 6,5 6,8 of Triton® X-100 & 2%
10%(w/v) Triton®X-405 4,6 6,6 (w/v) Triton® X-405
2%(w/v) Tween® 20 6,8 6,9 Slow Flow Increases with higher
5%(w/v) Tween® 20 4,6 4,6 % (w/v) of Tween® 20
10%(w/v) Tween® 20 4,5 4,5 Faster than 2%
(w/v) Tween® 20
Table 3.12.2: Comparison of wicks impregnated with various detergents. Colour 
intensity results at 3 and 5 minutes for the test line (*TL) and control line (*CL) and 
flow observations with positive urine no.37 (Rotunda Hospital)
Based upon the results described above it was decided to evaluate wicks impregnated 
with Triton® X-100 and Triton® X-405 at concentrations ranging between 1-3% 
(w/v) with a low positive sample to determine the optimum conditions for maximum 
sensitivity. The results are outlined in Table 3.12.3 overleaf.
As can be seen from Table 3.12.3 overleaf, wicks impregnated with 2% (w/v) 
Triton® X-100 gave C.I results with the most acceptable differentiation between the 
positive and negative samples and 2% (w/v) Triton® X-100 was thus selected for the 
impregnation of wicks for use in the wick assay. Tests possessing wicks with lower 
concentrations of Triton® X-100 were not sensitive enough and those with higher 
concentrations (i.e.: 2.5 and 3% (w/v) exhibited false positive results of varying 
intensities. False positive C.I. results were also a factor with Triton® X-405
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Vtfick Description
C.l. Result for 0 IU/L 
(*TL, *CL)
C.l. Result for 25 IU/L 
(*TL, ‘ CL)
At 3 min At 5 min At 3 min At 5 min
ABI \Vick 0 0 1 2
Unimpregnated 0 0 0 0
1%(w/v) Triton® X-405 0 0 0 0
1.5%(wA/) Triton® X-405 0 0 0 0
2%(w/v) Triton0 X-405 0 0.5 0 1
2.5%(w/v) Triton0 X-405 0.5 1 1 1
3% (w/v) Triton0 X-405 1 1 1 2
1%(w/v) Triton0 X-100 0 0 0 0.5
1.5%(w/v) Triton0 X-100 0 0 0 0.5
2%(w/v) Triton0 X-100 0 0 0.5 1
2.5% (w/v) Triton0 X-100 0 0.5 0.5 1
3%(w/v) Triton0 X-100 0.5 0.5 1 1
Table 3.12.3: Comparison of wicks impregnated with 1-3% (w/v) Triton® X-405 & 
Triton® X -100. Colour intensity results at 3 and 5 minutes for the test line (*TL) and 
control line (*CL) using a 0 IU/L and 25 lUA. hCG urine sample.
concentrations of 2% (w/v) and higher (3% (w/v)). Concentrations lower than this 
did not possess the required sensitivity. It was necessary to evaluate the chosen wick 
with a large number of urine and serum samples to monitor performance of the ‘in- 
house5 wick assay.
29 hCG negative and 37 hCG positive urine samples and 50 hCG positive sera were 
run on the ‘in-house’ wick assay and the ABI wick assay. The results are listed in 
Tables 3.12.4 and 3.12.5. All devices flowed within the desired time specifications 
(i.e.: 3 minutes for urine samples and 5 minutes for serum samples). 100% specificity 
was observed for both the ABI and the ‘in-house’ assays. Similar colour intensity 
results were achieved for both assays using the 37 positive urines.
•  Conclusion
The in-house wick device utilising 2% (w/v) Triton® X-100 matched the ABI device 
with regard to performance and flow times.
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In
Houso
No.
‘In-Housa' Assay a t 3 min ABI Assa] at 3 min
C.l. 1
i J IL
le&ult
.CL)
Flow Time 
(m in,sec)
C.l. R
(TL
eault
CL)
Ffow Time
. ®e°)
B S S I | I Pos. Neg. m r n m
1 0.7 6,7 1,20 1,11 0.7 6,7 1,30 1.25
2 0,7 6.8 1,42 1,16 0.7 6.7 1,26 1,26
3 0,7 5.8 1,09 1,22 0.7 6,8 1.03 1,35
4 0,7 6,7 1.29 1.41 0,7 6,7 1,19 1,43
5 0.7 6.8 1.16 1,36 0.7 6.7 1,10 1,30
e 0,7 6.7 1,10 1,33 0.7 6,9 1,07 1,54
7 0,7 6,10 1.15 1.21 0.7 6,8 1.06 1,24
8 0,7 6.7 1.08 1,17 0,7 6.7 1,07 1,22
9 0-7 5,6 1.14 1.06 0,7 8.7 1.14 1.12
10 0,7 6.6 1,14 1,14 0.7 6,7 1.22 1,22
11 0.7 6,7 1,14 1,46 0,7 6,8 1,34 1,34
12 0.7 6.9 1.24 1.35 0.7 6.9 1,35 1.26
13 0.7 7,10 1,33 1,28 0,7 8.8 1,15 1,10
14 0,7 6.8 1,12 1.44 0.7 6,7 1.07 1,39
15 0,7 6,9 1,05 1,39 0,7 6,8 1.12 1,33
16 0.7 9.10 1.24 1.23 0.7 8.9 1,46 1,32
17 0,7 5,8 1,22 1.20 0.7 5.6 1.07 1.34
18 0.7 6,8 1,10 1,47 0,7 6,7 1,10 1,39
19 0.7 6,7 1,40 1,50 0,7 6,8 1.20 1,41
20 0.7 6,10 1.21 1.08 0.7 6.7 1,08 1.02
21 0.7 4.8 1.13 1.13 0.7 5.7 1,14 1,20
22 0.7 6,6 1,20 1,24 0.7 6,7 1,13 1,33
23 0.7 5,5 113 1,22 0,7 6.7 1,13 1.19
24 0,7 6.9 1,18 1,34 0.7 7.8 1.13 1,42
25 0,7 7,10 1,24 1,18 0,7 7,8 1,17 1,26
26 0.7 6.10 1.13 1.03 0,7 6,7 1,19 1,10
27 0,7 6.7 1,30 1,33 0,7 6,8 1.20 1,45
28 0.7 8.8 1.18 1.45 0.7 7,8 1,14 1,51
29 0.7 8.9 1.20 1,27 0.7 8.8 1,15 1.33
30 6.7 1,14 6,7 1,17
31 6,7 1.07 6,7 1,06
32 7,6 1,15 6.8 1.21
33 7,10 1,20 7.8 1,15
34 6,9 1.55 6,7 1,47
35 6,7 1.23 6,6 1,30
36 6,8 1.27 6 J 1.24
37 8,9 1.19 8.8 1,14
Table 3.12.4: Assessment of the Performance o f the ‘In-House’ Wick assay in
comparison with the ABI wick assay. Colour intensity results for the test line (TL) 
and control line (CL) at 3 minutes and flow times (min.sec) for 29 hCG-negative 
urine samples from St. James Hospital, Dublin & 37 hCG-positive urine samples
from the Coombe Hospital, Dublin.
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In House 
No.
‘In-House’ Assay a t 5 minutes ABI Assay a t S minutes
C.l. Result 
(TL.Ct)
Flow Time <min, 
sec)
C.l. Result 
(TL.CL)
Flow Time (min, 
sec)
1 6, 8 2,20 7,8 2,14
2 6, 8 2,12 5, 8 3,00
3 6 ,8 2,15 8 ,8 2,10
4 4 ,6 1,58 8, 8 2,12
5 7,8 2,04 6 ,8 2,16
6 6, 8 2,01 6 ,8 2,18
7 6, 8 2,13 6,8 2,30
8 6, 8 2.21 6. 8 2,40
9 6, 8 2.05 6. 8 2.34
10 6, 8 1,56 6, 8 2,50
11 6, 8 2,07 6, 8 2,14
12 6 ,8 1,58 6. 8 2,36
13 6.8 2.02 6. 8 2,26
14 6, 8 2,06 6, 8 2,34
15 8, 8 2,02 6,8 2,20
16 6, 8 2,16 6. 8 2,22
17 6, 8 2.27 6.8 2,07
18 6, 8 2,04 7, 8 2,09
19 6, 8 2,12 6, 8 2,14
20 6,8 1,59 7.8 2,30
21 6, 8 2,00 6,8 3,00
22 6, 8 2,40 6, 8 3,30
23 6, 8 2,21 6, 8 2,30
24 6.8 2,07 6, 8 2,30
25 7,8 2,11 6, 8 3,15
26 6, 8 2,17 6, 8 2,42
27 8, 8 2,04 8.8 2,06
28 8, 8 2,08 8,8 2,35
29 6,8 2,10 8.8 2,33
30 8. 8 2,14 8, 8 2,29
31 8, 8 2,20 8 ,8 2,25
32 6, 8 2,06 6, 8 3,00
33 0, 8 1,57 0 ,8 2,56
34 6 .8 2,03 8, 8 2,30
35 6, 8 2,14 6 ,8 2,40
36 6, 8 2,17 6 ,8 2,30
37 6, 8 2,22 6, 8 2,30
38 6,8 2,05 8, 8 2,24
39 6, 8 2,07 6, 8 2,28
40 6 ,8 2,13 8 .8 2,34
41 8. 8 2.29 8, 8 2,38
42 6, 8 2,14 8,8 2,24
43 6, 8 1,56 6 , 8 2,17
44 6 ,8 2,01 8, 8 2,43
45 _6, 8 2,08 8, 8 2,28
46 8,8 2,11 6, 8 3,22
47 8,  8 2,15 6 , 8 2,40
48 6.8 2.06 6,8 2,20
49 8,8 2,06 8, 8 2,46
50 7,8 2,03 7, 8 2,39
Table 3.12.5: Assessment of the Performance o f the ‘In-House’ Wick assay in
comparison with the ABI wick assay. Colour intensity results for the test line (TL) 
and the control line (CL) at 5 minutes and flow times (min.sec) for 50 hCG positive 
serum samples from the Coombe Hospital, Dublin.
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3.13 Format of the Cassette and Wick ‘In-House’ Assay 
following the introduction of serum samples
The function of this section is to highlight the ‘new’ format o f the ‘in-house’ assay 
following the changes made to the test as a result of the evaluation of serum samples 
and the assessment of the ‘wick’ assay during the development which is described in 
sections 3.11-3.12. The format is summarised below in Table 3.13.1 and is an update 
on the format shown in Table 3.10.1.
Component Component Details Used at:
Test Line Antibody Antibody no. 9 1.0 mg/mL
Test Line Position n/a 12 mm (Cassette) 
9.75mm (Wick)
Test Line Thickness n/a 1 mm
Control Line Antibody Goat Anti-Mouse Antibody 1 mg/mL
Control Line Position n/a 19 mm (Cassette) 
20mm (Wick)
Nitrocellulose Membrane Membrane no. 1 n/a
Gold Conjugate 
Antibody
Anti p-hCG Monoclonal 
(Conjugate C)
As20nm 1-0
Gold Conjugate 
Impregnation Buffer
As per formulation outlined 
in Section 3.10.
See Table 3.10.2, 
Section 3.10.
Sample Pad Sample Pad F n/a
Sample Volume n/a 250¡ji (5 drops)
Assay Time n/a 3 minutes (Urine) 
5 minutes (Serum)
Wick Impregnation Solution Triton® X-100 in 
deionised water
2% (w/v)
Table 3.13.1: Format of assay following the introduction o f serum samples and the 
improvement o f sample flow times. See Appendix I and Materials, section 2.1 for
further details on components.
I
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3.14  Validation Trials on the Final ‘In-House’ Assay Format
3.14.1 Testing samples positive for heterophilic antibodies and 
Human anti-mouse antibodies (HAMA) on the ‘In-House’ Assay.
Heterophilic and human anti-mouse antibody (HAMA) positive samples are a range 
of samples, which bind non-specifically in many immunoassay formats. hCG assays 
are particularly prone to non-specific interference by such samples (see Discussion, 
section 4.9.1). 25 known heterophilic positive samples and 24 HAMA positive 
samples (see Materials, section 2.1) were run on the ‘in-house’ assay and on the ABI 
assay. Each test was examined for colour intensity, if  any, at the time intervals shown 
below in Table 3.14.1 and 3.14.2 where the relevant C.I. results are described. At 
each time interval, the number of tests, if any, which developed a false positive result 
within this time frame was recorded in Table 3.14.1 and 3.14.2.
Heterophilic Positive Samples
Time elapsed  
(min)
Number of False Positive Results
‘In-House’ ABI
5 0 0
10 0 0
15 0 0
20 0 0
30 0 1
40 2 2
60 3 4
Total 5 7
Table 3.14.1: Examination o f the appearance o f false positives with 
known heterophilic samples on the ‘In-House’ assay and the 
ABI reference assay over 60 minutes.
HAMA Positive Samples
Tim e elapsed
(min)
Number of False Positive Results
‘In-House’ ABI
5 0 0
10 0 1
15 0 0
20 0 1
30 0 2
40 1 0
60 0 0
Total 1 4
Table 3.14.2: Examination o f the appearance o f false positives 
with known HAMA positive samples on the ‘In-House’ assay and the 
ABI reference assay over 60 minutes.
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Five false positive results were noted for the ‘in-house’ assay when heterophilic 
positive samples were run and the first of which was not visible until 40 minutes 
after the sample had been added. 7 false positives were present with the same 
samples on the ABI assay, the first of which appeared at 30 minutes.
Only one false positive result was recorded for the ‘in-house’ assay at 40 minutes 
with the addition of HAMA positive sample no. 30. Conversely, the ABI assay 
resulted in a total of 4 false positives, which were first noted at 10 minutes (sample 
no. 30).
• Conclusion
The ‘in-house’ assay demonstrated superior specificity to that observed for the ABI 
device upon evaluation with heterophilic and HAMA positive samples.
3.14.2 Interference Study for the ‘In-House’ Cassette and Wick 
Assays
The objective of this study was to ensure that no interference occurred with the ‘in- 
house’ assay when everyday occurring substances were present in either the urine or 
serum sample being assayed.
Potentially interfering drugs and physiological substances common to urine/serum 
(see Discussion, section 4.9.2) were spiked into female negative urine and serum and 
into both 25 IU/L and 50 IU/L hCG positive urine and serum standards at the levels 
outlined in Table 3.14.4 -  3.14,9. The same negative, 25 IU/L and 50 IU/L hCG 
positive urine and serum samples which had not been supplemented with any of the 
interfering substances were run in parallel with the samples described above. The 
results were determined by comparison to the non-supplemented negative, 25 IU/L 
and 50 IU/L hCG positive urine and serum standards. The study was carried out for 
both the cassette and wick formats of the assay.
The tests were scored visually by comparison to the negative control and a 25 IU/L 
samples. All samples whose test line was fainter than that of the 25 IU/L sample 
were determined as negative.
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A summary of the results obtained with the various interfering substances with their 
corresponding supplementation level are outlined for urine in Table 3.14.4 and in 
Table 3.14.6 and for serum in Table 3.14.5 and 3.14.7. The flow times for the urine 
and serum samples with the average C.I. results at 3 and 60 minutes for urine and 5 
and 60 minutes for serum are summarised with the ABI assay in these tables. Tables 
3.14.10-3.14.20 show the actual C.I. results and flow times for both tests with both 
sample types.
No interference was observed for any of the urine or serum negative or positive 
samples with either the cassette or wick assay. All of the negative urine/serum 
samples, both supplemented and unsupplemented, with both ‘in-house’ assay formats 
yielded their expected negative results. Similarly, all positive samples supplemented 
and unsupplemented gave positive results on both formats. Each test was re­
examined at 60 minutes for colour intensity. All tests from both formats still 
remained without interference at this point.
Substance
Added
Cone.
(mg/dl)
‘In-House* Assay Visual Result
Urine 0 IU/L Urine 25 IU/L Urine 50 IU/L
Acetaminophen 20 Negative Positive Positive
Ascorbic Acid 20 Negative Positive Positive
Acetylsalicylic Acid 20 Negative Positive Positive
Albumin 2000 Negative Positive Positive
Caffeine 20 Negative Positive Positive
Estriol 2 Negative Positive Positive
Gentisic Acid 20 Negative Positive Positive
Glucose 2000 Negative Positive Positive
Haemoglobin 50 Negative Positive Positive
Phenothiazine 20 Negative Positive Positive
Table 3.14.4: Summary table of Interference study on the ‘In-House’ hCG Cassette assay
with urine samples spiked with various substances.
Substance
Added
Cone.
(mg/dl)
'In-House* Assay Visual Result
Serum 0 IU/L Serum 25 IU/L Serum 50 IU/L
Acetylsalicylic Acid 20 Negative Positive Positive
Albumin 2000 Negative Positive Positive
Estriol 2 Negative Positive Positive
Glucose 2000 Negative Positive Positive
Haemoglobin 50 Negative Positive Positive
Table 3.14.5: Summary table of Interference study on the ‘In-House’ hCG Cassette assay
with serum samples spiked with various substances.
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Substance
Added
Cone.
(mg/dl)
in -H ouse’ Assay Visual Result
Urine 0 IU/L Urine 25 IU/L Urine 50 IU/L
Acetaminophen 20 Negative Positive Positive
Ascorbic Acid 20 Negative Positive Positive
Acetylsalicyllc Acid 20 Negative Positive Positive
Albumin 2000 Negative Positive Positive
Caffeine 20 Negative Positive Positive
Estriol 2 Negative Positive Positive
Gentisic Acid 20 Negative Positive Positive
Glucose 2000 Negative Positive Positive
Haemoglobin 50 Negative Positive Positive
Phenothiazine 20 Negative Positive Positive
Table 3.14.6: Summary table of Interference study on the ‘In-House’ hCG Wick assay with 
urine samples spiked with various substances.
Substance Cone. ‘in-House* Assay Visual Result
Added (mg/dl)
Serum 0 IU/L Serum 25 IU/L Serum 50 IU/L
Acetylsalicylic Acid 20 Negative Positive Positive
Albumin 2000 Negative Positive Positive
Estriol 2 Negative Positive Positive
Glucose 2000 Negative Positive Positive
Haemoglobin 50 Negative Positive Positive
Tabla 3.14.7: Summary table of Interference study on the ‘In-House’ hCG Wick assay with
serum samples spiked with various substances.
Sample
Added
in-H ouse' Assay ABI Assay
C.i. Result 
at 3 min
C.I. Result 
at 60 min
Average 
Flow time 
(min,sec)
C.I. Result 
at 3 min
C.I. Result 
at 60 min
Average 
Flow time 
(min,sec)
0 IU/L Urine 0 0 1,18 0 0 1,17
25 IU/L Urine 1 3 1,15 1 4 1,18
50 IU/L Urine 2 6 1,13 2 5 1,16
0 IU/L Serum 0 0 2,10 0 0 2,15
25 IU/L Serum 1 4 2,15 2 4 2,15
50 IU/L Serum 3 5 2,18 3 5 2,18
Tabla 3.14.8: Summary table of Interference study data for the ‘In-House’ 
and ABI hCG Cassette assays.
Sample
Added
in-H ouse’ Assay ABI Assay
C.I. Result 
at 3 min
C.I. Result 
at 60 min
Average 
Flow time 
(min,sec)
C.I. Result 
at 3 min
C.I. Result 
at 60 min
Average 
Flow time 
(min,sec)
0 IU/L Urine 0 0 1,30 O 0 1,18
25 IU/L Urine 1 4 1,16 1 4 1,15
50 IU/L Urine 2 5 1,15 2 5 1,13
0 IU/L Serum 0 0 2,25 0 0 2,14
25 IU/L Serum 2 3 2,21 2 4 2,19
50 IU/L Serum 4 5 2,15 3 5 2,14
Tabla 3.14.9: Summary table of Interference study data for the ‘In-House’
and ABI hCG Wick assays.
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Substance
Added
C.l. Result a t 3 min 
(TL.CL)
C.l. Result a t 60 min Flow Time 
(TL,CL) (m in,sec)
‘In-House’ ABI 'In-House' ABI ‘In-House’ ABI
None 0, 8 0.6 0, 9 0. 8 1,16 1.19
Acetaminophen 0,8 0. 6 0,9 0, 8 1,18 1,16
Ascorbic Acid 0,8 0 .6 0, 9 0,8 1,17 1.20
Acetylsalicylic acid 0, 8 0. 6 0, 9 0. 8 1,17 1,14
Albumin 0, 8 0, 6 0, 9 0, 7 1,15 1.20
Caffeine 0.8 0,6 0,9 0, 8 1,17 1.17
Estriol 0. 8 0.6 0, 9 0, 8 1,20 1.19
Gentisic acid 0. 8 0. 6 0,9 0, 8 1,22 1,15
Glucose 0.8 0. 6 0, 9 0. 8 1,18 1.23
Haemoglobin 0, 7 0, 8 0,8 0, 8 1,15 1.17
Phenothiazine 0,8 0, 6 0,9 0 ,8 1,19 1,11
Table 3.14.10: C.l. results and flow times (min,sec) forO IU/L hCG urine samples 
(supplemented & unsupplemented) with the 'In-House’ and ABI cassette assays.
Substance C.l. Result at 5 min C.l. Result a t60 min Flow Time
Added (TL,CL) (TL,CL) (mln,sec)
‘ In-House' ABI ‘In-House’ ABI ‘In-House’ ABI
None 0, 8 0 .6 0,9 0, 8 2,24 2,06
Acetylsalicylic acid 0,8 0, 6 0, 9 0, 8 2,07 2,14
Albumin 0, 8 0 .8 0,9 0,9 2.13 2,45
Estriol 0 ,8 0 ,6 0,9 0. 8 2,05 2,02
Glucose 0, 8 °. 7 0,9 0.8 2.06 2,18
Haemoglobin 0, 8 0, 8 0, 9 0,9 2,08 2,03
Table 3.14.11: C.l. results and flow times (min.sec) forOIU/L hCG serum samples
(supplemented & unsupplemented) with the ‘In-House’ and ABI cassette assays.
Substance C.l. Result a t 3 min C.l. Result a t 60 min Flow Time
Added <TL,CL) (TL.CL) (min,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 0,8 0,6 0,9 0. 8 1,42 1,30
Acetaminophen 0, 8 0 ,6 0, 8 0 ,8 1,50 1,16
Ascorbic Acid 0.8 0, 6 0, 8 0, 8 1,32 1,22
Acetylsalicylic acid 0, 7 0, 6 0, 8 0 ,8 1,33 1,14
Albumin 0, 8 0, 6 0,9 0. 7 1,15 1,20
Caffeine 0,8 0 .6 0, 8 0,8 1,26 1,17
Estriol 0,8 0, 6 0, 8 0, 8 1,26 1,16
Gentisic acid 0, 8 0 ,6 0, 8 0, 8 1,30 1,15
Glucose 0,8 0, 6 0,8 0.8 1,33 1,23
Haemoglobin 0, 7 0, 8 0, 8 0.8 1,15 1.17
Phenothiazine 0 .8 0, 6 0. 8 0, 8 1,28 1,08
Table 3.14.12: C.l. results and flow times (min.sec) for 0 IU/L hCG urine samples
(supplemented & unsupplemented) with the ‘In-House’ and ABI wick assays.
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Substance C.l. Result a t 5 min C.l. Result a t 60 min Flow Time
Added (TL,CL) (TL.CL) (min,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 0, 8 0, 6 0,8 0, 8 2,16 2,06
Acetylsalicylic acid 0, 8 0,6 0, 8 0, 8 2,41 2,14
Albumin 0,8 0, 7 0,9 0, 8 2.11 2,18
Estriol 0, 8 0 ,6 0, 8 0, 8 2,21 2.00
Glucose 0,8 0,5 0,8 0,8 2,45 2.31
Haemoglobin 0, 8 0, 7 0, 9 0, 8 2,11 2,16
Table 3.14.13: C.l. results and flow times (min.sec) for 0 IU/L hCG serum samples 
(supplemented & unsupplemented) with the ‘In-House’ and ABI wick assays.
Substance C.l. Result a t 3 min C.l. Result a t 60 min Flow Time
Added (TL.CL) (TL .C t) (min,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 1, 8 1, 7 3,9 4.8 1.18 1,21
Acetaminophen 1, 8 1, 7 3, 9 4,8 1,12 1,16
Ascorbic Acid 1. 8 1, 6 4.9  ^ 4.8 1,11 1,18
Acetylsalicylic acid 1,8 1, 8 4,9 3.8 1,15 1,20
Albumin 1. 8 1, 8 4, 9 4.8 1,18 1,19
Caffeine 1, 8 1, 7 4,9 4, 8 1,16 1,17
Estriol 1, 8 1, 8 3,9 4.8 1,14 1,20
Gentisic acid 1, 8 1, 6 3,9 3 .8 1,13 1.15
Glucose 1, 8 1, 7 4.9 4, 8 1,19 1,20
Haemoglobin 1.8 1, 8 4.9 4, 9 1,19 1,21
Phenothiazine 1, 8 1. 7 3,9 3 ,8 1,14 1,16
Table 3.14.14: C.l. results and flow times (min,sec) for 25IU/L hCG urine samples 
(supplemented & unsupplemented) with the ‘In-House’ and ABI cassette assays.
Substance C.l. Result a t 5 min C.l. Result a t 60 min Flow Time
Added (TL.CU) (TL.CL) (mln,sac)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 2, 8 2 ,6 4, 8 4,8 2,21 2,11
Acetylsalicylic acid 2 ,8 1, 6 4.8 3 ,8 2,41 2,19
Albumin 1, 8 2, 7 3.9 4,8 2,11 2,15
Estriol 1, 8 1,8 4, 8 3 ,8 2,04 2,03
Glucose 1,8 1,5 4, 9 3, 8 2,01 2,20
Haemoglobin 1,9 2.8 3,9 4. 8 2,11 2,24
Table 3.14.15: C.l. results and flow time (min.sec) for 25 IU/L hCG serum samples 
(supplemented & unsupplemented) with the ‘In-House’ and ABI cassette assays.
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Substance C.l. Result a t 3 mitt C.l. Result a t 60 min Flow Time
Added (TL.CL) (TL.CL) (min,sec)
’In-House' ABI ‘In-House’ ABI ‘In-House’ ABI
None 1,9 1. 7 3, 9 3, 8 1,20 1,19
Acetaminophen 1, e 1, 7 4,9 4, 8 1,16 1,13
Ascorbic Acid 1, 8 1, 6 4, 8 3, 8 1,15 1,12
Acetyisalicylic acid 1. 8 1, 8 3 ,8 3, 9 1,18 1,14
Albumin 1, 8 1, 8 3, 9 4,8 1,25 1.27
Caffeine 1.8 1, 7 4 ,9 4, 8 1,10 1,17
Estrió1 1, 8 1,8 3,9 4,8 1,06 1,16
Gentisic acid 1. 8 1, 6 4. 9 3, 8 1,08 1,15
Glucose 1.9 1. 7 4.9 4 .8 1,20 1,11
Haemoglobin 1. 8 1, 8 3,9 4 ,9 1,23 1,11
Phenothiazine 1.8 1. 7 3 .8 3, 8 1.12 1.14
Table 3.14.15: C.l. results and flow times (min.sec) for 25IU/L hCG urine samples
(supplemented & unsupplemented) with the ‘In-House’ and AB! wick assays.
Substance C.l. Result a t 5 min C.l. Result a t 60 min Flow Time
Added (TL'CL) (TL.CL) (mln,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 2,8 2. 7 4,9 4.8 2,13 2.15
Acetyisalicylic acid 2 .8 2, 6 4. 8 3. 8 2,41 2,19
Albumin 1. 8 2, 7 3,9 3.8 2,42 2,39
Estriol 1. 8 1. 8 4. 8 3, 8 2,04 2.09
Glucose 2.8 2, 6 4,9 4, 8 2,01 2,18
Haemoglobin 2, 9 2,8 4.9 4. 8 2.11 2.13
Table 3.14.16: C.l. results and flow time (min.sec) for 25 IU/L hCG serum samples
(supplemented & unsupplemented) with the ‘In-House’ and ABI wick assays.
Substance Added C.l. Result a t 3 min C.l. Result a t 60 min Flow Time
(TL.CL) (t l ,c l ) (mln,sec)
•In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 2. 7 2, 7 5.9 5,8 1,18 1.15
Acetaminophen 2,8 2 J 6,9 5, 8 1,11 1,11
Ascorbic Acid 2 ,8 2. 7 5.7 5.8 1,19 1,20
Acetyisalicylic acid 2, 8 2,8 5,9 5.9 1,04 1,17
Albumin 2, 7 2,8 6,8 4,8 1,18 1,20
Caffeine 2. 7 2, 8 6.9 5 ,8 1.10 1,13
Estriol 2, 8 2 ,8 6,9 4,9 1,10 1,14
Gentisic acid 2 ,7 2. 7 5,8 5 ,8 1,09 1,19
Glucose 2, 8 2. 8 5. 9 5, 8 1,14 1,16
Haemoglobin 2 .8 2.8 5.9 5. 9 1,14 1.18
Phenothiazine 2, 8 2, 7 6. 9 5 ,9 1,20 1,14
Table 3.14.17: C.l. results and flow times (min.sec) for 50 IU/L hCG urine samples
(supplemented & unsupplemented) with the ‘In-House’ and ABI cassette assays
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Substance C.l. Result a t 5 min C.l. Result a t  60 min Flow Time
Added (TL.CL) <TL,CL) (min,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 3, 8 3, 6 6, 8 5 ,8 2,22 2,10
Acetylsalicylic add 4, 8 3 ,6 5,9 5,8 2,16 2,19
Albumin 3, 8 3, 7 4, 8 4, 7 2,41 2,37
Estriol 3, 8 2. 6 5,8 5,8 2.11 2,03
Glucose 4, 8 3 .7 6,9 5.8 2,15 2,22
Haemoglobin 3, 8 3. 8 5 ,8 5, 8 2,01 2,16
Table 3.14.18: C.l. results and flow time (min.sec) for 50IU/L hCG serum samples 
(supplemented & unsupplemented) with the ‘In-House’ and ABI cassette assays.
Substance C.l. Result a t 3 min C.l. Result at 60 min Flow Time
Added (t l ,c l ) (TL.CL) (mln,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 2,8 2, 8 5,9 5, e 1,13 1,12
Acetaminophen 2,8 2, 7 5.9 5,8  _ 1,21 1,13
Ascorbic Acid 2, 8 2, 7 5 .7 5, 8 1,17 1,11
Acetylsalicylic acid 2. 8 2, 8 5 ,9 5,9 1.12 1,17
Albumin 2. 7 2 ,8 6, 8 5, 8 1,22 1.25
Caffeine 2, 7 2, 8 5,9 5 ,8 1,08 1,05
Estriol 2 .8 2, 7 6,8 4, 7 1,15 1,04
Gentisic acid 2, 7 2, 7 5,8 5,8 _ 1,13 1.10
Glucose 2. 8 2 ,8 5, 9 5, 8 1,19 1,17
Haemoglobin 2. 8 2 ,8 5, 9 5,9 1,05 1,18
Phenothiazine 2, 8 2 ,7 6.9 5,9 1,16 1,12
Table 3.14.19: C.l. results and flow times (min.sec) for 50IUA hCG urine samples
(supplemented & unsupplemented) with the ‘In-House’ and ABI wickassays.
Substance C.l. Result a t 5 min C.l. Result a t 60 min Flow Time
Added <t l ,c l > (TL'CL) (mln,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
None 3, 7 3, 7 5 ,8 5, 8 2,11 2,09
Acetylsalicylic acid 3 ,8 3. 7 5,9 5, 8 2,04 2,14
Albumin 3 ,8 3 ,6 5,8 5, 7 2,33 2,26
Estriol 3, 8 3. 7 5, 8 5, 8 2,15 2,08
Glucose 3, 8 3, 7 5, 9 5, 8 2,16 2,14
Haemoglobin 3 ,8 3. 8 5,8 5, 8 2.09 2,10
Table 3.14.20: C.l. results and flow time (min,sec) for 50 IU/L hCG serum samples 
(supplemented & unsupplemented) with the ‘In-House’ and ABI wick assays.
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3.14.3 Specificity study of the ‘In-House’ Assay
The hormones described below were examined with the ‘in-house’ cassette and wick 
assay to determine if any of these physiological hormones would cross react with the 
test line and/or gold conjugate used in these assay formats.
The following honnones were added, at the levels quoted, to both negative and 
positive (25IU/L and 50 IU/L) urine and serum samples:
0  Follicle Stimulating Hormone (FSH) -  1000 mlU/mL
@ Thyroid Stimulating Hormone (TSH) -  1000 jjJU/mL
© Lutenising Hormone (LH) -  500 mlU/mL
The urine and serum samples (spiked with hCG to the following levels: 0, 25 and 50 
IU/L) to which the above hormones (1-3) were added, were directly compared with 
samples (spiked to the same levels with hCG) without any addition of the above 
honnones (1-3). The tests were scored visually by comparison to the negative 
control and a 25 IU/L samples. All samples showing C.I. results lower than that 
observed for the 25 IU/L sample were recorded as negative.
The results are illustrated in Table 3.14.21-3.14.24.
None of the three hormones supplemented into either urine or serum samples 
affected the specificity o f the ‘in-house’ cassette or wick assay. All samples devoid 
of hCG, whether supplemented or not with the three hormones, provided negative 
C.I. results as expected. All positive samples spiked with the three hormones 
displayed C.I. results I line with those observed for the control positive samples (i.e.: 
those without FSH, TSH and LH).
• Conclusion for Section 3.14.1 -  3.14.3
From the results outlined in this section, none of the interfering substances examined 
affected the performance of either the cassette or wick ‘in-house’ assay with positive 
and negative urine or serum samples.
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Sample C.l. Result at 3 
mlns. (TL,CL)
C.l. Result a t 30 
mins. (TL,CL)
Flow Time 
(m in,sec)
‘In-House’ ABI ■In-House' ABI ‘In-House’ ABI
0 IU/L (hCG) 
only
0,8 0,8 0,9 0,9 1,24 1,12
25 IU/L (hCG) 
only
1.8 1, 8 2,9 2,8 1,30 1, 14
50 IU/L (hCG) 
only
2 ,8 2,8 4,9 3,9 1,26 1, 17
0 IU/L (hCG), 
1000 mlU/mL FSH
0, 8 0, 8 0,9 0,9 1,20 1, 19
25 IU/L (hCG), 
1000 mlU/mL FSH
1, 8 1,8 2,9 3, 8 1,37 1, 14
50 IU/L (hCG), 
1000 mlU/mL FSH
2,8 2,9 4,9 2,9 1,20 1, 15
0 IU/L (hCG), 
1000 filU/mL TSH
0, 8 0,9 0,9 0, 9 1,28 1, 19
25 IU/L (hCG), 
1000 filU/mL TSH
1,8 1,9 2,9 2,9 1,27 1, 18
50 IU/L (hCG), 
1000 f/IU/mL TSH
2,8 2, 8 4,9 3,9 1,21 1, 21
0 IU/L (hCG), 
500 mlU/mL LH
0,8 0, 8 0,8 0,9 1,27 1, 14
25 IU/L (hCG), 
500 mlU/mL LH
1, 8 1, 8 2,9 2, 9 1,28 1, 16
50 IU/L (hCG), 
500 mlU/mL LH
2,8 2, 8 4,9 3,9 1,23 1 18
Table 3.14.21: C.l. results and flow 
hormones and without) for the
imes (min.sec) for urine samples (with 
‘In-House’ and ABI wick assays.
Sample C.l. Result a t 5 
mins. (TL,CL)
C.l. Result a t 30 
mlns. (TL,CL)
Flow Time 
(min,sec)
‘In-House’ ABI ‘In-House1 ABI ‘In-House’ ABI
0 IU/L (hCG) 
only
0, 8 0, 8 0,9 0,9 2,10 2, 16
25 IU/L (hCG) 
only
1, 8 1, 8 2,8 2 ,8 2,11 2, 18
50 IU/L (hCG) 
only
2, 8 2, 8 3,9 3,9 2,14 2, 21
0 IU/L (hCG), 
1000 mlU/mL FSH
0, 8 0, 8 0,9 0, 9 2,12 2, 14
25 IU/L (hCG), 
1000 mlU/mL FSH
1, 8 1, 8 2, 8 2 ,8 2,16 2, 17
50 IU/L (hCG), 
1000 mlU/mL FSH
2, 8 2, 9 3,9 2,9 2,25 2, 20
0 IU/L (hCG), 
1000 jjlU/mL TSH
0,8 0, 8 0,9 0,8 2,22 1, 19
25 IU/L (hCG), 
1000 MlU/mL TSH
1, 8 1, 8 2, 8 2, 8 2,02 1, 18
50 IU/L (hCG), 
1000 ulU/mL TSH
2, 8 2, 8 3 ,9 3,9 2,00 2, 01
0 IU/L (hCG), 
500 mlU/mL LH
0, 8 0, 8 0,8 0,9 2,08 1, 14
25 IU/L (hCG), 
500 mlU/mL LH
1, 8 1, 8 2,8 2,9 2,04 1, 16
50 IU/L (hCG), 
500 mlU/mL LH
2, 8 2, 8 3,9 3 ,9 2,08 2, 10
Table 3.14.22: C.l. results and flow times (min,sec) for serum samples (with 
hormones and without) for the ‘In-House '  and ABI wick assays.
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Sample C.l. Result a t 3 
mins. (TL,CL)
C.l. Result a t 30 
mlns. (TL,CL)
Flow Time 
(m ln,sec)
In-House’ AB! 'In-House’ ABI ‘In-House’ ABI
0 IU/L (hCG) 
only
0, 8 0, 8 0, 9 0,9 1,20 1,18
25 IU/L (hCG) 
only
1,8 1,8 2, 8 2 ,8 1,20 1,16
50 IU/L (hCG) 
only
2,8 2,8 3,9 3,9 1,16 1,20
0 IU/L (hCG), 
1000 mlU/mL FSH
0, 8 0, 8 0, 9 0,9 1,18 1,13
25 IU/L (hCG), 
1000 mlU/mL FSH
1,8 1, 8 2,9 3, 8 1,19 1,17
50 IU/L (hCG), 
1000 mlU/mL FSH
2,8 2, 8 3,9 2,9 1,21 1,10
0 IU/L (hCG), 
1000 ^U/mL TSH
0, 8 0, 9 0, 9 0,9 1,16 1,21
25 IU/L (hCG), 
1000 ^U/mL TSH
1, 8 1,8 2, 9 2,9 1,20 1,19
50 IU/L (hCG), 
1000 MlU/mL TSH
2,8 2,8 3,9 3,9 1,12 1,14
0 IU/L (hCG), 
500 mlU/mL LH
0 ,8 0, 8 0,8 0,9 1,14 1,16
25 IU/L (hCG), 
500 mlU/mL LH
1, 8 1,8 2,9 2, 9 1,16 1,14
50 IU/L (hCG), 
500 mlU/mL LH
2,8 2,9 3,9 3,9 1,27 1,20
Table 3.14.23: C.l. results and flow times (min.sec) for urine samples (with 
hormones and without) for the 'In-House’ and AB! cassette assays.
Sample C.l. Result a t  S mins. 
(TL.CL)
C.l. Result 
(TL,
a t 30 mins. 
CL)
Flow Time 
(min,sec)
‘In-House’ ABI ‘In-House’ ABI ‘In-House’ ABI
0 IU/L (hCG) 
only
0,8 0,8 0,9 0,9 2,20 2,02
25 IU/L (hCG) 
only
1,9 1,8 3,8 2,8 2,20 2,16
50 IU/L (hCG) 
only
2,8 2,8 4,9 3,9 2,23 2,14
0 IU/L (hCG), 
1000 mlU/mL FSH
0,8 0,8 0,9 0,9 2,17 2,06
25 IU/L (hCG), 
1000 mlU/mL FSH
1,8 1,8 2,8 2,8 2, 15 2, 12
50 IU/L (hCG), 
1000 mlU/mL FSH
2,9 2,9 3,9 2,9 2,22 2,15
0 IU/L (hCG), 
1000 M'U/mL TSH
0,8 0,8 0,8 0,8 2,18 2,04
25 IU/L (hCG), 
1000 ulU/mL TSH
1,9 1,8 2,8 2,8 2,24 2,11
50 IU/L (hCG), 
1000 MlU/mL TSH
2,8 2,9 3,9 3,9 2,01 2,01
0 IU/L (hCG), 
500 mlU/mL LH
0,8 0,8 0,9 0,9 2,48 2,14
25 IU/L (hCG), 
500 mlU/mL LH
1,8 1,9 2,9 2,9 2,54 2,04
50 IU/L (hCG), 
500 mlU/mL LH
2,8 2,8 3,8 3,9 2,08 2,06
Table 3.14.24: C.l. results and flow times (min,sec) for serum samples (with 
hormones and without) for the ‘In-House’ and AB! cassette assays.
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3.14.4 Prozone Study
hCG assays are prone to prozone results caused by the very high levels of hCG 
present in a substantial number of samples during the first trimester of pregnancy 
(see Discussion, section 4.9.4). Due to this phenomenon it was necessary to 
determine at what level of hCG did this prozone effect occur.
Negative urine was spiked with hCG according to Method 2.2.5.2 to the levels 
outlined in Table 3.14.25 and the effect on C.I. results was recorded in the same 
table.
hCG Concentration (IU /L) C.I. Result a t 3 minutes
1,000,000 0
750,000 0
500,000 0
250,000 0.5
200,000 1
125,000 2
100,000 4
10,000 6
1,000 8
100 4
0 0
Table 3.14.25: Examination o f the effect o f prozone samples 
on the ‘In-House’ Assay.
•  Conclusion
From the C.I. results illustrated in Table 3.14.25 it is clear that negative C.I. results 
are obtained when samples contain over 250,000 IU/L of hCG, i.e.: the prozone 
effect is apparent with this level of analyte.
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3.14.5 Clinical Trials for the Final Format of the ‘In-House’ Assay
The cassette and wick formats of the ‘in-house’ assays were evaluated separately for 
performance in both external and internal clinical trials. This section details the 
results achieved with both of these assay formats for several clinical trials using both 
urine and serum samples. The ABI test (see section 2.1, Materials) was used 
throughout the clinical trials as the predicate device.
Internal and External Clinical Trials for the Cassette Device
302 hCG-negative urines were examined on the cassette device. 135 of these samples 
were sourced internally at Trinity Biotech Pic., 117 samples were received from St. 
James Hospital, Dublin and a further 50 hCG-negative samples were obtained during 
a customer perception study at Dublin City University (D.C.U.) (see page 157-158). 
All of the urines tested yielded negative results on both the ‘in-house’ cassette assay 
and on the ABI test.
275 hCG-positive urine samples were evaluated on the cassette device. Of these, 
volunteers assayed 100 samples as part of the customer perception study carried out 
in D.C.U. Since the results were interpreted as either positive or negative, no C.I. 
result grading was determined for these 100 samples. Subsequently, they are not 
included in the histogram shown overleaf in Figure 3.14.1. All of the hCG-positive 
urines tested gave positive results on the cassette device.
313 hCG-negative serum samples were assayed on the cassette device. All of these 
samples were received from Pelican House, Dublin and all displayed negative C.I. 
results.
260 hCG-positive serum samples were tested on cassette format of the ‘in-house’ 
assay. Four of these samples were interpreted as negative for hCG. However, all four 
of these samples were heavily blood-stained and should have been centrifuged before 
testing since the blood made it difficult to read the test result. The remaining 256 
positive C.I. results are summarised in the histogram in Figure 3.14.2.
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Overall, for the sample populations examined on the cassette device demonstrated 
100% sensitivity and specificity with urine and 100% specificity and 98.5% 
sensitivity with serum samples. This concurred with the results obtained for the ABI 
device as can be clearly seen from the similar sample distributions in both of the 
histograms shown in Figures 3.14.1 and 3.14.2.
■ in-house'
■  A B I
Figure 3.14.1: Histogram results displaying the frequency at \Ahich particular 
C.l. results occurred for both the 'in-house'cassette assay and the ABI test for 
hCG-positive urines from the same sample population.
In -house '
ABI
Figura 3 .14.2: Histogram results d isplaying the frequency at which 
particu lar C.l. results occurred for both  the 'in-house' cassette assay and the 
ABI test for the sam e sam pie population o f hCG-positive serum samples.
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Internal and External Clinical Trials for the Wick Device
As carried out for the cassette device, the wick device was tested alongside the ABI 
wick device. 129 hCG-negative urine samples were evaluated on this format. 
Volunteers from the customer perception study at D.C.U. ran 100 of these hCG- 
negative urines; these are described overleaf. A further 29 samples were obtained 
from St. James’ Hospital, Dublin. All samples tested negative, as expected.
With regard to hCG-positive urine, 169 samples were run. 100 of these samples were 
tested as part of the customer perception study in D.C.U., another 32 of the samples 
were supplied by the Rotunda Hospital, Dublin and the remaining 37 samples were 
obtained from The Coombe Hospital, Dublin. The results are summarised in Figure 
3.14.3. It should be pointed out that one of the samples tested at D.C.U. gave a 
negative result when first tested. A positive result was achieved upon repeat testing 
and this result was included in the histogram below.
100 hCG-negative serums were tested on the wick device. These samples were 
received from the Cork Blood Bank. Two of these samples yielded low positive C.I. 
results. It should, be pointed out, however, that these samples were among a group of 
samples, which had been thawed from -20°C one week previous to testing and 
displayed some signs of deterioration.
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156 hCG-positive sera were assayed on the ‘in-house’ wick device. 100 of these had 
been received from the Rotunda Hospital, Dublin and 56 were obtained from the 
Coombe Hospital, Dublin. All 156 samples gave positive C.I. results and as can be 
seen from Figure 3.14.4 below, quite similar sample distributions were observed for 
the ‘in-house’ and ABI tests.
■  In-house'
■ ABI
Figure 3.14.4: Histogram showing the frequency at which particular C.I. 
results occurred for both the 'in-house' wick assay and the ABI test forhCG-
positive serums.
In summary, the wick device demonstrated 100% specificity and 99.4% sensitivity 
for urine samples. 98% specificity and 100% sensitivity were achieved with serum 
samples on the wick device. It is probable that by using fresh samples and by 
centrifuging any bloodstained samples that 100% specificity and sensitivity could 
have been achieved.
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Clinical Trial and Customer Perception Study
The ‘in-house’ wick assay was evaluated against the ABI wick assay by fifty 
volunteers at Dublin City University, Glasnevin. These volunteers provided a urine 
sample each (all of which were negative for hCG) and ran their own sample on both 
the ‘in-house’ assay and the ABI test.
Each volunteer was then supplied with a set of three coded hCG controls, one 
negative (0 IU/L), one low positive (50 IU/L) and one high positive control (200 
IU/L) to run on the ‘in-house’ assay. The control bottles were labelled with code 
numbers in such a way as to allow for a completely blind study regardless of how 
many volunteers were running the assay at the one time. Each volunteer was asked to 
interpret the results obtained as positive or negative based on a diagram similar to 
that shown in the provided instruction sheet (see Appendix II). Comments were also 
invited from volunteers on their perceptions of the assay, a summary of which is 
illustrated in Figure 3.14.5.
Therefore in total, 100 negative samples (50 from the volunteers and 50 from the 
coded controls), 50 low positive samples and 50 high positive samples were assayed 
on the ‘in-house’ assay.
A summary of the results obtained is shown below:
Performance of Assay
in-House' ABI
% Sensitivity 100 (100/100) 100 (50/50)
% Specificity 99 (99/100) n/a*
Table 3.14.26: Summary o f the ‘In-House’ Assay Performance 
*Volunteers ran positive controls on the ‘in-house’ assay only.
No false positive results were obtained on either the ‘in-house’ assay or the ABI hCG 
wick tests. All the 100 negative samples were interpreted as negative by the 50 
volunteers. All 50 of the high positive controls (200 IU/L hCG) were interpreted as 
positive by the volunteers, while 49 of the 50 low positive samples resulted in
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positive interpretations by the volunteers (i.e.: only one false positive result was 
observed with the ‘in-house’ assay.
It is important to note that many volunteers commented on the ease of use and 
rapidity of the test and some expressed a preference for the ‘in-house’ assay over the 
competitor device (See Figure 3.14.5 below).
Figure 3.14.5: Summary of responses from a customer perception 
study on the 'in-house' assay
Well structured test »
Test lines superior 
on 'In-house' assay
m
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s
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•  Conclusion
Excellent specificity and sensitivity were achieved for the sample populations tested 
with the ‘in-house’ assay. The cassette and wick formats of the ‘in-house’ assay 
compared favourably to the predicate device, i.e.: the ABI test. Positive feedback 
was received when potential customers were asked to give their views on the test, 
with most participants (70%) declaring that the test was ‘user-friendly’.
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3.15 Stability of the ‘in-House’ Assay
The stability of both the cassette and wick formats of the ‘in-house’ hCG assay was 
evaluated in this study in accordance with method 2.3.5.9, which was adapted from 
that described by Anderson and Scott (1991). The stability studies carried out 
employed the accelerated time method as summarised in Table 3.15.1 below.
Weeks a t 37°C Equivalent Tim e a t 20 -  25°C
14 12 months
21 18 months
28 24 months
Tabla 3.15.1: Accelerated Time Stability Study
‘In-House’ Cassette Assay Stability Study
The cassette devices were placed in a 37°C incubator and tested at the time intervals 
outlined in Table 3.15.1 above. Therefore the devices were tested at an accelerated 
time of 12 months, 18 months and 24 months. The C.I. results and flow times for the 
devices are recorded in the tables, which follow, for urine and serum samples with 
unstressed (Control) devices and at accelerated times of 12, 18 and 24 months (see 
Table 3.15.2 and 3.15.3). The results for ABI devices incubated under the same 
conditions are also shown. These results are summarised in Figures 3.15.1 and 
3.15.2.
Sample C .I. Result a t 3 mlns Flow Time
Control* 12 mths 18 mths 24 mths Control* 12 mths 18 mths 24 mths
Urine
OIU/L 0, 8 0, 8 0, 8 0 ,6 1,11 1,35 2,04 2,57
OIU/L 0, 8 0,8 0, 8 0, 6 1,24 1,37 1,59 2,52
25 IUÆ 0.5, 8 0.5, 8 0.5, 8 0.5, 6 1,19 1,29 2,11 2,41
200 IU/L 3, 8 3, 8 3, 8 1.6 1,22 1,40 2,13 2,54
2000IUÆ 6, 7 7, 7 8, 7 9, 7 1,31 1,39 2,21 2,58
Seram
OIU/L 0, 7 0, 8 0, 7 0.5, 6 2,35 2,47 3,59 4,59
OIU/L 0, 7 0, 7 0, 7 0.5, 6 2,40 2,54 3,45 4,35
25 IU/L 1, 7 1, 7 1, 6 1,6 2,33 2,57 3,52 4,24
200 IU/L 6, 7 6, 7 7, 6 6, 6 2,42 2,55 3,24 4,37
2000 IU/L 8, 6 8, 8 9 ,6 9,6 2,37 3,05 3,46 4,40
Table 3.15.2: C.I. results & flow times for test and control ‘in-house’ devices, which 
were stressed at 37°C for time periods equivalent to 12, 18 & 24 months at 20-2&C. 
(* = unstressed device results at Day 0)
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Sample C .l. Result for the Mn-house'control 
device a t 3 mlns
C.I. Result for the ABI test 
e t 3 mlns
Day 0 12 mths 18 mths 24  mths Day 0 12 mths 18 mths 24 mths
Urine
0 IU/L 0,8 0,8 0, 7 0, 7 0,8 0, 8 0,6 0,6
OIU/L 0,8 0, 8 0, 7 0, 7 0, 8 0,8 0, 6 0,6
25 IU/L 0.5, 8 0.5, 8 1. 7 0.5, 7 0.5, 8 0.5, 8 0.5, 8 0.5, 6
200 IU/L 3, 8 4,8 6, 8 6,8 3, 6 3, 7 3,6 3, 6
2000 IU/L 6, 7 8,6 8, 6 8, 6 7, 6 7, 6 8, 6 8, 7
Serum
OIU/L 0, 7 0, 7 0, 7 0, 7 0, 7 0, 7 0, 7 0.5, 8
OIU/L 0, 7 0, 7 0, 7 0, 7 0, 7 0, 7 0, 7 0, 8
25 IU/L 1, 7 1, 7 1, 7 1, 7 1, 7 1, 7 1, 6 1,6
200 IU/L 6, 7 6,8 6, 8 6,8 6, 7 6, 7 8, 6 6, 6
2000 IU/L 8,6 8, 6 8, 6 8,6 8, 6 8, 7 10, 6 10, 3
Table 3.15.3: C.l. results for the 'in-house' control devices (i.e.: unstressed) and ABI 
devices, used for comparison with the test devices which were being examined at 
accelerated time periods at 37°C, which were equivalent to 12, 18 & 24 months at 20-25°C.
Figures 3.15.1 and 3.15.2 (see page 161,162) demonstrate a predicted stability of the 
‘in-house’ assay for up to 18 months at room temperature. The ‘in-house’ device 
presented satisfactory C.l. results at 12 and 18 months in comparison to those 
recorded for the control devices. It is important to note that positive C.L results were 
noted for the negative urine samples at 24 months (accelerated). For the same time 
interval the 200IU/L serum sample resulted in much lower colour intensity than seen 
for the same sample at 18 months (accelerated). The C.l. result for the 2000 IU/L 
serum sample was seen to increase significantly with each time interval.
From Figure 3.15.2, it should be noted that the flow time for the assay increased 
gradually with increasing storage periods at 37°C. Most importantly, the flow time 
required to see the ‘in-house’ assay to completion with both the urine and serum 
samples increased dramatically at 24 months (accelerated).
•  Conclusion
These results show the cassette to be stable for 18 months according to the shelf life 
equivalency table, however the specificity declines at 24 months and the time taken 
for the assay to complete at this time interval was unsatisfactory.
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Figure 3.15.1: PlotofC.I. results for urine and serum samples for the 'in-house'control 
and test (stressed) devices, following accelerated stability studies at 37°C, equivalent to 12,
18 and 24 months at 20-25°C.
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2000 IU/L Urine 
0 IU/L Serum 
0 IU/L Serum 
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Figure 3.15.2: Plot of  flow times for urine and serum samples  with the ' in-house'  
control and test (i.e.: stressed) devices following accelerated stability studies at  3 7 °  C,
equivalent  to 12, 18 and 24 months a t  2 0 - 2 5 °  C.
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Section 4: 
Discussion
4.0 Discussion
The presence of the hormone, human chorionic gonadotropin (hCG), in urine and 
serum is normally indicative of pregnancy. As detailed in section 1.2 (Introduction), 
hCG is a dimeric protein, consisting of an a  and (3 subunit. As reported by Gosling 
(1990) the greatest variety and sophistication in the formulation of immunoassays are 
seen for over the counter (OTC) kits such as pregnancy tests. A wide range of 
pregnancy tests, which qualitatively detect this hormone, are currently available on 
the market. These vary from the over the counter ‘stick’ or ‘pen’ devices available 
from chemist shops for home use to the point of care (POC) cassette devices 
commonly used in the GP’s office. Various EIA hCG assays are also commercially 
available for use in the clinical laboratory situation where the quantitation of exact 
hCG concentrations is important. Inferences can be made about the origin of the hCG 
and its related molecules in a given sample (e.g.: pregnancy, hydatidiform mole, 
persistent trophoblast disease, choriocarcinoma and ‘phantom’ or false positive hCG) 
(Cole, 1999b).
The OTC pregnancy tests were some of the first immunoassays to find application in 
the home with an ease of use suitable to the untrained or lay person. Due to their 
simplicity of operation, these tests enable a woman to determine for herself in the 
privacy of her own home whether or not she is pregnant without the expense of a 
blood test and a doctor’s visit (Price et al., 1997). New technology has ensured that 
these tests are now highly reliable and easy to use with results taking as little as 3 
minutes to read and capable of detecting hCG as early as the first day of a missed 
period.
The reasons for developing a new rapid pregnancy immunoassay were several fold. It 
would be prudent to question the wisdom of placing another OTC/POC pregnancy 
test on the market when so many already exist (see Table 1.10.1, section 1.10, 
Introduction). The decision to develop a new gold-based immunochromatographic 
assay was mainly based on predicted figures researched by the marketing department 
at Trinity Biotech, where all of the research and development of the test took place. It 
was forecast that by the year 2000 the worldwide market for POC/OTC in vitro 
diagnostics (IVD) would be worth $6 billion from a figure of $2 billion in 1995 (30%
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growth p.a.) (Shine, 1998). The scale of the growth in the POC/OTC market deemed 
the development of such a test feasible. It was also the aim of Trinity Biotech to 
develop a test that was faster for urine testing than competitors on the market (3 
minutes for the ‘in-house’ urine test vs. 5-10 minutes for other assays already on the 
market, see Table 1.10, section 1.10, Introduction). This knowledge from the pre­
development survey justified the proposed inclusion of the rapid hCG test on the 
market.
As discussed in section 1.11.4 of the Introduction the aim was to develop a test, 
which could match or exceed those already on the market (see Table 1.10.1, 
Introduction) with regard to several parameters: ® assay time, © ease of use, © no 
requirement for equipment/reagents © low skill factor, © no refrigeration required, 
© low cost and © safety.
This discussion will examine the results achieved during the development and 
evaluation of a cassette and wick hCG test, both of which fulfil the above criteria.
4.1 The selection of the test line antibody
This section of the discussion details the initial developmental work on the selection 
of a suitable test line antibody, which was described in sections 3.2-3.3.
Newman and Price, 1997a, state that in order to select a suitable antibody for 
immunoassays there are four main characteristics to consider in connection with final 
assay performance: specificity, sensitivity, reaction time and stability. It is known 
that the desired specificity, sensitivity and reaction time are dependent on the affinity 
constant (K a) and paratopic conformation of the antibody. Although thermal stability 
can vary between different antibodies, thereby conferring stability at higher 
temperatures for some antibodies, the overall stability of the antibody will probably 
be largely dependent on the solid phase to which it is bound (Newman and Price, 
1997a).
For the initial test line antibody selection studies (see section 3.2, Results), it was 
necessary to assume that all of the potential test line antibodies being examined 
would be stable on the nitrocellulose membrane. This was a logical assumption since
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many papers have reported on the robustness of immunoglobulin molecules and on 
their retention of immunological activity when conjugated to solid phases (Butler, 
1991; Thakkar et al, 1991). Once a test line antibody had been chosen, interim 
stability studies were performed throughout the development of the test to verify this 
assumed stability (results not shown). The binding of antibody to nitrocellulose 
membrane occurs non-covalently (Harvey, 1991), therefore, no harsh coating and/or 
washing procedures are required to bind the antibody to the membrane. It should be 
pointed out that while it was known that the manufacture of the test would involve 
vacuum drying procedures, the assumption was made that once the antibody was 
dried in a suitable stabilising buffer (Jones, 1999(a), Millipore, 1996) no adverse 
effects would be apparent on the chosen antibody. This assumption can be 
substantiated by reports that the coupling of antibodies to solid phases which are 
subsequently dried and stored desiccated ensures that the antibody is stable almost 
indefinitely (Newman and Price, 1997b).
As mentioned on the previous page, the specificity, sensitivity and reaction time of 
the antibody can be assessed by determining the affinity constant and paratopic 
conformation for the antibody in question. For the purposes of this test, however, 
such investigations were neither required nor practicable due to time limitations and 
insufficient instrument resources. The affinity was indirectly evaluated by spraying 
each of nine antibodies, sourced as test line antibodies (one polyclonal and eight 
monoclonal IgG antibodies) at similar concentrations on the same nitrocellulose 
membrane, using the same gold conjugate. This also provided sufficient indication 
with respect to the specificity and sensitivity of the antibodies. The C.I. results at 5 
and 10 minutes were examined (see section 3.2, results). It should be emphasised that 
the results were read at 5 and 10 minutes as the other components were not optimised 
at this point and it was more likely that significant assay observations would be 
obtained with a slightly extended assay time.
The various antibodies evaluated were raised against different isoforms of the hCG 
antigen (see Table 4.1, overleaf). The results from the evaluation showed that 
antibody nos. 1, 8 and 9 gave the most satisfactory positive/negative discrimination 
for the samples evaluated (see section 3.2, Results). These three antibodies consisted 
of two monoclonal antibodies raised against intact hCG (nos. 1 and 8) and a
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Antibody No. Antigen ralsad against
1 Intact hCG molecule
2 J3-hCG
3 Intact hCG molecule
4 p-hCG
5 p-hCG
6 P-hCG
7 P-hCG
e Intact hCG molecule
9 a-hCG
Table 4.1: List o f antibodies evaluated as the test line antibody (see section 3.2) 
and the antigen to which each o f these antibodies was raised.
polyclonal antibody (no. 9) raised against a-hCG. The benefit of a test line antibody 
raised against intact hCG was apparent since it appeared that no potential steric 
hindrance problems arose between the binding of the antigen to both the test line 
antibody and the gold-conjugated antibody simultaneously. This was because the 
gold-conjugated antibody bound only to the P-hCG subunit of the molecule and the 
test line bound to the intact hCG molecule (i.e.: a  and P subunits).
With regard to the polyclonal antibody, it was initially thought that an antibody 
raised against the a-subunit of hCG might cause crossreactivity problems with the 
homologous a-subunits o f the other peptide hormones (see section 1.2, Introduction). 
It should be noted, however, that it is generally easier to produce high-affinity 
polyclonal antibodies (Newman and Price, 1997a). Also if a high affinity anti-P-hCG 
monoclonal antibody was used for the gold conjugate this would ensure that only 
molecules of intact hCG would bind to the test line. This is explained by the fact that 
free P-hCG isoforms and other hCG metabolites present in some samples would not 
be capable of binding to the anti-a-hCG test line antibody. It is preferable to have a 
pregnancy test for the o f the detection of intact hCG only. This is due to the 
significant variation and discordant results reported for tests which rely on anti-P- 
hCG antibodies for the detection of hCG (Cole et al., 1993a). It should be noted that 
free P-hCG is an extremely minor component of normal pregnancy serum, making 
up <1% of the hCG concentration (Cole, 1997). Many commercial pregnancy tests 
rely on the use of anti-P-hCG detector reagents because of the homology that exists 
between the a-subunits of the glycoprotein hormones. Specificity for a particular
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glycoprotein hormone is governed by its (3-subunit (see section 1.2, Introduction). 
However, it is known that many isoforms of the hCG molecule can exist (see section 
1.4, Introduction). It is also known that some of these isoforms, particularly P-hCG, 
can be present at different levels in the urine and blood of the individual at the same 
time (Norman et al., 1987). Obviously, for the purposes of the assay being developed 
within this thesis (i.e.: one, which detects hCG in both urine and serum) such a 
situation must be avoided. This, then, can only be possible by the use of an antibody 
pair which detects intact hCG only.
Quite variable results were achieved with antibodies raised against the same isoform 
of the hCG molecule. This was noted, in particular, for the antibodies raised against 
P-hCG (antibodies no. 2 and nos. 4-7). However, this variation in affinity for the 
hCG antigen corresponds with current theory. It is possible to have more than one 
non-identical antibody reactive to an antigenic site, each with a different affinity 
depending on the composition of the idiotype of the antibodies in question (Steward 
and Steensgaard, 1983). Alternatively, it is also possible that the antibody molecules 
were reacting with different antigenic determinants on the P-hCG molecule (Bassion, 
1989). Also, since the gold-conjugated antibody was raised against P-hCG it is 
probable that, due to the positioning of some of the antigenic determinants, steric 
hindrance played a role in the poor results obtained for antibodies nos. 2 and 4 
(Newman and Price, 1997a). Antibody nos. 3, 5, 6 and 7 all displayed poor 
positive/negative discrimination, therefore, the low affinity of these antibodies for 
the antigen (i.e; the hCG molecule) was not sufficient for this assay.
Following further evaluation (section 3.2.2 and 3.3) the polyclonal anti-a-hCG 
antibody (no. 9) was chosen as the test line antibody. Consequently, since a 
polyclonal antibody was selected for use as the test line antibody, it was possible to 
avoid the licensing restrictions and legal ramifications on the use of paired 
monoclonal antibodies in assays which use the ‘sandwich’ format (i.e.: the assay 
format being utilised for this test). This would have increased the cost per test due to 
royalties incurred by licensing U.S. patent no. 4376110 assigned to Hybritech, in 
respect of the detection of antigens by the use of two monoclonal antibodies in a 
‘sandwich’ format.
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4.2 The selection of a suitable gold conjugate
The question arises at this point in the discussion as to why a gold-labelled conjugate 
was used for this rapid pregnancy test since so many other market leaders have found 
success using latex conjugates (e.g.: Clearview by Unipath; OSOM hCG Combo by 
Wyntek Diagnostics) (see Table 1.10.1, section 1.10, Introduction).
There are several important reasons as to why gold labelling was chosen over latex 
beads. Due to the significantly larger size of latex beads, generally 0.1-0.4jam for 
diagnostic strip tests (Singer, 1992), it is possible to achieve very clear and dense 
lines on a lateral flow assay. However, because of the size of the particles the 
sensitivity of the assay can be compromised due to significant steric hindrance of the 
large antibody-coated latex beads. The use of antibodies conjugated to such large 
labels can also be limited by the high non-specific binding of the label (Gosling, 
1997). This effect is much reduced for gold-conjugated antibodies. Throughout the 
development of this test 40nm gold particles were used for the conjugation based on 
recommendations from gold conjugate manufacturers (Chandler, 1997). Typically, 
an antibody of approximately 150,000 Da molecular weight will have a linear 
dimension of 8nm (Chandler, 1999). Thus a lnm gold particle, attached to the Fc 
portion of the antibody will hardly impede the antibody’s activity. A 40nm gold 
particle, albeit more visible, will produce increased steric hindrance by its proximity 
to the antigen binding region of the antibody (Chandler, 1999). It is clear then, that 
the attachment of a latex particle of size 0.1-0.4jam would have considerably greater 
steric hindrance effects on the binding of the antibody to the antigen (in this case, the 
hCG molecule) than that seen for a 40nm gold label. Despite that, theoretically, there 
are less antibodies bound to the smaller gold label than to the larger latex bead due to 
the smaller available surface area, the sensitivity is better with the smaller gold- 
labelled conjugates. The increased sensitivity with the smaller particles is directly as 
a result of more of the antibodies on the gold label being free to bind to the hCG 
antigen due to the smaller nature of the label. Obviously, the steric hindrance effect 
could be reduced when using latex conjugates if  suitable spacer arms were utilised 
(Griffin et al., 1994). However, the cost and time factors involved in producing such 
complex labels were not acceptable. The aim was to provide the customer with a low 
cost assay and to develop a test which was relatively straightforward to manufacture
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Criteria for tha selection of a conjugate
(D Sensitivity
' Colour desired
® Amount of antibody required for conjugation
©  Membrane type used in device
> Ease of preparation and reproducibility
©Stability
®Scale-up issues
Table 4.3: The criteria for selecting a conjugate for a rapid membrane-based 
immunoassay. (Recommendations from Colanduoni, 1997 and Gosling, 1990).
as opposed to the highly labour intensive procedure, which would be required for the 
manufacture of such latex conjugates.
The criteria used for the selection of a suitable conjugate are detailed in Table 4.3 
above. These criteria can be applied to the selection process, which was conducted 
during the development of the ‘in-house’ assay.
® Section 3.3 of the results section dealt with the evaluation of six gold conjugates 
with two different test lines and with the subsequent selection of the most sensitive 
and specific gold-labelled antibody. As described on the previous page, the 
sensitivity of a labelled antibody can be dependent on the size of the attached label. It 
should be noted with regard to conjugate sensitivity that the size of the gold label 
used can easily be controlled by various reduction methods (DiScipio, 1996; 
Hermanson, 1996 and Handley, 1989).
(D Since only one analyte was to be detected in this assay only one colour was 
required for the detector label therefore, a 40nm gold label, which provided strong 
red colour due to its high label content (Colanduoni, 1997) was ideal for use in this 
assay with regard to label colour.
(D During the conjugation procedure antibody is added to gold sols in order to 
stabilise the sol, thus resulting in binding of the antibody to the gold beads (i.e.: the 
formation of gold conjugates) (see section 1.11.4.2, Introduction). The amount of 
antibody required to stabilise each mL of gold sol for this test was similar for all of 
the gold-labelled antibodies examined in section 3.3 (results not shown). Typically, 
the average amount of antibody required per litre of gold sol was 6-10mg, which 
would provide enough gold conjugate for approximately 17,000 tests.
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@ The membrane type (no. 2, see Appendix I), which was kept constant for these 
initial studies, provided a fast flow of sample/reagents (refer to section 1.11.4.1, 
Introduction). It has been suggested that the pore size of the membrane used should 
be l/lO111 of the size of the detector label to allow free movement of the labelled 
antibody on the membrane (Bangs and Meza, 1995). As the gold particle was only 
40nm in diameter it was not anticipated that the gold conjugate would be hindered in 
its progression up the test strip as a result of the pore size of the membrane.
© No reproducibility problems had been observed for gold conjugates that had 
previously been manufactured in Trinity Biotech. These gold conjugates were 
constantly under validation by Trinity Biotech staff, who regularly monitored the 
sensitivity and specificity of completed tests using these reagents. It was, therefore, 
decided to continue with the use of a similar conjugate for this assay.
© The stability of the selected gold-labelled antibody was monitored as the 
development of the assay progressed and was seen to be satisfactory (see section 
3.15, Results and section 4.9.6, Discussion).
© Scale-up issues did occur in the manufacture of the gold conjugate, leading to 
sensitivity and specificity problems for the final product (results not shown). These 
problems pertained to the difficulty in manufacturing batches of more than one litre 
of gold conjugate at a time. This was due to difficulties in determining a method 
suitable for such conjugates, which ensured homogeneity of the gold conjugate 
solution. However, as 1 litre of gold provided approximately 17,000 tests this did 
not impede the production of this gold conjugate once its manufacture was kept to 
batch sizes of one litre and below.
Section 3.3 of the results section describes the comparison of six monoclonal anti- 
hCG gold conjugates with two test line antibodies. It also details the further 
assessment of various test line and gold conjugate antibody pairs until conjugate C 
(see Appendix I for details) was selected for use with test line antibody no. 9.
In order to carry out the determination of usable conjugates a positive minus negative 
value (P-N value) was employed. In the early stages of the development of the ‘in- 
house’ assay it was necessary to compare the positive and negative results obtained 
for different combinations of sprayed membrane and gold conjugate. In an attempt to 
facilitate more straightforward comparisons it was decided to employ a ‘P-N value’,
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which was essentially the positive result minus the negative result obtained for a 
particular test combination. This P-N value was used as opposed to a P/N ratio as, for 
this type of assay, a negative result of 0 is not uncommon and therefore could not be 
used to determine a value based on ratios. This P-N value served as an indicator of 
the strength of the colour intensity of the positive result, in comparison with that of 
the negative. Therefore, it is obvious that greater P-N values were more 
advantageous for this assay and consequently, the aim of the testing carried out in 
section 3.3 was to choose the antibody which provided the highest P-N value.
Since the assay parameters were not at an optimum, all of the results for this section 
were recorded at 5 and 10 minutes, instead of 3-5 minutes, as is ordinarily required 
for rapid chromatographic hCG assays. This longer assay time allowed for a longer 
reaction time, thereby increasing the probability of sample being bound to the 
membrane and detected by the various gold conjugates under examination.
Four of the monoclonal antibodies used for conjugation were raised against P-hCG 
(A, C, E and F) while two were raised against the intact hCG molecule (B and D). 
Each of the gold conjugates had been previously evaluated with hCG positive and 
negative solutions to determine a working A52onm at which they should be 
impregnated. Poor P-N values were obtained for conjugates A, B, E and F. No 
positive/negative discrimination was apparent for these conjugates using test line no. 
8 with only marginally better P-N values seen with test line no. 9. It was also 
observed that conjugates C and D presented much higher P-N values than the other 
conjugates with test line no. 8. However, these values were almost half of those seen 
with test line no.9. It should be emphasised at this point that test line antibody no. 8 
was directed against the intact hCG molecule while test line no. 9 was directed 
against the a-hCG subunit. For reasons similar to those described in section 4.1 for 
the selection of the test line antibody it is possible that poor affinity for the analyte 
was responsible for the high false positive results seen for conjugates A, B, E and F 
with both test line antibodies. Why one antibody might have stronger affinity for the 
antigen than another has already been discussed in section 4.1 in relation to the test 
line antibodies. The same principles apply here with the possibility of greater steric 
hindrance problems due to the attached 40nm gold label. This is most likely what is
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being demonstrated with the lower P-N value, which was seen for conjugates C and 
D with test line antibody no. 8, an anti-intact hCG antibody.
Gold conjugates C and D were chosen for further evaluation with test line antibody 
no. 9. It was found that gold conjugate D did not possess the required sensitivity (see 
Figure 3.3.3, Section 3.3, Results). This was most likely due to the steric hindrance 
between the anti-a-hCG test line and the anti-intact hCG gold conjugated antibody, 
which may have been binding to an antigenic determinant on the hCG molecule in 
close proximity to that also used by the test line antibody. From the studies carried 
out in section 3.2 and 3.3, gold conjugate C was optimised with the chosen test line 
antibody no. 9 to give the desired signal response.
4.4 Resolving specificity problems with female hCG-negative urines
Section 3.4.1 of the results section demonstrated 100% specificity when hCG 
negative male urine samples were used. However, only 48% specificity was observed 
with hCG-negative female urine samples. Up to this point male urines had been used 
to manufacture controls since it was difficult to attract female urine donors due to 
emotional fears associated with donating samples for a pregnancy test. Since the 
intended sample for use with this assay was either female urine or serum, this 
specificity problem was of great concern. The gold conjugate/test line antibody 
combinations were re-evaluated using only female urine samples.
What is termed as ‘non-specific’ binding in immunoassays, is in some cases, in 
actual fact, unintended specific reactions. In general, three types of binding reactions 
can be witnessed in immunoassays. These are (a) the intended specific reactions, (b) 
the unintended specific reactions and (c) the unintended non-specific reactions 
(Leunissen, 1999). Reaction (a) consists of the desired reaction, i.e.: the binding of 
the antigen, if  present, to the detector antibodies (in this case the test line antibody 
and the gold conjugate). There may be several possible reasons for the manifestation 
of reaction (b) in immunoassays: the test antibodies may recognise epitopes in 
molecules other than the antigen the test was intended to detect (i.e.: crossreactivity). 
The relationship between an antibody and its antigen is never of an exclusive nature. 
In addition to recognising the antigen against which it was raised, an antibody will
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always bind to a variety of related antigens that share some structural features with 
the antigen used for immunisation (Regenmortel, 1997). Immunological non- 
specificity is due to the presence of the same (shared reactivity) or similar (cross­
reactivity) epitopes on different antigen molecules (Tijssen, 1985). This was a logical 
explanation for what was occurring with the ‘in-house’ assay at this point since the 
reaction could have been due to the presence of hormones such as luteinising 
hormone (LH) in significant quantities in female urine and which has a structure very 
similar to that of hCG (see section 1.2, introduction). Consequently, this molecule 
would be likely to cross-react with the assay test line and/or gold conjugate. Reaction 
(b) can also be caused by the presence in the sample material of circulating IgG to 
various antigens to which the subject has been exposed. Normal adult serum IgG 
levels are in the range 8-16mg/mL (Jackson, 1989). Some of this circulating IgG may 
have been capable of recognising an antigenic determinant on the antigen being 
detected. This was unlikely to be the reason in this instance as urine samples were 
used, which contain little or no IgG in solution (Boehringer Mannheim, 1999). 
Reaction (c) is governed by general physico-chemical properties such as 
hydrophobicity and charge determined forces. The characteristics of the sample, 
solid phase (for this test, nitrocellulose) and the antibodies utilised in the assay have 
considerable influence, causing the labelled antibody to bind non-specifically to the 
solid phase or test line (Leunissen, 1999). Porous materials such as nitrocellulose 
should not be considered inert as the pretreatment of the surface of this membrane 
can largely affect whether or not non-specific binding will be a problem for a 
particular assay (Price et al., 1997). This phenomenon is generally removed by 
‘blocking’ or coating the unreacted sites on the nitrocellulose membrane with one or 
more of: proteins, surfactants and man-made polymers (Jones, 1999(c); Esser, 1997; 
Liddell and Cryer, 1991; Jitsukawa, 1989 and Harlow and Lane, 1988). Some have 
reported that this ‘blocking’ is unnecessary and sometimes harmful (Gosling, 1990; 
Mohammed and Esen, 1989). The nitrocellulose membrane was not ‘blocked’ for 
this assay as blocking generally reduces the flow rate of the sample and reagents on 
the test surface. This would not be satisfactory for a test to be interpreted at 3 
minutes for urine and 5 minutes for serum. It was unlikely that reaction (c) had 
caused the disappointing results seen with female urines because it would be 
expected that a general ‘background’ problem would exist for the assay if this was
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so. Since ‘background’ problems were not an issue with this particular gold 
conjugate it was concluded that the false positives were due to reaction (b).
The problem of reaction (b) can be avoided by the use of antibodies with higher 
affinity for the antigen being detected. This can be achieved by the examination of 
other monoclonal antibodies or by the preparation of antisera with the purest 
available form of the antigen (Leunissen, 1999). Nevertheless, it was known that the 
antibodies selected for the test line and conjugate had demonstrated the highest 
affinity for the hCG antigen in male urine. Additionally, gold conjugates A, B and D 
were re-examined with female urines and as seen for male urines, displayed notably 
lower affinity for hCG than the chosen antibodies. These conjugates also 
demonstrated strong background binding to the nitrocellulose membrane. This 
phenomenon would have undoubtedly created difficulties in the interpretation of low 
positive and negative results. Consequently, it was decided to maintain the selected 
antibodies within the assay format but to attempt to ‘block’ the occurrence of 
reaction (b) as described earlier with the use of various non-specific serums in the 
conjugate in an attempt to eliminate false positives (Harlow and Lane, 1988).
Various serums, goat, human and rabbit serum and FBS and mouse IgG were 
included in the gold conjugate solution (refer to section 3.4.2, results). It was hoped 
that the inclusion of such serums, which ordinarily contain substantial levels of IgG 
molecules, generally about lOmg/mL of total IgG (Harlow and Lane, 1988), would 
ensure that the unknown component contained in female urine which was responsible 
for the non-specific binding would be bound by the free IgG in these serums. This 
unknown component would thus be unable to bind to the test line antibody.
It should be noted that the human serum used was from a non-pregnant patient from 
the Rotunda Hospital, Dublin. This serum sample was included at lower 
concentrations than the goat and rabbit serum due to the possibility of the presence of 
potentially interfering human serum proteins or substances (e.g.: luteinising hormone 
(LH) or follicle stimulating hormone (FSH)). It was also possible that safety issues 
may have arisen with the use of large volumes of human serum in the manufacture of 
the test. Male serum was not used because of the conflicting results observed with 
male and female urines in the assay. The mouse IgG was added at similarly lower 
percentages since the active component being sought (i.e.: IgG) was in its purified 
state and therefore, lower concentrations of this solution were required in comparison
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with that used for the various serums. This is because the reactive molecule (i.e.: 
IgG) in this solution is not masked by other serum constituents, as would possibly 
occur with the serum solutions.
The results for each sample were recorded at 3, 5 and 10 minutes. Since the test was 
at a more advanced stage it was feasible to test at 3 minutes, i.e. the proposed reading 
time for the test with urine samples. It was necessary to read the tests at 5 and 10 
minutes to monitor the results for the negative samples to observe whether or not 
there were false positive problems with the combinations being tested.
20% (v/v) goat and rabbit serum gave good P-N values for female urines as did 5% 
(v/v) mouse IgG. It is possible that the result seen for the 20% (v/v) rabbit serum 
could have been improved even further by the addition of a higher percentage of 
serum. However, since excess serum in the conjugate solution could contribute to the 
destabilisation of the gold conjugate (Leunissen, 1999; Hermanson, 1996) it was not 
feasible to examine such higher percentages of this serum. Due to its reducing effect 
on the positive C.I result and equally due to its cost element (i.e.: purified IgG as 
opposed to untreated serums) the mouse IgG was not selected as the ‘blocker’.
4.5 The first clinical trial and methods to resolve issues arising from 
this trial
Section 3.7 of the results section describes the outcome of the first internal clinical 
trial. In summary, while the ‘in-house’ assay displayed identical sensitivity (98.9%) 
to that observed for the AB1 reference assay, three problems were identified with the 
assay format at this point in the development. These were ® weak control lines 
(observed for 24/116 samples), ® false positive results (‘in-house’ specificity was 
only 70% (ABI-95%)) and ® uneven release of the gold conjugate. This section of 
the discussion deals with attempts to overcome these problems and the reasons why 
such approaches were taken.
4.5.1 Optimisation of the control line
A good control line is a vital part of any rapid assay, since it protects the consumer 
from relying on invalid test results. The ideal control line for a rapid assay is one 
which reacts with equal colour intensity for both negative and strongly positive
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samples. The principle by which the control line works is described in section 1.11.3 
of the Introduction.
There were two possible reasons why the control line yielded low colour intensities. 
Firstly, the release of the rehydrated gold conjugate from the gold conjugate pad, 
upon the addition of the liquid sample for the ‘in-house’ assay was unsatisfactory, 
thereby resulting in control lines and test lines which were less intense than those 
observed for the ABI reference test. This problem is addressed in section 4.5.3. 
Several test results demonstrated faint control lines, but unlike the tests described 
above, these were accompanied by test lines which were more intense in colour than 
those noted for the ABI test with the same samples. In other words, not enough 
excess gold conjugate was available to bind to the goat anti-mouse (GAM) antibody 
on the control line. The high concentration of the antigen was bridging most of the 
available conjugate with the test line antibody, leaving little gold conjugate free to 
bind to the GAM antibody. These particular 24 samples, which displayed faint 
control lines, were most likely strong positives. This would leave smaller amounts of 
unbound gold conjugate available to bind with the control line, which concurs with 
the theory outlined above. It appeared that the test line antibody used in the ‘in- 
house’ assay had a higher affinity for the hCG antigen than that used in the ABI 
assay. Since it was not desirable to employ a test line antibody of lesser affinity, due 
to the effect this might have had on the detection of lower levels of hCG, it was 
decided to supply an excess of gold conjugate by adding a non-specific gold 
conjugate to the gold conjugate solution impregnated on the gold conjugate pad. The 
ideal non-specific gold conjugate was one which would bind only to the control line 
and would have little or no affinity for either the antigen or test line antibody. This 
was successfully achieved by the addition of anti-HepB gold conjugate in the gold 
strip, which was shown not to interfere with the performance of the assay (see 
section 3.8.1).
4.5.2 Examination of problems associated with false positives
With regard to the false positive issue, several approaches were taken. These are 
described in the following pages.
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® The affinity of the ‘in-house’ assay antibodies and antibodies previously evaluated 
were examined by dot blotting to determine if  the correct test antibodies had been 
selected (section 3.8.2). This study confirmed that test line antibody no. 9 had high 
affinity for the hCG antigen. The antibody used for gold conjugate C had 
satisfactory, albeit somewhat lower, affinity than that observed for antibody no. 9. 
Ideally, these antibodies should also have been evaluated against the LH antigen to 
ensure that no cross-reactivity existed; however, the reagents for such an experiment 
were not available at the time. Both the rabbit anti-mouse and goat anti-rabbit-HRP 
conjugates were used at identical concentrations to ensure that there was no variation 
in the method. However, it should be pointed out that it was stated in the relevant 
product catalogue that the rabbit anti-mouse-HRP conjugate required a minimum 
titre of only 1 in 40,000 (ELISA) whereas the goat anti-rabbit-HRP conjugate 
required a minimum titre of 1 in 12,000 (ELISA). Although these figures are with 
reference to ELISA tests, they indicate that the rabbit anti-mouse-HRP conjugate has 
a higher affinity for its antigen than the goat anti-rabbit-HRP conjugate. Therefore, 
the true affinity of the rabbit anti-a-hCG is not fully reflected in the blot seen in 
section 3.8.2, Results. As the test line antibody displayed such high affinity for the 
hCG antigen and was known to be a highly purified polyclonal, it was decided to 
retain these previously chosen antibodies as the test line and gold-conjugated 
antibodies.
® The inclusion of an anti-luteinising hormone (anti-LH) line sprayed 2mm below 
the test line was also examined. LH is a glycoprotein hormone possessing 
considerable structural similarities to hCG. The a-subunits of the glycoprotein 
hormones are essentially identical (Gabbe et al., 1996). The glycoprotein hormones 
also exhibit significant similarity for their P-subunits. Most importantly, the P- 
subunits of hCG and LH display 80% homology in their amino acid sequences 
(Bischof et al., 1997) (see section 1.2.2, Introduction). The potential for LH 
interference in hCG assays has been a subject of much scientific debate. In some 
cases it is reported that many hCG assays have fallen victim to the high immunologic 
cross-reactivity with LH (Bischof et al., 1997). Others suggest that while this may 
have been the case for earlier generations of hCG assays, today’s immunoassays 
have little or no cross reactivity with LH (Cole and Kardana, 1992). However, since 
no evidence was available to confirm or reject either hypothesis, it was decided to
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evaluate the benefits (if any) of spraying an anti-LH line beneath the sprayed test line 
antibody.
By placing an anti-LH line beneath the test line it was intended that this line would 
bind out any LH, which may have been present in considerable quantities in some 
samples and consequently, may have been cross-reacting with the test line antibody 
due to the structural similarities between LH and hCG. Some of the negative samples 
which gave positive readings were from gynaecology patients who may have been 
undergoing fertility treatment with hormones or who may have donated their samples 
at the peak of their LH cycle. It was hoped that the presence of this anti-LH line 
would reduce the positive C.I. seen for the negative samples, which were evaluated 
in the first clinical trial, without affecting the true positive results. Indeed, from 
section 3.8.3 it is apparent that the opposite was reported. In attempting to explain 
these results it is presumed that since the positive results were reduced on the anti- 
hCG line, and quite high on the anti-LH line, that the anti-LH antibody has a certain 
affinity for the hCG antigen, thus removing some of the available hCG antigen for 
binding to the hCG test line. This is quite possible if  the antibody was raised against 
a region of the LH molecule, which may be homologous with certain areas on the 
hCG antigen (see section 1.2.2, introduction). The high C.I. results seen for the anti- 
LH line with the negative sample would indicate that this sample did, as suspected, 
contain a significant amount of LH. The increased C.I. results for the anti-hCG line 
with the same sample is most likely an exaggeration of the false positive seen 
without the anti-LH line due to the proximity of high concentrations of bound LH on 
the anti-LH line, which was positioned just below the anti-hCG line.
4.5.3 Improvement of the release of the gold conjugate from the gold 
conjugate pad
Of fundamental importance to any immunoassay is the availability of the detector 
reagents employed to capture the antigen of choice. In immunochromatographic 
assays, such as the one developed within this thesis, the solid phase detector reagent, 
i.e.: the test line antibody is readily available for binding of the antigen, in this case, 
hCG. The availability of the second detector reagent, i.e.: the gold-conjugated 
antibody is dependent upon the extent to which it is rehydrated within the sample pad 
and subsequently released from the gold conjugate pad and further still on its
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progression, if any, up the nitrocellulose test strip to reach the test line antibody. 
Sufficient sample volume (250fa,L) was added to each test to ensure that all of the 
impregnated strip (gold conjugate pad) beneath the sample pad (see Figure 1.11.2, 
Introduction) was completely rehydrated and available for release from the gold 
conjugate pad. The release from this pad is affected by several parameters. The mesh 
structure and composition of the material used as the gold conjugate pad play a 
significant role in the release of the conjugate, since they can physically hinder the 
progress of the gold conjugate through the pad. Another critical choice concerned 
with the release from the pad is the selection of the buffer in which the gold 
conjugate is dried and impregnated, as this can alter the flow characteristics and 
stability of the resuspended gold conjugate solution (Weiss, 1997a; Wells, 1997).
The most suitable material with regard to release of the gold conjugate and end test 
result (Jones, 1999d; Weiss, 1997a; Wells, 1997) was selected for use as the gold 
conjugate pad in section 3.8.4, Results. This study verified that optimum release was 
obtained with a glass fibre pad. The importance of a good conjugate release material 
cannot be stressed enough. According to Weiss (1997a), the role of the conjugate pad 
is to © hold a consistent volume of the detector reagent, © transfer the sample 
volume consistently onto the membrane, © maintain the stability of the detector 
reagent, © to release the detector reagent consistently and quantitatively, © to 
control the volume of sample to be analysed (i.e.: the volume which migrates before 
or with the detector reagent) and © if blocked, to prevent non-specific binding. For 
this assay a glass fibre material was employed as the gold conjugate release pad. 
Glass fibre is known to be very wettable, moderately low protein binding with a 
moderate to high bed volume (Jones, 1999d). From section 3.8.4 it was confirmed 
that glass fibre was the most suitable release pad, as it absorbed the greatest volume 
with ease and delivered good positive/negative discrimination when used in an assay.
Following this, studies were carried out determining the effect on the release of the 
gold conjugate by various gold conjugate dilution buffers (GCDB), in which the gold 
conjugate was suspended before impregnation. It is obvious that the components 
contained within this buffer could play a significant role in determining the stability, 
release upon hydration and performance of the gold conjugate from the dried glass 
fibre pad (Wells, 1997). Several components were added to this buffer in order to
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rectify the poor gold conjugate release and to decrease the frequency of false positive 
results, as observed in the first clinical trial.
In section 3.8.5 it is described how Triton® X-100, Tween® 20 and PEG ranging 
from 0.2 up to 20K in size were added in various combinations to the GCDB. These 
buffers were examined for flow rates on the strip and end test result, in liquid format 
as opposed to within the dried conjugate strip. The buffers were examined in liquid 
format as the examination of such an array of buffers (16 in total) with various 
samples would have proven far too time consuming and would have significantly 
depleted large quantities of other test components. The reasons why these reagents 
were selected for inclusion in the GCDB are many.
Triton® X-100 and Tween® 20 are both non-ionic surfactants of low molecular 
weight. The term surfactant is generally used when referring to wetters, solubilisers 
and emulsifiers. Surfactants have a bipartite structure consisting of a distinct 
hydrophobic and hydrophilic part (Neugebauer, 1992; Harlow and Lane, 1988). At 
this point it should be noted that gold conjugates have a net negative charge and are 
hydrophobic (Leunissen, 1999) and similarly the nitrocellulose membrane is also 
hydrophobic. In most cases, the membranes are pre-treated with surfactants during or 
post manufacture to make them more wettable (Harvey, 1991), but it is not 
uncommon for these manufacturing treatments to evaporate from the membrane over 
time, thereby exposing the hydrophobic membrane surface once again (Millipore, 
1996). Because of their bipartite structure, as mentioned above, surfactants have the 
ability to disperse hydrophobic molecules in aqueous medium. It was hoped that the 
ability of Triton® X-100 and Tween® 20 to disperse such molecules would aid in the 
even distribution of the gold conjugate upon addition of the sample to the test, 
thereby allowing for a consistent flow of the detector reagent up the membrane strip. 
Additionally, surfactants are almost always employed to reduce attractive 
interactions between like particles and bring them to unlike surfaces (Neugebauer, 
1992; Esser, 1997). Clearly, this effect would aid in the distribution of the gold 
conjugate (hydrophobic) to the nitrocellulose membrane (hydrophilic, when post­
manufacture treated). Since most surfactants possess wetting properties (i.e.: they 
reduce the surface tension of a liquid), the presence o f surfactants in the gold 
conjugate strip would, therefore, improve the re-wetting of the membrane upon
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sample addition. Surfactants can also suppress many hydrophobic interactions, which 
could cause non-specific binding and are capable of breaking up existing 
hydrophobic complexes due to surface forces (Leunissen, 1999; Liddell and Cryer,
1991). All of these above properties have, therefore, significant application in the 
immunochromatographic test system and would assist in the aim of these
(Dexperiments i.e.: to improve the release and flow of the gold conjugate. Triton X- 
100 was selected not only for its properties (described above) but because it is 
reported as being very compatible for applications using enzymes (Neugebauer,
1992), which was perceived as being beneficial to the application for this assay. 
Tween® 20 was also chosen for the reasons previously mentioned and also because it 
is a non-haemolytic surfactant. This latter property was thought to be an advantage 
should the test ever be required to run using whole blood samples, a requirement 
which is becoming ever more popular (Newman and Price, 1997c). Additionally, it 
was known that some surfactants (e.g: Tween® 20) have a significant impact on the 
membrane’s ability to bind proteins (Millipore, 1996).
The PEG molecule consists of repeating units of ethylene oxide, which terminate in 
hydroxl groups on either end of a linear chain. Most of the forms of PEG useful in 
bioconjugate applications have molecular weights less than 20000 (Hermanson, 
1996). PEG coupled to other molecules has been used to increase the stability of 
proteins in solution and to prevent protein adsorption to surfaces. The properties of 
PEG in solution are especially unusual, frequently displaying amphiphilic tendencies 
and having the ability to solubilise on hydrophobic membranes. Whether in solution 
or attached to other insoluble surfaces, PEG has a tendency to exclude other 
polymers and forms a protein-rejecting region that is effective in preventing non­
specific protein binding (Hermanson, 1996). It is for these solubilising properties and 
its capabilities to reduce non-specific binding that PEG was chosen for addition in 
the GCDB.
The study carried out (section 3.8.5) confirmed the hypothesis that the addition of 
Tween® 20 and Triton® X-100 would be beneficial for the assay. The test results 
with the lowest non-specific binding of the gold conjugate to the membrane were 
buffers nos. 15 and 16, which contained Tween® 20 (no. 15) and Triton® X-100 (no. 
16). Both of these buffers also contained PEG 15-20K. These buffers provided an
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even flow and distribution of the gold conjugate on the strip and the highest intensity 
control lines. It was also observed from the results of this study that the larger PEG 
polymer (i.e.: 15-20K) was required to add viscosity to the sample/gold solution and 
to provide an even and consistent flow of gold conjugate (Bangs and Meza, 1995). 
The addition of PEG (15-20K) in combination with either of the detergents (Tween® 
20 or Triton® X-100) gave rise to the most satisfactory test and control line C.I. 
results. Those tests run using buffers with smaller sized PEG molecules displayed 
faster flow and an uneven release of the gold conjugate from the gold conjugate pad.
Due to the success of this study it was decided to examine these and other reagents at 
various concentrations (see section 3.8.5i). The reagents examined were Triton X- 
100, Tween® 20, PEG (15-20K), PVP K-30, BSA and sucrose. The concentrations 
selected for evaluation were based on experimental results obtained when using these 
components in other Trinity Biotech rapid assays.
PVP K-30 was selected due to its known functions as a film former, a protective 
colloid and suspending agent and binder and stabiliser (ISP, 1994). It was anticipated 
that these properties would have the benefit of keeping the gold conjugate stable 
under the harsh conditions of the drying procedure carried out after impregnation. It 
has already been reported that attachment of such polymers to labelled proteins can 
provide cryoprotection for proteins, which are sensitive to freezing (Hermanson, 
1996). The viscosity that this polymer would lend to the reconstituted dried gold 
conjugate would ensure that the solution would travel up the membrane in an even 
manner (Williams, 1997).
BSA was included in the study as it was already used in the gold conjugation method 
as a blocking agent. Therefore, its addition to the GCDB was justified in that it 
would be expected to mask any remaining sites of gold-gold or protein-gold 
interactions, thus preventing aggregation of the gold conjugate or non-specific 
binding during the assay (Hermanson, 1996).
Sucrose was added to the GCDB since it has been suggested that protecting the 
antibody-coated gold from aggregation by ‘treating’ the gold conjugate and/or the 
membrane where they would be dried with a hydrophilic substance, such as sucrose,
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would allow the dried conjugate to readily rehydrate upon addition of the sample 
(Bangs and Meza, 1995). Sucrose also confers some viscosity on the rehydrating 
solution enabling the solution to travel evenly towards the top of the test strip.
Each buffer at each concentration was examined for sensitivity and specificity, the 
flow speed and appearance and the buffer front. The buffer front is the distance 
between the flow ‘front’ of the sample and the gold conjugate solution as they 
progress up the test strip. Large sample/gold conjugate fronts are to be avoided. This 
is where the sample washes ahead of the gold conjugate while flowing up the 
membrane and can result in the test line antibody being washed off the membrane. 
The concentrations of Triton® X-100 and Tween® 20 chosen for the final buffer were 
intermediate levels (see Table 3.8.8). These were selected as they balanced the 
positive effects (such as keeping the gold conjugate monodispersed) resulting from 
their addition with their possible negative effects, such as the removal of the 
membrane bound antibody (Harvey, 1991; Millipore, 1996; Wells, 1997). The 
sucrose and BSA levels chosen corresponded to concentrations which were already 
being used in Trinity Biotech for other similar assays. The selected concentration for 
sucrose was also within the range, 5-15% (w/v) as recommended by Wells (1997). 
The concentrations of PEG (15-20K) and PVP K-30 chosen were the lowest 
concentrations examined. This was based on advice from Millipore, a nitrocellulose 
manufacturer and ISP, a PVP manufacturer, that as little of these polymers should be 
used as possible with an absolute maximum of 0.5% (w/v) recommended (Millipore, 
1996; ISP, 1994). This is because both PVP K-30 and PEG interfere with the 
electrostatic binding of proteins to the nitrocellulose membrane. While this is an 
advantage at lower concentrations for removing non-specifically bound proteins, it 
can be detrimental to the sprayed test line antibody at higher concentrations.
This new GCDB was validated in section 3.8.5ii by directly comparing gold 
conjugate strips dried in the GCDB substituted with these chemicals with those in the 
original GCDB, keeping all other test components constant. Higher C.I. results were 
observed with the new GCDB for both the positive test results and the control line. 
This confirmed that better gold conjugate release was obtained. Significantly, 
improved specificity was observed with negative urines from the first clinical trial, 
which had previously caused false positive results with the original GCDB. Also,
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100% specificity was noted when 30 negative urines and 30 negative serums were 
evaluated. This confirmed that some of the added chemicals functioned as blocking 
agents.
4.6 Evaluation of test line thickness and position
Despite the improved specificity achieved by the optimisation processes described in 
section 4.5, one out of the three negative urines from the Rotunda Hospital gave a 
low positive result. This indicated that the issue of specificity was not fully resolved. 
Another method for improving the specificity of the assay was to determine the 
effect of moving the spraying position of the test line antibody and the thickness of 
the line sprayed. The principle behind this idea was that the closer the test line is to 
the gold conjugate pad the longer the period of exposure to the gold 
conjugate/sample solution. For example, a test line at the top of the membrane would 
be in contact with the gold conjugate/sample solution, which is running up the test 
strip, for a much smaller percentage of the assay time than a line, which is sprayed at 
the bottom of the membrane. In other words the reaction time for the antigen/gold 
conjugate to bind to the test line is longer for strips closer to the bottom of the 
membrane. A test line position of 12mm from the bottom edge of the membrane was 
shown to be the most suitable, which verifies this theory. Less non-specific binding 
was also observed at this position due to the shorter reaction time. The test line 
thickness was set at 1mm as this provided the most acceptable sensitivity and 
specificity. Specificity problems were noted for thicker test lines as a result of the 
higher amounts of antibody present, which increases the chances of non-specific 
binding occurring.
4.7 Methods to decrease the assay time for serum samples
An aim of this project was to develop a test suitable for use with either urine or 
serum samples. It was necessary to reduce the flow time of the in-house assay so that 
it would conform to assay times used by competitor kits on the market (see Table 
1.10.1, Introduction). For example, the ABI reference kit allowed urine samples to be 
read at 3 minutes and serum samples to be read at five minutes. Due to the different 
nature of the samples themselves (i.e.: serum being significantly more viscous than
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urine) a compromise with regard to assay flow had to be achieved in order that the 
above assay times be met for both samples on the one test.
This was achieved on three fronts: © by changing the nitrocellulose to a faster 
flowing membrane, © by selecting a sample pad which allowed a faster throughput 
of sample and ® by increasing the sample volume.
As can be seen in section 3.11.1, three membranes were examined. Each had to be 
individually optimised because as the pore size of the membrane changes, so too 
does its protein binding capacity. Increasing the porosity in a membrane decreases 
the available surface area for protein binding (Harvey, 1991); therefore, this must be 
compensated by adding more test line antibody to achieve similar results to the 
smaller pore size membrane. In addition, a faster flowing membrane would require 
more antibody to achieve the same result in its shorter assay time than a more slow 
flowing membrane with a longer reaction time. These principles are laid out in more 
detail in section 1.11.4.1, Introduction. From the testing carried out it was decided to 
change from a membrane with 5p.m pore size to one with an 8)j.m pore size.
The replacement of the original membrane with a faster flowing membrane reduced 
the assay time. However, the new assay time was still not fast enough. Five sample 
pads were evaluated together with two sample volumes, initially on the basis of flow 
time. The sample pad plays an important role in the flow dynamics of the rapid 
chromatographic test. Its function is to control the flow of the gold conjugate and 
sample onto the strip, to remove particulate matter from the sample and in some 
cases it can be used to adjust the pH or viscosity of the sample before reaching the 
membrane (Weiss, 1997b). A sample pad which allowed for faster release of the 
sample and test reagents onto the nitrocellulose, accompanied by the use of a larger 
sample volume, was shown to provide the desired assay times for both urine and 
serum without affecting the end test result. It was important that the sample volume 
was not increased beyond the absorption capacity of the sample pad material, as this 
would have resulted in leaching of the sample off the sample pad and directly onto 
the membrane without having passed through the gold conjugate pad. Additionally, a 
very short flow time which would have reduced the signal for the positive results and 
control lines, would have resulted.
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4.8 The selection of a suitable detergent for the wick
The wick or ‘stick’ assay was essentially identical to the cassette assay with the 
exception of the wick and the plastic housing. The same test strip was contained in 
both versions of the test. Since the housing was inert and played no significant role in 
the use of the assay, the only important element of the wick test, which required 
examination was the wick itself. Its function was purely to deliver the sample as 
quickly as possible to the test strip so that the assay time could be identical for both 
test formats. The benefits of surfactants and their wetting and solubilising properties 
are described in detail in section 4.5.3. Due to these beneficial properties it was 
decided to impregnate the wick (see section 3.12) with various detergents to 
determine which would deliver the sample quickly and evenly, without affecting the 
test results. From the studies carried out in section 3.12, 2% (w/v) of Triton X-100 
fulfilled the above criteria and this concentration was incorporated into the wick 
before assembly with the test strip.
4.9 Validation trials on the final ‘in-house’ assay format
4.9.1 Evaluation of HAMA and HA positive samples with the ‘in-
house’ cassette and wick assay formats
The importance of assessing a hCG ‘sandwich’ assay for interference by human anti­
mouse antibodies (HAMA) or heterophilic antibodies (HAs) was clearly 
demonstrated recently (Cole et al., 1999a). This case, involving HAMA and/or HA 
interference in a hCG assay is currently the subject of a lawsuit in the USA involving 
several women who were allegedly misdiagnosed based on their hCG test results. 
Based on persistent elevated hCG results for several months using the Abbott 
AxSym and Abbot IMX hCG assays, four patients received multiple courses of 
chemotherapy, two patients underwent hysterectomies and one other underwent an 
oophorectomy. It was discovered at a later date that all six cases contained no intact 
hCG, subunits or metabolites. Such persistently positive results on hCG assays, 
which are later shown to be incorrect are termed ‘phantom’ hCG results. The 
‘phantom’ hCG results were most likely due to either HAMA or HAs as previously 
demonstrated by Cole (1998).
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The effects of HAMA and HAs in patient plasma and serum is well documented 
(Cole et al., 1999a; Fitzmaurice et al., 1998; Boerman el al., 1990; Nahm and 
Hoffman, 1990; Boscato and Stuart, 1988). These antibodies generally arise from 
treatment given to patients involving mouse monoclonal antibodies (e.g.: 
radioimaging of tumours). Significantly, it should be pointed out that such antibodies 
can also arise as a result of incidental or occupational exposure to foreign proteins, as 
in the case of veterinarians, farm workers and food preparers or by the presence of 
domestic animals in the home environment (Fitzmaurice et al., 1998). It has been 
estimated that the prevalence of FIAMA and HAs in the general population is as high 
as 40% (Boscato and Stuart, 1988 and Nahm and Hoffman, 1990). These HAMA and 
HAs are typically IgG antibodies which recognise epitopes on the Fc portion of the 
foreign immunoglobulin; some, however, have also been known to bind to the Fab 
portion (Fitzmaurice et al., 1998). The presence of high titers of such antibodies in 
some samples leads to false positive results in ‘sandwich’ assays by cross-linking the 
capture and label antibodies in the absence of the specific antigen (see Figure 4.1
(a)). These antibodies can also falsely decrease assay results by affecting analyte 
recognition by the capture and label antibodies. This is possibly due to steric 
hindrance as a result of the HAMA and HAs binding to the capture and/or label 
antibodies which may form complexes of various sizes (Boscato and Stuart, 1988) 
(see Figure 4.1 (b)).
No interference was observed for the ‘in-house’ assay with any of the HAMA or 
HA-positive samples run on the assay (see section 3.14). Despite these promising 
results there should be no complacency with regard to HAMA and HA interference. 
The majority of commercially available kits, including those described as being 
susceptible to HAMA and HA interference, already contain some type of non­
specific ‘blocker’ immunoglobulins, such as mouse IgG, MAK-33 (polymerised 
murine IgGi, Boehringer Mannheim), HBR (monoclonal anti-human HA, 
Scantibodies) and IIR (formulation of anti-HAM A Ig’s, Bioreclamations). It should 
be emphasised that failure to observe interference for these HAMA and HA samples 
does not guarantee against such interference occurring when the test is on the market. 
Many different forms of such antibodies exist and some have also been known not to 
be species-specific; therefore, cross-linking between antibodies of different species
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can occur (Fitzmaurice et al., 1998). It is probably to the advantage of the ‘in-house’ 
assay that
(a) Fa lse  Positive Result (b) Fa lse  Negative Result
Key: Capture Antibody Label Antibody
® Label — ^  HAMA and/or HA
O Antigen
Figure 4.1: The possible effects of human anti-mouse antibodies (HAMA) and heterophilic 
antibodies (HAs) on 'sandwich ’ assays, (a) False positive result due to the cross-linking 
of the capture and label antibodies, (b) False negative result due to the complexing 
of the labelled antibody and/or steric hindrance effects.
such a high percentage of goat serum, 20% (v/v), is contained in the GCDB. Such a 
solution would subsequently consist of substantial quantities of Ig, which may non- 
specifically absorb HAMA and HA which may be present in the test samples.
4.9.2 Examination of potentially interfering substances on the cassette 
and wick ‘in-house’ assays
Female hCG-negative (0 IU/L) and hCG-positive (25 IU/L and 50 IU/L) urine and 
serum samples were supplemented with each of the substances outlined in Table 4.4. 
All test samples were then examined on both the ‘in-house’ and ABI cassette and 
wick assays. The substances added were either physiological components of urine 
and/or serum or potentially interfering drugs, which could possibly be present in 
significant quantities in the urine and/or serum of women who might use this test. It 
was, therefore, necessary to demonstrate that these potentially interfering substances 
did not adversely affect the sensitivity and specificity of either the cassette or wick 
assays being developed in this thesis. These substances may have interfered in the
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assay results through unintended non-specific reactions, which are described in 
section 4.4, Discussion. Table 4.4 lists the substances added with a brief description 
in order to clarify why each particular substance was added. No interference was 
observed for any of the substances added on either the cassette or wick assay.
Substance Description*
Haemoglobin Oxygen bearing protein found in red blood cells.
Albumin Any of several water soluble proteins that am found in blood serum and 
various animal tissues.
Bilirubin A compound derived from haemoglobin during normal and pathological 
destruction of red blood cells.
H  Estriot Found in the ovaries and in the urine o f pregnant mammals.
Glucose A mixture of dextrose, maltose and dextrins. Fasting plasma glucose levels 
are between 80-100mg/dL of serum.
Acetytsalicylic Acid Also known as Aspirin, used in tablet form as an antipyretic and analgesic.
Caffeine Found in tea, coffee and kola nuts and used as a stimulant and diuretic.
Ascorbic Acid A vitamin found in citrus fruits, tomatoes, potatoes and leafy green 
vegetables.
Phenothiazine Used in insecticides, livestock anthelminitics (a compound to destroy 
intestinal worms), and dyes.
Acetoaminophen Used in medicine to reduce pain and fever.
Gentisic Acid Used to season tobacco and in perfumes, dentrifices, and germicides.
Table 4.4: List of potentially interfering substances and their description. 
(* Descriptions obtained from Sigma-Aldrich Co., 1999).
It should be noted that other possible interférants exist which are sometimes 
implicated as interfering agents in urinary assays (e.g.: creatinine, urate, urea). These 
potential interférants were not evaluated on the in-house assay within the scope of 
this thesis as these interférants were not known to interfere in hCG assays. Only 
those interférants which were known from literature and other competitor hCG test 
kit inserts to interfere in hCG assays, were investigated here.
4.9.3 Cross reactivity study examining the effect of adding the 
glycoprotein hormones LH, FSH and TSH to the ‘in-house’ 
cassette and wick assays.
As for the interference study, the substances being examined were added to 0 IU/L, 
25 IU/L and 50 IU/L hCG female urine and serum samples and run on both the 
cassette and wick assays to determine if  they would cross-react with the test line 
antibody. Such a reaction would be classed as an unintended specific reaction, which 
is outlined in section 4.4, Discussion. The substances tested were three hormones, 
which possess considerable homology with the hCG antigen (see section 1.2.2, 
Introduction), which could potentially bind non-specifically to the test line. These
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hormones were: ® Follicle Stimulating Hormone (FSH) at 1000 mlU/mL, © Thyroid 
Stimulating Hormone (TSH) at 1000 fiIU/mL and ® Lutenising Hormone (LH) at 
500 mlU/mL. The hormones were added to the samples at these concentrations since 
these were their normal physiological levels. No cross reactivity was observed for 
any of the urine or serum samples spiked with these hormones on either the cassette 
or wick assay.
4.9.4 Study to determine when the prozone effect occurred in the 
assay
The prozone or hook effect can best be described as a false negative result occurring 
due to an excess amount of antigen (in this case, hCG) binding to all of the available 
detector antibodies (for this assay, the anti-hCG gold conjugate), thereby leaving no 
available antigen to bind to the solid phase antibody (here, the test line antibody) 
(Shine, 1998). Since the hCG levels in the urine of pregnant women in their first 
trimester can peak to 100,000 IU/L (see section 1.7, Introduction) it is apparent why 
the determination at what hCG level this effect may be seen is so important for a 
pregnancy test.
An experiment is described in section 3.14.4 to determine this point. A female hCG- 
negative urine was spiked with a hCG solution to give samples ranging from 100- 
1,000,000 IU/L hCG. It was observed that levels greater than 250,000 IU/L caused a 
false negative result. This was a satisfactory result and was on a par with competitor 
devices. One of the market leaders, the Clearview test by Unipath was reported as 
possessing ‘an impressive detection limit and analytical range’ (Price et ah, 1997) 
when it successfully detected hCG levels ranging from 19-47,800 IU/L in 130 
samples (Price et ah, 1997). From this study, it is apparent that an analytical range 
which exceeded that reported for the Clearview test was well within the capabilities 
of the assay developed in this thesis.
4.9.5 Results from clinical trials on the final assay formats
Section 3.14.5 of the Results section describes both internal and external clinical 
trials, which were undertaken to determine the performance characteristics of both 
the ‘in-house’ cassette and wick assays using both urine and serum samples. Table
4.5 overleaf lists the % sensitivity and specificity obtained for both the ‘in-house’
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cassette and wick assays in comparison with the ABI cassette and wick devices, 
which were used as the reference tests.
Excellent sensitivity and specificity were obtained with both formats of the ‘in- 
house’ assay when compared with results from the ABI reference tests. These % 
sensitivity and specificity values were comparable with most of the rapid pregnancy 
tests on the market (e.g.: from ABI cassette pack insert: 100% sensitivity and 
specificity with urine and serum; from Wyntech Diagnostics OSOM test pack insert: 
> 99% concordance with another commercial assay and from BioTipp pregnancy test 
pack insert: 99% accurate results). Therefore, these clinical trial data in combination 
with the results obtained from the cross reactivity study inferred that excellent 
sensitivity and specificity was a feature of both of these ‘in-house’ assays. It would 
be prudent to bear in mind that these % sensitivity and specificity values are 
calculated for the sample population tested only.
Test Sample Sensitivity Specificity
'In-house'
Caasette
Urine 100% 100%
‘In-houeo1
Cassette
Serum 98.5% 100%
‘In-house1
Wick
Urine 99.4% 100%
‘In-house’
Wick
Serum 100% 98%
Table 4.5: % sensitivity and specificity for the ‘in-house’ assay following internal & 
external clinical trials using hCG-positive & negative urine & serum samples.
Impressive feedback was also obtained with regard to the overall appearance, 
operation and presentation of the assays (see Figure 3.14.5, Results). 50 volunteers 
from Dublin City University (DCU) were asked to assay negative and positive urine 
samples and controls on the ‘in-house’ wick test. This study was carried out with the 
intention of establishing a customer perception of the product and to anticipate any 
potential difficulties that the customer may encounter in performing and interpreting 
the assay results. It was preferable to discover such problems at this stage in the test 
development than during the transfer of the test to full production, where it would 
prove more difficult and costly to rectify. No problems were noted by the volunteers 
with regard to the test methodology and the interpretation of test results. 34% of 
volunteers commented that the test was easy to interpret and 30% praised the ‘fast 
assay time’. Encouragingly, 70% of test volunteers described the test as ‘user-
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assay time’. Encouragingly, 70% of test volunteers described the test as ‘user- 
friendly’. Based on the results of the clinical trials, the interference and cross 
reactivity studies and the customer perception study it was concluded that the 
development of the cassette and wick ‘in-house’ assays was a success.
4.9.6 Stability of the final test format
Section 3.15 concerns itself with the determination of the stability of the final format 
of the ‘in-house’ assay by accelerated means. The importance of generating stability 
data on a completed assay cannot be stressed enough. Such data is required by the 
developers of an immunoassay in order to assign a realistic shelf-life to the product 
and also to identify any limitations that the assay might possess.
While ‘real-time’ stability studies are obviously the ‘gold standard’ in determining 
the shelf life of a product, this is often not feasible, particularly if the product is new 
and no idea exists of how the test might vary over long periods of time. Stability is 
the inverse of degradation and the dominant variable affecting the degradation rate is 
temperature. Anderson and Scott, 1991 and Zakowski, 1991 state that the shelf-life 
of a product can be defined as the time that essential performance characteristics are 
maintained under specific handling conditions. Accelerated stability testing 
(stressing) is often carried out during the development of clinical reagents to provide 
an indication of product shelf life and, thereby shorten the development schedule. 
For this purpose the product is placed at high (warmer than ambient) temperatures 
and the amount of heat input required to cause product failure is determined 
(Anderson and Scott, 1991). This information can then be applied to predict product 
shelf life. Generally the stressed material is compared to unstressed material from the 
same batch. The sample recovery for the stressed product is then expressed as a 
percentage of the unstressed material. This utilisation of the product itself as a 
control is extremely valuable when no suitable reference material is available.
From the results shown in section 3.15 it can be seen that the final format of the ‘in- 
house’ assay is stable with regard to sensitivity and specificity for an accelerated 
time of 18 months. Specificity problems were encountered at 24 months accelerated 
time. Based on these results the assays could be sold with a shelf life of up to 18 
months. According to Porterfield and Capone (1984), the release of a product based
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on accelerated stability studies can be reasonable but the importance of regular 
monitoring of multiple lots at real time/temperature conditions should be 
acknowledged.
4.10 Future Developments
4.10.1 The continuing importance of hCG and the standardisation
of hCG assays
Traditionally, hCG has been qualitatively detected for the diagnosis of pregnancy by 
the use of various forms of rapid immunoassays. Quantitative hCG assays have long 
been used to monitor the progress of pregnancy; to screen for ectopic pregnancy, 
hydatidiform mole and Down’s Syndrome and to follow the course of trophphoblast 
disease, testicular cancer and certain nontrophoblastic maligancies (Cole and 
Kardana, 1992). The capability now exists to adapt the rapid hCG immunoassay for 
the detection of those conditions previously only detected by the quantitative assays. 
This could be achieved by the use of more sensitive rapid assays using the relevant 
antibody combinations for the detection of the isoform of hCG common for the 
condition in question (see below). The use of semi-quantitative rapid assays and what 
are termed as multi-analyte tests (Price et al., 1997) may also prove useful.
The relationship between hCG and trisomy 21 (Down Syndrome) has been well 
documented (Cole, 1999b; Cole et al., 1999c). The median serum hCG and free 13- 
subunit level in a Down Syndrome pregnancy is twice the level in a normal 
pregnancy. This, however, would not enable a test to distinguish between normal and 
Down Syndrome pregnancies due to the wide variation in hCG levels in normal 
pregnancy (see Figure 1.7.1, Introduction). In general, what is employed to 
determine such genetically abnormal pregnancies is a combination of elevated hCG 
and free P-hCG levels with other biochemical agents such as alpha-fetoprotein, 
unconjugated estriol and inhibin (Haddow et al., 1998). Theoretically, it would be 
possible to manufacture a test which detected all of these markers. As the levels of 
these markers in the patient’s serum are important, the test capture and tracer 
reagents could be formulated in such a way that they would only detect levels equal 
to or above a pre-determined cut-off value. A new marker has also been determined 
for Down syndrome. This is an isoform of hCG called hyperglycosylated hCG, the
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levels of which are elevated 9-fold in Down Syndrome pregnancies when compared 
to normal pregnancies (Cole, 1999b; Cole et al., 1999c). This may prove to be a 
more accurate indicator of genetic abnormality in the second trimester of pregnancy
(Col eetal., 1999c).
The detection of ectopic pregnancies is quite difficult and can be of extreme 
importance in the hospital emergency room situation. The levels of hCG in such 
cases are generally one fifth to one fiftieth of normal pregnancy hCG levels (Cole, 
1999b). As described above, it would be difficult to diagnose ectopic pregnancies 
based on lower than average hCG levels due to the range of levels that exists in 
normal pregnancy. Progesterone is another biochemical marker for ectopic 
pregnancy. Progesterone has been shown to have a cut off value of 5ng/mL at 4 
weeks gestation, at 5 weeks lOng/mL and at 6 weeks 20ng/mL (Stern et al., 1993) 
while most viable pregnancies have a serum concentration of >25ng/mL (Stovall et 
al., 1992). Clearly a test which semi-quantitatively detected a combination of these 
two markers, could give an indication of ectopic pregnancy in emergency situations. 
Such a test has already been welcomed once its result is followed up with further 
clinical examination (Grudzinskas and Stabile, 1993). A rapid test has been evaluated 
with complicated pregnancies with some success (Ikomi et a l, 1998).
Persistent trophoblast disease and choriocarcinoma both display higher than average 
levels of free p-hCG and nicked hCG (2-10% of intact hCG level in trophoblast 
disease and 5-40% of intact hCG level in choricarcinoma) (Cole, 1999b). By 
changing the antibody pair combination used for the detection of hCG one could 
develop a test specific for the nicked hCG and free P-hCG found for these 
conditions.
It should noted, however, that considerable variation exists between commercial 
assays due to poor selection of the antibody pair. Over eight different antibody 
binding sites have been identified on different parts of the hCG molecule. Each 
commercial test uses a different combination of capture and tracer antibodies, which 
recognise any two of the eight different binding sites (Cole, 1999b). Each assay 
measures intact hCG and one of seven other hCG-related molecules (Cole, 1997). 
This is a source of much interassay variation. While more than two-fold variation can 
be noted for pregnancy samples between different manufacturers’ assays, even
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greater discordance is observed for results from samples from irregular gestations, 
cancers and trophoblast disease (Cole, 1997). One problem with hCG assays is the 
heterogeneity of hCG, its different isoforms and degradation products. This problem 
is also compounded by the wide variation in hCG concentrations observed in serum 
and urine samples throughout pregnancy.
The variation seen in rapid pregnancy tests, similar to the tests developed within this 
thesis, is not significant enough to affect the qualitative detection of normal 
pregnancy urine or serum levels of hCG. However, considerable variation might be 
observed should such tests be adapted for the diagnosis of cancers or irregular 
gestations.
4.10.2 New applications for hCG
Evidence has been produced that hCG may protect the developing foetus from HIV 
(Notkins, 1999). This phenomenon may be explained by the fact that researchers 
have isolated three proteins in the urine of pregnant women. The proteins were 
distinct from hCG but tended to adhere to the pregnancy hormone (Bayer, 1999). 
Could this be the future for hCG, as a new method of AIDS treatment with few side 
effects due to the abundance of hCG, naturally occurring in the urine of pregnant 
women. (Bayer, 1999).
Also in relation to HIV, a pregnancy test which combines the detection of the HIV 
virus may be of use in third world countries. Rapid tests are currently available for 
the detection of the HIV virus. With increasing numbers of the population in African 
countries presenting with HIV infection, it would be useful to screen women who 
present with positive pregnancy test results for HIV so that treatment can begin 
immediately.
Another use for rapid hCG assays is in the area of drugs testing in athletes. A ban has 
been imposed on hCG administration by the International Olympic Committee. 
Athletes use hCG because it stimulates testicular steroidogenesis, especially 
testosterone. It is also abused by body builders in order to counteract the feedback 
effects related to the abuse of anabolic steroids (Delbeke et al., 1998). The 
concentration at which a sportsperson might be considered positive has been set at 5 
IU/L (Delbeke, 1998). The test developed within this thesis could be redeveloped to
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allow for more sensitive detection of the hCG molecule (i.e.: a minimum of 5 IU/L) 
for the purposes of a test which could be used for hCG misuse in sport.
4.10.3 The introduction of automated hCG test devices and readers
The use of tests such as the cassette and wick tests developed in this thesis, while 
popular in the home and at various non-laboratory healthcare situations (e.g.: GP’s 
office, health clinic, emergency departments etc.), do not lend themselves to the large 
scale screening required in the clinical laboratory setting. In order to make these tests 
more ‘user-friendly’ for the clinical laboratory technician an automated system for 
the reading and interpretation of such devices is necessary. Test strips and automated 
readers already exist for the rapid urine testing market, for example the Boehringer 
Mannheim Supertron® Fully Automated Urine Analyser, which can throughput a 
maximum of 300 samples per hour (Boehringer Mannheim, 1999).
Such a system exists, albeit in its infancy stage. This system, manufactured by a 
company called Cozart, is currently used for a drugs of abuse test only and is known 
as the COZART Rapiscan Saliva DoA (Cozart, 1999). The system consists of a 
disposable test cartridge which is inserted into the Rapiscan instrument for reading 
once the test is completed. The Rapiscan instrument is similar in size and weight to a 
mobile phone and is capable of being linked to a computer for data analysis. The 
possibility exists of adapting such a reader to read several devices at once and to 
store and analyse this information for hospital records, thereby allowing an avenue 
for these POC tests to be introduced into the clinical laboratory. The screening of 
large amounts of samples quantitatively for hCG may become a reality in the future 
as a marker for conditions such as Down’s Syndrome, ectopic pregnancies and 
choriocarcinoma.
In conclusion, what was initially offered as a rapid pregnancy test could be evolved 
into a sophisticated diagnostic tool aiding clinicians in the differential diagnosis of a 
broad spectrum of diseases. The rapid hCG test need not be limited to pregnancy 
testing. As described earlier, with improvements in sensitivity or changes in the 
choice of antibody pairs used to detect hCG isoforms relevant to particular 
conditions or diseases, the format used for hCG detection by the assays developed 
here can be manipulated to provide a wide range of clinically useful immunoassays.
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Section 5: 
Conclusion
5.0 Conclusion
The detection of the dimeric glycoprotein hormone, hCG, has long been used for the 
diagnosis of pregnancy in female urine and/or serum (Gabbe et al, 1996). Qualitative 
measurements of urine/serum hCG are used to diagnose pregnancy, while 
quantitative measurements are used for monitoring various conditions and 
malignancies, all of which express either hCG or one of its metabolites (Cole and 
Kardana, 1992). The aim of the work described in this thesis was to develop a 
qualitative cassette and wick test for the detection of hCG in urine and serum. Both 
tests developed in this study detect either nicked or non-nicked intact hCG. This 
detection method is preferable for a pregnancy test, as these forms of hCG are 
present in varying quantities (see section 1.7, Introduction) during the course of 
pregnancy, peaking in the first trimester. In general, the nicked hCG component 
makes up one quarter of the total hCG content in any given sample from a patient 
presenting with a normal pregnancy. The intact hCG constitutes the remaining three 
quarters of the total hCG content (Cole et al., 1991).
Both assays developed were based on lateral flow immunochromatography, using the 
‘sandwich’ format, which was made up of a polyclonal anti-a-hCG antibody and a 
gold conjugated monoclonal anti-P-hCG antibody. This assay technology lends itself 
to the requirements of the test being designed in this thesis. Specified parameters for 
such a test are laid out in section 1.11, Introduction and section 4.1, Discussion. 
Success was achieved in the development of the rapid cassette and wick assays as all 
of these parameters were fulfilled. Conveniently, both assays utilise either urine or 
serum as the sample medium. The test possesses a sensitivity of 25 IU/L with results 
available in 3 minutes for urine and 5 minutes for serum. This compares favourably 
with other commercially available tests for hCG detection (see Table 1.10.1, 
Introduction). Untrained individuals can easily perform the assay and no refrigeration 
of the product is required for storage. The cost of the test has been maintained at a 
minimum (approximately $1.50 for either a cassette or wick device) and there are no 
safety risks involved in running the assay, as the sample is absorbed within the 
sample pad and thus, contained within the test device.
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Following optimisation of both assays, external and internal clinical trials were 
performed. 100% sensitivity and specificity were achieved for the cassette assay with 
urine samples and 98.5% sensitivity and 100% specificity were noted for serum 
samples on the same test format. The wick assay generated a sensitivity of 99.4% 
(urine) and 100% (serum) and a specificity of 100% (urine) and 98% (serum). None 
of the potentially interfering or cross reacting substances tested on both formats 
showed a negative effect on either assay using either urine or serum. The tests 
developed are equal to those on the market in relation to sensitivity and specificity.
These excellent performance characteristics and the knowledge that the test is 
estimated, from accelerated stability studies, to remain stable for approximately 18 
months will ensure that these assays will compete well with the other tests on the 
market. It should be emphasised that a positive result on these assays indicates the 
presence of hCG in the urine/serum rather than the impending arrival of a baby. It 
would be prudent to follow all positive results with further clinical examination as 
there are other physiological conditions, some serious, which can show elevated 
levels of hCG (e.g: choriocarcinoma) (Cole, 1999b). It is a measure of the success of 
the assays that predicted sales for the first six months of the year 2000 are -$60,000 
for the cassette assay while -$100,000 worth of sales are forecast for the wick assay 
(Shine, 1999).
198
Section 6: 
Bibliography
6.0 BIBLIOGRAPHY
Albertson, B.D. and Swanson, J.R., 1996. Assay techniques available for the 
toxicologist. In: John A. Travers, ed. Endocrine Methods. London: Academic 
Press, 13-79.
Anderson, G. and Scott, M., 1991. Determination of product shelf life and activation 
energy for five drugs of abuse. Clin. Chem., 37 (3), 398-402.
Aschheim, S. and Zondek, B., 1927. Hypophysenvorderlappen - hormon und 
ovalrialhormon, Ham von Schwängern. Klin. Wochenschr., 6,1322-1325.
Aschheim, S. and Zondek, B., 1928. Pregnancy diagnosis with urine by the 
demonstration of the hormone. Klin. Wochenschr., 7, 8-11.
Aslan, M. and Dent, A. 1998. The characterisation of protein conjugates. In: M. Aslan 
and A. Dent, eds. Protein coupling techniques for the biomedical sciences. 
London: Macmillan Reference Ltd., 703-704.
Bangs, L.B. and Meza, M.B., 1995. Microspheres, part 2: ligand attachment and test 
formulation. IVD Technology (Canon Company Inc.), Mar/Apr, 6-11.
Bassion, S., 1989. Immunological reactions. In: L.A. Kaplan and A.J. Pesce, eds. 
Clinical chemistry, theory, analysis and correlation (2nd ed.). Philadelphia: The
C.V. Mosby Company, 153-164.
Bayer Corporation, 1999. Anti-HIV proteins discovered [online]. Available from: 
http://labnews.com/faxwatch/fx172. shtml [Accessed 8th November 1999],
199
Beers, P. C., 1981. Immunoassay in Reproductive Medicine. /«: E. Norbert and M. 
Gleicher, eds. Reproductive Immunology, (70) New York: Alan R. Liss Inc., 
21-28.
Bischof, P., Gruffat, C. and Campana, A., 1997. The invisible human chorionic 
gonadotropin [online]. Available from:
http://matweb.hcuge.ch/matweb/Repro..,e hum anchorionic gonadotropin.html 
[Accessed 22nd October 1998],
Boehringer Mannheim, 1999. Rapid diagnostics/point o f care: urinalysis [online].
Available from: http://www.magnet.ch/boehringer/rapid/urinalvsis/MoAnat EN.html
[Accessed 29th May 1999],
Boerman, O.C., Segers, M.F.G., Poels, L.G., Kenemans, P. and Thomas, C.M.G., 1990. 
Heterophilic antibodies in human serum causing falsely increased results in the 
CA 125 immunofluorometric assay. Clin. Chem., 36 (6), 888-891.
Boscato, L.M. and Stuart, M.C., 1988. Heterophilic antibodies: a problem for all 
immunoassays. Clin. Chem., 34 (1), 27-33.
Boyden, S.V., 1951. The absorption of proteins on erythrocytes treated with tannic acid 
and subsequent haemagglutination by anti-protein sera. J. Exp. Med., 93, 107- 
120.
Braunstein, G.D., Rasor, J., Adler, D., Danzer, H. and Wade, M.E., 1976. Serum human 
chorionic gonadotropin levels throughout normal pregnancy. Am. J. Obstet. 
Gynaecol., 126 (6), 678-681.
Braunstein, G.D., Rasor, J., Wade, M.E., Karow, W.G. and Gentry, W.C., 1978. First 
trimester hCG measurements as an aid in the diagnosis of early pregnancy 
disorders. Am. J. Obstet. Gynaecol., 131 (1), 25-33.
200
Butler, J.E., 1991. The behaviour of antigens and antibodies immobilised on a solid 
phase. In: M.H.V. Van Regenmortel, ed. Structure o f antigens, Vol I. New 
York: CRC Press, 209-260.
Chamberlain, G., (ed.), 1995. Obstetrics by ten teachers. London: Arnold Press, 40-42.
Chandler, J., 1997. Personal communication. Cardiff, Wales: British Biocell 
International.
Chandler, J., 1999. How to choose a gold conjugate [online]. Cardiff, Wales: British 
Biocell International. Available from: http://www.researchd.com/goid/pickgold.html 
[Accessed 29th of May 1999],
Colanduoni, J., 1997. Reagent systems. In: Solid phase membrane-based
immunoassays, Sept. 1997. Paris, France, Millipore Corp.
Cole, L. A., Kardana, A, Andrade-Gordon, P., Gawinowicz, M., Morris, J.C., Bergert, 
E.R., O’Connor, J. andBirken, S., 1991. The heterogeneity of human chorionic 
gonadotropin, III: The occurrence and biological and immunological activities 
of nicked hCG. Endocrinology, 129, 1559-1567.
Cole, LA. and Kardana, A., 1992. Discordant results in human chorionic gonadotropin
assays. Clin. Chem., 38 (2), 263-270.
Cole, L.A., Seifer, D.B., Kardana, A. and Braunstein, G.D., 1993a. Selecting human 
chorionic gonadotropin immunoassays: consideration of cross-reacting
molecules in first-trimester pregnancy serum and urine. Am. J. Obstet. 
Gynecol, 168 (5), 1580-1586.
Cole, L.A., Kardana, A., Park, S. and Braunstein, G.D., 1993b. The deactivation of hCG 
by nicking and dissociation. J. Clin. Endocrinol. Metab., 76, 704-710.
201
Cole, L.A., 1997. Immunoassay of human chorionic gonadotropin, its free subunits and 
metabolites. Clin. Chem., 43 (12), 2233-2243.
Cole, L.A., 1998. Phantom hCG and phantom choriocarcinoma. Gynecol. Oncol., 71, 
325-329.
Cole, L.A., Rinne, K.M., Shahabi S. and Omrani, A., 1999a. False-positive hCG assay 
results leading to unnecessary surgery and chemotherapy and needless 
occurences of diabetes and coma. Clin. Chem., 45 (2), 313-314.
Cole, L.A, 1999b. hCG Reference Service [online]. Available from: 
http://info.med.vale.edu/obavn/phantom-hcg/index.html [Accessed 9th of December 
1999],
Cole, L.A., Shahabi, S., Rinne, K.M., Oz, U.A, Bahado-Singh, R.O. and Mahoney, M.J., 
1999c. Urinary screening tests for foetal Down Syndrome: II. 
Hyperglycosylated hCG. Prenat. Diagn., 19, 340-349.
Coons, A.H, Creech, H.J. and Jones, R.N, 1941. Immunological properties of an 
antibody containing a fluorescent group. Proc. Soc. Exp. Biol. Med., 47, 200- 
202 .
Cozart, 1999. Cozart RapiScan saliva drugs o f Abuse Trial [online]. Available from: 
http://www.cozart.co.uk [Accessed 8th November 1999],
Cunningham, G.F., McDonald, P. C. and Grant, N. F., 1989. The placental hormones. 
In: William’s Obstetrics. (18th ed.) New York: Prentice-Hall International Inc., 
67-71.
202
Delbeke, F.T., Van Eenoo, P. and De Baker, P., 1998. Detection of human chorionic 
gonadotropin misuse in sports. Int. J. Sports Med., 19, 287-290.
DiScipio, R. G., 1996. Preparation of colloidal gold particles of various sizes using 
sodium cyanoborohydride. Analytical Biochemistry, 236, 138-170.
Dorland, 1994. In: Dorland’s illustrated medical dictionary (28th ed.). Philadelphia: 
WB Saunders Comp, 23 & 841.
Engvall, E. and Perlman, P., 1971. Enzyme-linked-immunosorbent-assay (ELISA) of 
immunoglobulin G. Immunochemistry, 8, 871-874.
Esser, P., 1997. Detergent in polystyrene ELISA. In: Nunc Bulletin No. 8 (2nd ed.). 
Denmark: Nalge Nunc International, 1-5.
Fitzmaurice, T.F., Brown, C., Rifai, N., Wu, A.H.B. and Yeo, K.T.J, 1998. False 
increase of cardiac troponin I with heterophilic antibodies. Clin. Chem., 4 (10), 
2212-2214.
Flynn, S.D, and Seifer, D.B., 1996. Clinical application of human chorionic
_   xU
gonadotropin. In: J.B. Henry, ed. (19 ed.) Clinical Diagnosis and Management 
by Laboratory Methods. New York: WB Saunders and Co, 483-491.
Friedman, M.H. and Laplan, M.E., 1931. A simple rapid method for the laboratory 
diagnosis of early pregnancies. Am. J. Obstet. Gynaecol., 21, 405-406.
203
GGabbe, S.G., Niebyl, J.R., and Simpson, J.L. (eds.) (1996). Endocrinology and 
diagnosis of pregnancy. In: Obstetrics: Normal and Problematic Pregnancies. 
(3rd ed.). London: Churchill Livingstone, 34-57
Gard, P.R., (ed.), 1998. In: Human Endocrinology. London: Taylor and Francis, 96-99.
George, D.A., (ed.) 1996. Hormones of the human pituitary gland. In: Scripps News, 10 
(1). San Diego, CA, USA: Scripps Laboratories Inc., 1-4.
Gosling, J.P, 1990. A decade of development in immunoassay methodology. Clin. 
Chem., 36 (8), 1408-1427.
Gosling, J.P, 1996. Enzyme Immunoassay. In: Immunoassay. London: Academic Press, 
207-308.
Gosling, J.P., 1997. Enzyme immunoassay: with and without separation. In: C.P. Price 
and D.J. Newman (eds.) Principles and practise o f immunoassay (2nd ed.). 
London: Macmillan Reference Ltd. 351-388.
Griffin, C., Sutor, J. and Shull, B., 1994. Microparticle reagent optimisation.
(2nd ed.) Indiana, USA: Seradyn.
Grudzinskas, J.G. and Stabile, I., 1993. Ectopic pregnancy: are biochemical tests at all 
helpful? British Journal o f Obstetrics and Gynaecology, 100, 510-511.
Haddow, J.E., Palomaki, G.E., Knight, G.J., Williams, J., Miler, W.A., and Johnson,
D.O., 1998. Screening of maternal serum for foetal Down Syndrome in the first 
trimester. The New England Journal o f Medicine, 338(14), 955-961.
204
Handley, D.A., 1989. The development and application of colloidal gold as a 
microscopic probe. In: Colloidal gold: principles, methods and applications, 
Vol. 1. New York: Academic Press, Inc., 1-11.
Harlow, E. and Lane, D., 1988. Adsorption to remove non-specific binding. In: 
Antibodies, a laboratory manual. USA: Cold Spring Harbor Laboratory, 310 & 
632-633.
H art, G., 1980. Screening to control infectious diseases: Evaluation of control programs 
for gonnorrhea and syphilis. Rev. Infect. Dis., 2,701-702.
Harvey, M.A., 1991. Optimisation o f nitrocellulose membrane-based immunoassays. 
New Hampshire: Schleicher and Schuell.
Hermanson, G.T. (1996). Preparation of colloidal-gold-labelled proteins. In: 
Bioconjugate Techniques. (1st ed.). New York: Academic Press, 593-604.
Hoermann, R., 1996. Recognition and Clinical Relevence of Nicked Human Chorionic 
Gonadotropin. LabMedica International, 29-48.
Ikomi, A., Matthews, M., Kuan, A.M. and Henson, G., 1998. The effect of 
physiological urine dilution on pregnancy test results in complicated early 
pregnancies. British Journal o f Obstetrics and Gynaecology, 105, 462-465.
ISP, 1994. Polyvinylpyrrolidone, multi-purpose polymers. New Jersey: International 
Speciality Products.
205
Jackson, G.B., 1989. Immunoglobulin quantitation. In: L.A. Kaplan and A.J. Pesce, eds. 
Clinical chemistry, theory, analysis and correlation (2nd ed.) Philadelphia: The 
C.V. Mosby Company, 1051.
Jitsukawa, T., 1989. Increased coating efficiency of antigens and preservation of 
original antigenic structure after coating in ELISA. J. Immunol. Methods., 116, 
251-257.
Jones, K , 1999a. Capture line application and drying. In: Diagnostic 
Support '99, BioResearch Ireland, Dublin, July 1999.
Jones, K., 1999b. Troubleshooting nitrocellulose membranes. In: Diagnostic 
Support '99, BioResearch Ireland, Dublin, July 1999.
Jones, K , 1999c. Membrane blocking. In: Diagnostic Support '99, BioResearch 
Ireland, Dublin, July 1999.
Jones, K , 1999d. Optimisation of conjugate release material for lateral flow 
immunoassays . In: Diagnostic Support '99, BioResearch Ireland, Dublin, July 
1999.
Kardana, A. and Cole, L.A., 1994. Human chorionic gonadotropin (-subunit nicking 
enzymes in pregnancy and cancer patient serum. J. Clin. Endocrinol. Metab., 
19, 761-767.
Kingshott, M., 1995. The European market for home test diagnostics. Massachusetts: 
Decision Resources Inc.
206
Klee, G.G., 1994. Laboratory Medicine and Pathology-human chorionic gonadotropin.
Mayo Clin. Proc., 69, 391-392.
Klein, M., Graf, A.H., Hutter, W. and Hacker, G.W., 1995. Proliferative activity in 
ectopic trophoblastic tissue. Human Reproduction, 10 (9), 2441-2444.
Krieg, A. and Henry, J.P., 1974. Pregnancy tests and chorionic gonadotropin assays. In: 
J.B. Henry, ed. Clinical Diagnosis by Laboratory Methods. (15th ed.) New 
York: W.B. Saunders and Co.
Leunissen, J.L.M., 1999. Background suppression using Aurion BSA-C and/or Tween® 
20 [online]. Available from:
http://www.biovallev. mgn.fr/aurion/news le 1 .htm [Accessed 29th May 1999],
Liddell, J.L. and Cryer, A, 1991. Screening test design. In: A practical guide to 
monoclonal antibodies. England: John Wiley and Sons Ltd., 51-60.
Loraine, J.A. and Bell, E.T., 1966. In: Hormone Assays and their Clinical Applications. 
(2nd ed.). Baltimore: Williams and Wilkins, 74-81.
M arsden, A., 1999. Fibrous media for sample collection. In: Diagnostic 
Support ’99, BioResearch Ireland, Dublin, July 1999.
Millipore, 1996. Developing immunochromatographic test strips. Massachusetts: 
Millipore Corporation.
Mohammed, K. and Esen, A., 1989. A blocking agent and a blocking step are not 
needed in ELISA, immunostaining dot-blots and Western blots. J.Immunol. 
Methods, 117, 141-145.
207
Morgan, F. and Canfield, R.E., 1971. Nature of the subunits of human chorionic 
gonadotropin. Endocrinology, 88, 1045-1053.
Morgan, F., Canfield, R.E., Vaitukaitis, J.L. and Ross, G.T., 1974. Properties of the 
subunits of human chorionic gonadotropin. Endocrinology, 94 (6), 1601-1606.
Nahm, M.H. and Hoffman, J.W., 1990. Heteroantibody: phantom of the immunoassay. 
Clin. Chem., 36 (6), 829.
Neugebauer, J., 1992. A guide to the properties and uses o f detergents in biology and 
biochemistry (4th ed.). London: Calbiochem-Novabiochem Corpn., 2-3 & 29.
Newman, D.J. and Price, C.P., 1997a. Assessment and selection of antibodies. In: D.J. 
Newman and C.P. Price, eds. Principles and practice o f immunoassay. (2nd ed.). 
London: Macmillan Reference Ltd., 123-138.
Newman, D.J. and Price, C.P., 1997b. Separation techniques. In: D.J. Newman and
C.P. Price, eds. Principles and practice o f immunoassay. (2nd ed.) London: 
Macmillan Reference Ltd., 155-172.
Newman, D.J. and Price, C.P., 1997c. Introduction. In: D.J. Newman and C.P. Price,
j
eds. Principles and practice o f immunoassay. (2 ed.) London: Macmillan 
Reference Ltd., 1-12.
Nishimura, R., Ide, K., Utsunomiya, T., Kitajima, T., Yuki, Y. and Mochizuki, M., 
1988. Fragmentation of the (a-subunit of human chorionic gonadotropin 
produced by choriocarcinoma. Endocrinology, 123, 420-425.
Norman, R.J., Menabawey, M., Lowings, C., Buck, R.H. and Chard, T., 1987. 
Relationship between blood and urine concentrations of intact human chorionic
208
gonadotropin and its free subunits in early pregnancy. Obstetrics and 
Gynaecology, 69 (4), 590-593.
Notkins, A., 1999. Pregnancy hormone may help fight HIV [ online]. Available from: 
http://www.pslgroup.com/dg/22e6e.htm [Accessed 8th November 1999],
O ’Connor, J.F., Birkens, S., Lustbader, J.W., Krichevsky, A., Chen, Y. and Canfield, 
R.E., (1994). Recent advances in the chemistry and immunochemistry of 
human chorionic gonadotropin: impact on clinical measurements. Endocrin. 
Rev., 15, 650-683.
Porterfield, R.I. and Capone, J.J., 1984. The design of a stability assurance program.
MD&DI, (Oct), 47-50.
Price, C.P., Thorpe, G.H.G., Hall, J. and Bunce, R.A., 1997. Disposable integrated 
immunoassay devices. In: D.J. Newman and C.P. Price, eds. Principles and 
practise o f immunoassay. (2nd ed.) London: Macmillan Reference Ltd., 581- 
603.
Regenmortel, M.H.V.V., 1997. The antigen-antibody reaction. In: C.P. Price and D.J.
Newman (eds.), Principles and practise o f immunoassays, (2nd ed.). London: 
Macmillan Reference Ltd., 15-34.
Reid, D. E, Ryan, K.J. and Benirschke, K., 1972. Protein hormones. In: Principles and 
Management o f Human Reproduction. New York: W.B. Saunders, 28-39.
Ross, G.T., 1977. Clinical relevance of research on the structure of human chorionic 
gonadotropin. Am. J. Obstet. Gynaecol., 129, 795-801.
209
Roth, J. and Binder, M., 1978. Colloidal gold, ferritin and peroxidase as markers for 
electron microscopic double labelling lectin techniques. J. Histochem. 
Cytochem., 26, 163-169.
Salk, J.E., 1944. A simplified procedure for titrating the haemagglutinating capacity of 
influenza virus and the corresponding antibody../. Immunol., 44, 87-98.
Saxena, B.B., 1983. Human Chorionic Gonadotrophin. In: A. Klopper, ed. 
Endocrinology o f Pregnancy. (3rd ed.) London: Harpur and Row, 50-72.
Shine, A., 1998. Unigold (hCGpresentation). Dublin: Trinity Biotech Pic.
Shine, A., 1999. Personal communication. Dublin: Trinity Biotech Pic.
Singer, J.M., 1992. Use of latex particles in the biomedical field. In:Diagnostic 
applications o f latex technology, theory and practise, Indianapolis, Indiana, 
USA, May 1992. Carmel, Indiana, USA: Bangs Laboratories Inc., 1-26.
Steier, J.A., 1984. HCG in maternal plasma after induced abortion, spontaneous 
abortion and removed ectopic pregnancy. Obstet. Gynaecol., 64, 391-395.
Stern, J.J., Voss, F. and Coulam, C.B., 1993. Early diagnosis of ectopic pregnancy using 
receiver-operator characteristic curves of serum progesterone concentrations. 
Human Reproduction, 8 (5), 775-779.
Steward, M. and Steensgaard, J., (eds.), 1983. Antibody affinity: thermodynamic aspects 
and biological significance. Boca Raton, Florida, USA: CRC Press Inc., 101-105.
Stovall, T.G., Ling, F.W., Andersen, R.N. and Buster, J.E., 1992. Improved sensitivity 
and specificity of a single measurement of serum progesterone over serial
210
quantitative (-human chorionic gonadotropin in screening for ectopic 
pregnancy. Human Reproduction, 7 (5), 723-725.
Thakkar, H., Davey, C.L. and Medcalf, E.A., 1991. Stabilisation of turbidimtric 
immunoassay by covalent coupling of antibody to latex particles. Clin. Chem., 
37, 1248-1251.
Tijssen, P., 1985. Enzyme immunohistochemistry. In: R.H. Burdon and P.H. van 
Knippenberg, eds. Practise and theory o f enzyme immunoassays. Amsterdam: 
Elsevier S.C. Publishers B.V. 479-481.
Tisone, T., 1997. Equipment. In: Solid phase membrane-based immunoassays, Paris, 
France, September 1997. BioDot Inc.
Weiss, A., 1997a. Conjugate pad media. In: Solid phase membrane-based 
immunoassays, Paris, France, September 1997. BioDot Inc.
Weiss, A., 1997b. Sample preparation media. In: Solid phase membrane-based 
immunoassays, Paris, France, September 1997. BioDot Inc.
Wells, I., 1997. Membrane-based immunochromatographic assays. In: Theory and 
practise o f rapid immunodiagnostic tests, Amsterdam, The Netherlands, 
September 1997. BioDot Inc.
Wide, L. and Gemzell, C.A., 1960. An immunological pregnancy test. Acta Endocrin., 
35, 261-265.
211
Wilcox, A.J., Weinberg, C.R., O’Connor, J.F., Baird, D.D., Schlatterer, J.P., Canfield, 
R.E., Armstrong, E.G. and Nisula, B.C., 1988. Incidence of early loss of 
pregnancy. N.Engl.J.Med., 319 (4), 189-194.
Williams, L., 1997. Personal communication. Cardiff, Wales: British Biocell 
International.
Zakowski, J., 1991. Determination of stability. Clin. Chem., 37 (3), 313-314.
212
Section 7: 
Appendices
Appendix 1
ID No. Membrane Cat No. Supplier
1 AE105 Schleicher and Schuell
2 AE98 Schleicher and Schuell
3 n/a Advanced Microdevices
4 n/a Millipore
Table 1: Codes for Nitrocellulose Membranes
10 No. Antibody Cat No. Supplier
1 5008 Medix Biochemica
2 5006 Medix Biochemica
3 6601 Medix Biochemica
4 5009 Medix Biochemica
5 1817 British Biocell
6 108 Maine Biotechnology
7 106 Maine Biotechnology
8 105 Maine Biotechnology
9 Polyclonal Wyntech Diagnostics
Table 2: Codes for Antibodies
ID No. Antibody used for 
conjugation
Supplier of antibody
A 107 Maine Biotechnology
B 5008 Medix Biochemica
C 1817 British Biocell
D 9812 Genzyme
E 106 Maine Biotechnology
F 108 Maine Biotechnology
Table 3: Codes for Gold Conjugates
a
Appendix 2
The following pages display a copy of the test information and procedure handed out 
to volunteers of the external trial for the wick assay, which took place in Dublin City 
University (see Results, Section 3.14.5).
b
P R E G N A N C Y  T E S T  C O N S U M E R  S T U D Y
You will receive one test device ( labelled A B I) and four test devices ( labelled TI3 ) ,  
a urine sample container and a copy o f the product insert. Please read the instructions 
carefully. You will then provide a urine sample which will be brought back to the 
reception area , where you will nm the sample on the ABI test and a TB test. After 
performing the te s t , you will be asked to interpret the results. Three possible results, 
A, B and C are shown on page 3 . You will record which one o f these results you 
obtained in table 1 on page 4 in the relevant columns.
You will then be given three further samples to run on the remaining TB tests. You 
will interpret these results as before and record the results in table 2 on page 4. There 
is a  simple questionnaire to fill out at the end o f the study.
P R E G N A N C Y  T E S T  C O N S U M E R  S T U D Y
l.D  N u m b er : 
Date of B itih  :
Informed Consent :
I agree to voluntarily participate in the Trinity Biotech Pregnancy Test consumer 
study. I fully understand that all results and communication relating to  my participation 
in this study will be kept confidential.
Signature o f  Participant Date
P R E G N A N C Y  T E S T  C O N S U M E R  S T U D Y
O ne Step liCG  P rcgnancy T est
1. O bjectives:
Trinity Biolech PLC. are conducting a consumer clinical trial o f  the Unigold hCG 
pregnancy test. Your results and comments will be used to evaluate the perform ance o f  
the test and to determine how well consumers can perform this new home pregnancy 
test. You will be provided with a number o f devices , asked to read the instructions 
and to perform the test using the given procedure , just as would happen in the home. 
Once you have carried out the te s t , you are asked to record the test results on this 
form in the tables overleaf.
2. Interpretation of Results :
The following are three possible test results which you may see. Please record the 
relevant result code ( i.e : either A, B or C ) in the results tables.
A B C
3
P R E G N A N C Y  T E S T  C O N S U M E R  S T U D Y
3. Tes t  Results :
Your sample :
Table I
Sample ID Result ~  ABI test Result ~  TB lest
Samples Provided :
T ab le 2
Sample Code Result ~  TB test
Test performed and result recorded by :
Signature o f  Participant
Comments .
by: —   _________________________________________
4
